var title_f26_26_27040="Contents: Cerebrovascular disease";
var content_f26_26_27040=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/3/5182\">",
"       Cardiovascular Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Cerebrovascular disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Cerebrovascular disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Carotid artery disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/4/66\">",
"           Carotid artery stenting and its complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/27/40378\">",
"           Carotid endarterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6617\">",
"           Coronary artery bypass grafting in patients with cerebrovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/19/31033\">",
"           Evaluation of carotid artery stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/33/16922\">",
"           Management of asymptomatic carotid atherosclerotic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/1/21530\">",
"           Management of symptomatic carotid atherosclerotic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/24/9608\">",
"           Pathophysiology of symptoms from carotid atherosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/35/34361\">",
"           Screening for asymptomatic carotid artery stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/61/30682\">",
"           Secondary prevention of stroke: Risk factor reduction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cerebral embolism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/32/42506\">",
"           Antithrombotic therapy to prevent embolization in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/48/39689\">",
"           Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/35/10809\">",
"           Embolism from aortic plaque: Thromboembolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/15/31994\">",
"           Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/32/3593\">",
"           Patent foramen ovale",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/63/14328\">",
"           Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Classification",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/17/40216\">",
"           Clinical diagnosis of stroke subtypes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9208\">",
"           Etiology and classification of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/42/19112\">",
"           Intracranial epidural hematoma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/61/2010\">",
"           Intracranial large artery atherosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/55/6009\">",
"           Intraventricular hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/22/39273\">",
"           Posterior circulation cerebrovascular syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/33/30230\">",
"           Spinal cord infarction: Clinical presentation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/50/23333\">",
"           Spinal cord infarction: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/43/40631\">",
"           Spinal cord infarction: Vascular anatomy and etiologies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/25/406\">",
"           Subarachnoid hemorrhage grading scales",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/49/6936\">",
"           Subdural hematoma in adults: Etiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/47/43767\">",
"           Subdural hematoma in adults: Prognosis and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/35/33337\">",
"           Use and utility of stroke scales and grading systems",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/20/26952\">",
"           Cardiac complications of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/56/24458\">",
"           Cerebrovascular disorders complicating pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/63/34807\">",
"           Locked-in syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/12/17610\">",
"           Medical complications of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/43/25271\">",
"           Neurogenic pulmonary edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/47/3834\">",
"           Neurologic complications of cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/7/2168\">",
"           Prevention of neurologic complications of cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/54/10087\">",
"           Stroke-related pulmonary complications and abnormal respiratory patterns",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation and acute management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31688\">",
"           Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/29/33242\">",
"           Initial assessment and management of acute stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/11/10426\">",
"           Initial evaluation and management of transient ischemic attack and minor stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/26/6570\">",
"           Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/56/17290\">",
"           Neuroimaging of acute ischemic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/47/28410\">",
"           Overview of the evaluation of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/8/41098\">",
"           Reperfusion therapy for acute ischemic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/28/21960\">",
"           Spontaneous cerebral and cervical artery dissection: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/35/33337\">",
"           Use and utility of stroke scales and grading systems",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Intracerebral hemorrhage",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/6/32872\">",
"           Brain arteriovenous malformations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/8/37001\">",
"           Cerebral amyloid angiopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9208\">",
"           Etiology and classification of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/31/31226\">",
"           Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/55/6009\">",
"           Intraventricular hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/3/10298\">",
"           Management of warfarin-associated intracerebral hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/44/3786\">",
"           Moyamoya disease: Etiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/28/29130\">",
"           Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/56/32650\">",
"           Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/9/18584\">",
"           Vascular malformations of the central nervous system",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ischemic stroke",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/48/39689\">",
"           Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/16/11530\">",
"           Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/11/31930\">",
"           Cerebrovascular complications of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/10/40105\">",
"           Cryptogenic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/35/569\">",
"           Decompressive hemicraniectomy for malignant middle cerebral artery territory infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18773\">",
"           Definition of transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/37/36439\">",
"           Differential diagnosis of transient ischemic attack and stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9208\">",
"           Etiology and classification of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/46/40678\">",
"           Etiology and clinical manifestations of transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/61/2010\">",
"           Intracranial large artery atherosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/26/6570\">",
"           Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/59/4026\">",
"           Lacunar infarcts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/44/3786\">",
"           Moyamoya disease: Etiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/15/249\">",
"           Pathophysiology of ischemic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/33/32281\">",
"           Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/28/21960\">",
"           Spontaneous cerebral and cervical artery dissection: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/29/39383\">",
"           Stroke in patients with atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/16/9482\">",
"           Treatment and prognosis of cerebral venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/63/14328\">",
"           Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/35/33337\">",
"           Use and utility of stroke scales and grading systems",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mechanisms",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/11/31930\">",
"           Cerebrovascular complications of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/10/40105\">",
"           Cryptogenic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/26/7594\">",
"           Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32953\">",
"           Headache, migraine, and stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/44/3786\">",
"           Moyamoya disease: Etiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/36/7751\">",
"           Moyamoya disease: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/15/249\">",
"           Pathophysiology of ischemic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/30/10730\">",
"           Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/28/21960\">",
"           Spontaneous cerebral and cervical artery dissection: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/39/36471\">",
"           Subclavian steal syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/16/9482\">",
"           Treatment and prognosis of cerebral venous thrombosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35257\">",
"           Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/57/17305\">",
"           Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/35/2618\">",
"           Antiplatelet therapy for secondary prevention of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/32/42506\">",
"           Antithrombotic therapy to prevent embolization in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/36/32330\">",
"           Overview of hypertension in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/28/5576\">",
"           Overview of primary prevention of coronary heart disease and stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/60/40906\">",
"           Secondary prevention of cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/61/30682\">",
"           Secondary prevention of stroke: Risk factor reduction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Role of anticoagulation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/57/8089\">",
"           Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/36/33348\">",
"           Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/39/30327\">",
"           Anticoagulant and antiplatelet therapy in patients with brain tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35257\">",
"           Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/32/42506\">",
"           Antithrombotic therapy to prevent embolization in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/12/27849\">",
"           Risk of intracerebral hemorrhage in patients treated with warfarin",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Subarachnoid hemorrhage",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/39/38522\">",
"           Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/48/44806\">",
"           Late recurrence of subarachnoid hemorrhage and intracranial aneurysms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/3/10298\">",
"           Management of warfarin-associated intracerebral hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/50/38696\">",
"           Nonaneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/18/6441\">",
"           Perimesencephalic nonaneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/43/3767\">",
"           Screening for intracranial aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/28/21960\">",
"           Spontaneous cerebral and cervical artery dissection: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/25/406\">",
"           Subarachnoid hemorrhage grading scales",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/54/37738\">",
"           Treatment of aneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/40/25225\">",
"           Unruptured intracranial aneurysms",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Transient ischemic attack",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18773\">",
"           Definition of transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/46/40678\">",
"           Etiology and clinical manifestations of transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/11/10426\">",
"           Initial evaluation and management of transient ischemic attack and minor stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/33/32281\">",
"           Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vasculitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/19/13624\">",
"           Clinical features and diagnosis of Takayasu arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/26/9641\">",
"           Clinical manifestations and diagnosis of polyarteritis nodosa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/33/18969\">",
"           Clinical manifestations of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/56/21383\">",
"           Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/32/34314\">",
"           Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/50/25386\">",
"           Primary angiitis of the central nervous system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/29/28119\">",
"           Treatment and prognosis of polyarteritis nodosa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/60/3015\">",
"           Treatment of Takayasu arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/26/34217\">",
"           Treatment of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-D09DD10766-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f26_26_27040=[""].join("\n");
var outline_f26_26_27040=null;
var title_f26_26_27041="Supraspinatus isometric strength test";
var content_f26_26_27041=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Supraspinatus isometric strength test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen M Simons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_26_27041=[""].join("\n");
var outline_f26_26_27041=null;
var title_f26_26_27042="Color Doppler flow mapping of right and left ventricular outflow";
var content_f26_26_27042=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Color Doppler flow mapping of right and left ventricular outflow tracts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 400px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGQAe4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAopeM+1FACUUtJQAUUUUAFFFFABRXReBvCWqeMdetdP0uzvZonniiubi3tmmW1R22+Y+OgHJ5IHB5q+vhYaD4rbTPGWmaxAj7ltUZk08ztv2qxlnUqkZwSWwQMfiADjqK9Ou/CXhrT/Hk+h3CanOksVvJaq2p21oil4w8m66kTy3UZwrKoD9u2cCbwvZD4qN4XF/JbaedU+w/a7uPy2jj8zbvZTjBx64/CgDkKK9D+IfgePQPD9pqsWk6/ozNeyWUlprJVnfaoZZUYImVPzDGCARwx7eeUAFFFFABRRRQAUUUUAFFFFABRRS0AJRS4+n50YoASiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKUDNACUUuKSgAooooAKKKKACiiigAooooAKKKKAClAJIAGTSVJCfnX6j+dAHonhv4bfELTdU0vWrDwtdSvbTRXkHmAFHKsGXIDA4OB3FXLLwH46sNYvb2/8BpqQvFcSW95GzRjcwbcpSRXUgjghgcZHQmvuvwoc+GNJP8A06Rf+gCsjxldfZ7mAFioKE8fr+n8q4cxxUsJQdWCu0b4ej7aoodz4+l0Tx1dajcXOp/Dexv4njghhtp7eVY7VIRtRYikquBg8hmbd1bJ5rC8Y6X4zXT9T1LxT4VhRLjUEv7i+lttjqcFBCGVhtiO8fKO4XkYr69bUgD/AKxs8f1/qD/KvPPj/e+b8KdWjDlsvBz/ANtU9fpXiYTPa9etGk4Kzfmd9TLeSDlfY+WvEXiSbVrKz0+KwsdL0y0Z5IrKxD+X5j43SM0ju7MQqjLMcAADArApTSV9SeSFFFFABRRRQAUUUUAFFFFABSgZIFJSr1FAHeeHPDX9paSpiSz8wguTOhywJwBuB4+6T071JefDHxJPJv03SRMh4CwSGTPvzWx8PL5YbKKCU58wjr6V7FozS2CpLaXJweo3YxQJI+Xta8Ma1okgXVdKvLQnhfNiKg/jWRsbaW2nA6nHSvuFdXi1SMQ6tClwu3GJsMP1rF8UaPaaB4Tgk0iy0sSX900siyWayZRBgdfQnt60DPjaivoTU9RsJrSKLVvC2gXjxFisq25hPPYhCAa5bVrjwhdRw+Z4N8m4QMGayvniWTJ7qQcY6daAPJMGgjFen3Wn/Di7lje2/wCEl059gDQZilG/2Y4OPwq6fhp4Zvrjfo/jNxbNt2rc6c29TjnO1sYznpQB5FRXq1x8G71dRFtZ+KPDMySOEike4kj3Z9RsIX8TWV/wqDxpLdm3tdMtrh9xVBDqFs2/HcDzMn8qAPPqK7LUPhf44sLyS2n8Lau0idTDbNMnrwyZU/gar/8ACu/GeefCmu/+AEv/AMTQBytFdLd+A/FtnaSXV34Y1uG2jXc8sljIqqPUkrgCsL7Hdf8APvN/37NAFeirH2O5/wCfeb/vg1HJDLEAZI3TPTcpFAEdFLUwtbhvuwSkHphDQBBRVj7Hdf8APtN/3wansdH1K/u4rSx0+8uLqU7Y4ooWZ3PoABk0AUKK6tvh140BwfCevA+9hKP/AGWk/wCFd+M/+hU13/wAl/8AiaAOVorvtP8AhN45vrKW5j8M3kMMRw7XRS2I4yTiQqce/SpLP4T+IJYbia9udE0yCFQxkutRibdnsojLkn8KAPPaXtXqFv8ACu1WzabUPF2ko+8KkVlFLcswP8XRcCtZPhj4YttPEl3r+qX1w0mNlnYrEqJjqd7cnP8AOgDxmjFe0nw58PLK2ijez1y9ucnzJJrhYfphVBrRB8HRxQRad4MtJYo4wjPdzyPI7Z+8SMDpjtQB4KAScAEmnbDkqVIYHBBHSvpyDV4JI4xaaB4fsxGoWONLFWwR0OWySapfErw9Yf8ACQvqUFvZ+XexR3AMCBQSyjdxgY5zxQB8829hcTAbIHPGc44rVt7M20I8yzgaUfxSuSD9V6V6KNEjvI2MUnlAdhXM61YC0YqzM2O4oA5nV445La2mSCKIncknlLgbgT2+hFY7deR+VaGpBkYAbhHktg9M1nUAJRRRQAUUUUAFFFFABRRS4P50AJRS0lABTk+8PrTacv3h9aAP0z8J3Kp4V0bOCfscX/oArj/iZequqWgHeLkfiau+Gr3HhnSBnBFpF/6CK4n4o3wGqWY5yYc/qf8AAf5FeZm0ebDNeh62Sx5sXH5lf+0M445PXPf/AD17/wBa4n4zXpm+HmpIuQC8PXviQf8A1qtfbu+45/z/AJ/GuU+J9yZvBd8uT96M8/74r57A0LYiD8z6vMKSWGm7dGeBngmkpT1NJX2h+fBRRRQAUUUUAFFFFABRRS0AJT4RulQeppuR6Vb0xN95GM8daAO60OLymt8DBUV3tpeTvgI5wO2a89i85SDH86j3rZ0+4uFPGV9c0AdtPqNzbR5DHgZ61s+PPEYttP0HT5IzGEsROxYnLGRj69Pu/rXn8s01zeWlrHIPMnkSMbugJNP+KWrLqXji+2TPNDbrHaozDGPLQKwA9N26gBk2vwFHXyWYnocVgK01zOdiqM9OKtWhtY4SZBmpo7y0DYUMD6gUAY91pU7yEvGCfUVZ0+OSwGZA4Ue5robWUyqBHHvz0zT7nTpZwfNTYPYUAY9zfiVR5ZfPfmiC5nQbkZkb1zg0t3YGBh5HOOu6r1iUePbOgBx1oAzneVm3Ndzg+nmt/jT0d5CA8tw3biVv8a1v7NtZDlAQ1Mm027SI/Z1A9DQBrw65run6bDDb6vqMUCKFjRbhgFA6ADNZ/wDwlvihXyda1Nl9PtDdPzrnnbVd+ydWZBwKnEpVfnd0f0oA3v8AhNvFELLLDqN+WQ7hvnY8j1GeaS/+J/ivWSsesXFreRodypcWcUgU+oBU4rABuZSVR+D7VDNpV5anzcjHXmgDq7PxVKhVrqy0Zl7g6Xb/APxFdNqnxd1O90s2bXrxQEAfusRkAdACuCK8uWZtoWYL+Ap7WsU0RKkMPSgDrP8AhNLuUHZrupqw9Lt/8aYfG3iCFN0esai69j57f41yEMVvC20W7Fq04LRdgZw0Y6nNAEWq+JNQ1m8E2pT3U0ijYHeVidvPH05NUrvVI4o9onuA/tI3+NTXbR8hDVD7Es77iCfpQA6C6M4Ia4nbPUNISP51JDcR2cgYgYqSDTwMeSD+NXYdNt5cC65FAFiDxFYiPC4D49KSDWZbmby4ZmCn2qK58P2ezdE4UdayFBsph5Tkke9AHYLbRyIpdDK3uKvQRxhMbVQ+lcvF4o8hNkgOfSpYtUldxKECofzNAG1eTG2y+7gdMCrvi3WJLzwb4Wu47bY5Sa1kl5w/lvgE++O1YgvDeN5SRZz610U+n3Enw4u0mu1EGnXyTrbnqFkG0lf+BdaAOY0yVnHzMVU9cVDrcdsseNpZiO3NVTcGKJvJPPWs4Xtw7f6vcTQBz3iK0b7P5oXCA8VzFd/qa3F3YyK8IUAZrgWGGI9DigBKKKKACiiigAooooAK9K8CWNpcfB/4lXU9tDJc2y6f5MroC8W6chtp6jIGDjrXmtepfD3/AJIp8U/ppv8A6UGgDy5jk5pK1vDfh3VfEt/9i0OylvLraXMcZGdo6nkil8R+HdW8NX4sddsZLK7KCQRyEZKnoeDQBkU5PvD60lKBhhn1oA+7fD9yRoGljPS1jH/jorg/irebdVsjngRduuc/4V0Gh3JGiaaCRj7PH/6CK87+Ll2w1Wx5z+5JH51y4yHNTse3w+r42N+zMz7aefnwawPHVy0vhq5XPVkz/wB9D/P5VAL1ueOPTdWX4iuTJotyrcfdwM9fmH/1686hR5aiZ9nmaX1Sp6HntFKeppK9s/MQooooAKKKKACiiigAooooAK6PwbBG91JJL91RiucrqfDMZ+ysy4y1AHQzSxBv3fFOS7bgK9UZYJRgkEGoo4m8wbjt96AO9+G+mR6r420lLyNpIlm8wqpIztBYfToKpanpVze6pe3wVF8+d5WXsCSTitX4d3rafHr199o8mO10yRRICQ2+TCKFI75NULW8luAFhOM9jQBXj0VCvzt+FUZoorZyIx+ldNHYTbgzqRn0NQXunCQFXGM0AYVtqZt3BC9K2I9eE0ZUlc1zWoWd1YyHapK1V+0Sbf8AUfMKAOhvpjIucDBNQ20UbYZn/KsB7ydm2kFea0LbdsyTn2oA2EmnjbMIJA61p2mqSpj7QgC/Wudhu5FTaDioZLzJIlJYUAdNqt7aSx5Bwe4FcleXSGQ+Ujsc1dsrdLuYAbgvQ812Gk6NYRlfOKknuaAON0+ck4ZWH4VrXEk8ltyuY+3Fdwui6e4xHKozxxWlZ+GrPZ+8nBX3oA8XuVdiQsR+tRWvmK5wSG9K9X8RafYwfLbGM9jXKNpVsWJGATQBiRLcKd21ee5pLqe62YYDbXRWqQwMQzA/WqOpRRsQY196AMGNdzD5ea29N0/ehbdsPoRTrPT4/KErEg+lWA4jQgAkUAWraARsTIyMPYVQ1CKNGLMTtJ7Cq05lJ3Byo9Kns5wQVmXdnuaAKk0KSjq2z64rO1KG3ijAhOWPWr2oxyPnYxx6VkpsR/3w4FAEdrArv9zJrSeKRE6BQKILy3jPCrtpL68tpvmjIHtQA6z1BbI7iuSK6DQ/E1rqOj+J9PubeWRpdPaeJlbGxoTvGR36Vysai4XbhVU966f4Wae1n4/0wW12InuS9uxJABV0KkH65oA4u2uWnJ8qMketWxuj6rz7VZs9KWz3W8n+sgYxN9VOD/KrskRCbUCjjvQBliRjHIHHBGK851CPy7yVefvV6ULZ95Zzx6CuE8UQiHVHwOGGaAMeiiigAooooAKKKKACvUvh7/yRT4p/TTf/AEoNeW16l8Pv+SKfFP6ab/6UGgDzexv7mwmEtlPLBJjG+Ntppb6/ub+Xzb64lnl27d8jFj+tVKKAHDlqdxvHPQ9KjpynLD60AfVmj6jdDSbACwcgQIAfNUZ+Udq4T4n3ssuqWXmQ+SRCflLgk/N/n8q7HSJ/+JTY84/cpj8hXn3xUnJ1ax2nH7j+tZVItrc9HJpOnilNs5vzmqjrUpbTpVJHYj8x/n/PDDMc8fzqpqcpNq/OM9ff/OKxhC0kz6rHYvnw84+RztJSnk0ldZ8IFFFFABRRRQAUUUUAFFFFACjniuq0qIi2QI204zXLwrulUeprrIowUQdOByKANEJPKFWWbj1FDW5hbJk3iooYdh/1jE+lW0IkAQ0AdVpEsFt4A1yYwlpbi6trPduwFX55Tx3OYlH4mo9BKMwORwas6vAth8OtAhnu4fLurq6vjAJMFQPLiVmH1jkAPpn3rmrC6iRi9vcIUHXDdKpQk1ewHpL3LQxAhFcVAt6ZsgwAVgW+uwQx/wClTxon95mApLfXtMkkdl1GFcMVwzY/L1FVGjUkrpMC/qoMqFZU2jtXPfZFV+H3DNbeo3qSKNpDg9GByDWZDHJM/wAo4rNqwFe50pim+Fdx9KypHkg3J5TBvcV18Ek9sMNsK+9VNSkScYITPtQByQ888DgH1q9BboBmVhmiePY3HPPeo5VZk4/nQBZS9jtuEf8AKoZNalLHa5I9c1j3JIzg1QYyknBoA6BvEV4hwkjgD3p0PivU3UqHyAe7mufCEYZzgZqZozBOrcbXx+B71E20tDvy+nSqVVGqtGbw1+8LFpYtyfxFW5rpNHuoNRgEtuzcHawPBBrkYwPKHp15Nb/w4gSS+1DeQqfu+fX71ZUqrk7M9fN8qo4aiqtPQ6J9OSVSQPmrPvomjG0JnHeuzdbOL5Y3XPqTUUukx3ULuXUehFdB8ycFFcTxnaw3L6Cr8hE8GVQA1Dqdo9vKVB79agheSLByaAJFUZIYjHpSvFvYJEpx7VMm6bkIPqK2tLsTJ937/wBKAMo2jiIBYZGOOeKwb/TpQ5LrgHtXpE0F9HEAIdy+tc7qmnXDndIdn0oA4S5gkAI2AKO9LawqMEKHat+4sXwVZwfap9M09ozudFI9hQBkRyOAFaEAepqawna11S0uiiMIJUk2k9cMDj9K35Zbdm8oxDfnFZ+q6FLNEWSfZ3AFAFjxybXTPF2tW1vI4RbpyFc5K7jv69/vVz8tyZIz5bkt2xV34swXX9t6TfPOJ473SbVllD7i5RPLfPvuRh68VzOmxSk9W96ALglmQ/PJk+1c/wCLLeQ+XO+SDxXXWlhKzb2HHXNVPGkaPoeBjerUAeb0Up9qSgAooooAKKKKACvUvh9/yRT4p/TTf/Sg15bXqXw+/wCSKfFP6ab/AOlBoA8tooooAKVfvD60lOXqKAPo7S5v+JZZ8/8ALFP5CvPfinM/9q2RTH+o7/71dhp0uNOtB38pf5VxfxEzJf2hx0iI/Wu3AYVYusqT6lRqSpvmiccJpMdF/wAiorh5HjYMFx+NWfL56VHcR4iY/lXs4nIYUaUqivoW8VVkuVsxz1NJSnrSV8yZBRRRQAUUUUAFFFaXhyNJvEOlxyorxvdRKysMhgXGQR3FAGbRXr3xg/snwn+0XfNBpGnjR7K6tJH09bZBA0fkxM6+Xjbzlu3U5r0Lx34H0HwLpXxC8SvYaZNYaw0Ft4fElujxxeeu+R41I+Xbkldo4CcegAPmrTYfNuB6LzXQ2k3luNy8Dsa98bQtE0r4z6f8P7bw/pc3h57aOB5GtUa5nZ4t7T/aMeYGB/usFAB4qp4HtLW30v4h2stpot/FoVlO1hcT6VaySKyM4Dsxjy54H3sigDx37dFuBxiiS8RiPl2kdxWXqd213ey3MpgEkjbmWGFIUH+6iAKv0AFSadbvqN/bWUBUTXMiwR7jgbmIUZ/EigD1fxl4WW6sfDJFpJELfSIAwdjl3k3TOcHkfNKRj249K4+XwzEW+aIDB5A4Ir6n8X6NaXV0qyPulREjbb90bVAyPbg8e1ef3vhizMgRXwPyHbp+VfomS46gsJCnKPTseHUx7jVlBvZnip8MxAbhknqM5OP8+lULzShEpwBge3517lL4Zt/K2xOrZzxjuf1rn5fBN/c3GFt3ZDxkDP4+9e3SxeGaeyRdPHJvVnkNkbi2BFvdPGBnCEZH5VsWHidoDsv4U28BZIjzn3r0u88CaAthcJqV7PY3m3926ruUH3FeY3Hh23XUprSPUorwxnHmQg7Tx7/5618rntXLKVNylTd3s0tPv2PbyuhPMpctBq/mdDFrsEkYHlllPfFZl+wkO+IlSe1PHhvUbSIz2+ZowCSjH+VZovWSTZPG0Lg/xjA/OvhKeIp1fhZ6GKynE4b4o3XkWYbC6nAKOcGn3+nXVjAZJpY1j7l+K0ba9Vbd4pFO11Kkqecex/rVK4m0xNONhPDcTxFt+XcswPse1dMFF/EzzWYUbxTsdskbkehqxHEpIAVayRFa207GLzH/ALu/gj8qnjvY1wA4Bx1zx+dVOmnK1K7QGzHbKcbSB+FMubKN0xJk85qpFcSD5iwAp0l40hwDmshptO6LFvpUEjfNLOE4+QHg10Om2IgVYrcmKPrx1P19azNJjkYB2BK9+K6O2nhyqqrbqSSWxrUxFWqrTk2FxFNGhaOUk+9FtdaiUwJvl9Aa0QcrxExPvVb7NNK2FTHPUHFMxM6e6keXFwBtHX1qZ7uy8gDgNV2XRpY03yAEVzmrW+xSseOKANa0urIuRkk+gNdPpGrW9oQVQFe/PNeZWEU0blmBx7Gt6zuDHjK5Po1AHod94ljuECwwlRjqTXKalfyyZyVPtVaVpJ0yiDp2NZVzLJb53IAaAKl5cSmTCxvjpxzWjpD3rBV8iXZ7jFWPD2o2D3OLwAD1NdXP4j0G0gKiVN2MALyaAOdnt0iXzXUB/Ss68u5FXBYBam1LXY7yVhbqQh7kVUjt1uBl5AM80AaPia3i1Lwb4UvAjLPD9psHBPysqOJAw9D++I/Cuaj8i0x5rjd6Cu+gtZbr4b39tE0ZFnqUc4BI3Ro6FWI74LBRXB6np0SKWLhn9M0ARS6q5ysbYQ8YArG1WWS4tZE2kjBPNW7OxnmlGflX3rZa3tYE8pvmJXrQB5EwKsQeopKuarGIr+ZV6bjiqdABRRRQAUUUUAFepfD7/kinxS+mm/8ApQa8tr1L4ff8kU+Kf003/wBKDQB5bRWz4duNGtri4OvWNzewNA6xLBN5RSTHysTg5APasagApR1pKUUAe1WM/wDoNtkn/Vr/ACrnvFg866gbGfk/qau2lxiztx/sL/KobyP7Qyn04/z+de/w0r4+K8mRUdlc5ryfRTn6VBfRFbSU4wAB3ro/smTnFUdetzFpcx6dMj8a+8zamlgqr8mZRqXdjhm+8frSUp6mkr8kOgKKKKACiiigAqW1nktbmG4t22TQuJEbAOGByDg+9RUUAdV4p8fa94q+0trz6bdT3O0y3P8AZVpHcNtxj98kQfooHDdBjpxUOu+N/EWveHtK0LVtSe40rS1C2kBiRfLAXaPmCgtgcDJNc3SgE0AeveHfGvigaHAn9qPtitzaRXJgjNzFF/zzWcr5ir7BqxtN1280G01S00q+MNvqUBtbtCit5kZzlfmBI69Rg1U06+EejxQBSO54qnPGHJbBJPNAGbeLCP8AUgg10/wesYNU+J3hi1uldoGvUdgpwfl+Yc/VRXM3EGTlfpzXqP7PTJo/iy+126aJLXTrCRmZ+oZ8Im3jrk4qowlUahDd7CclFXZ9OeKit3Z7/M3Fnb5iCODg/wCf8485njkWRgr8HjntWrqXjLTdTgSOFijAEnnqx6n9RXNT61ZQzg3FyiKecu31/wA/hX1uQ4HF4XCKniV7+rfzbeh85jHGriJTpJ8ulr77IkFmVmErzvjOSN3Aq9rfiabTNHkbTpXN0i/Lt+90rg/E/jXS1Dx2E8lxNzxGpPH+TXKnVdamG6O3iRT08yb5h/8AXr2KssNBKWKmlbp/wC6WCqVbSaOl0K513xzqXlTMQI3AYyqFCk+9V9e8E3/hzVDcMZJlOC82OD1xx9MD8KxX8UeI9KkW4uHhW2LguUUNgZ/nXq3gzx3b+KLdNNuYh5sYz5h54J4U57jke/418bxfmbr4RPDP93F6qzS++x9nw5SnhcVzOCaa0s1p8jC0+90+505lacCUDpj9Kwdb0yK5t5FRVLMDt7c16Ld+EdO0u2k1Oby5YlJLPjCj8vbP51DqcOizWkciRtuYbl8k/lX5pTxMYy5qdz72NeEvh1TPBrQyWDvaSkDBJUEfnWY2s3LTBwkYQdVxnNeu+IPCC6jZSTxW9yZ0UlTCmW/L/D6V5pc+Ddct7Ka7fTbhLWEb3dkI4z15r73hzG4LEz9nid3ovU+PznK5U5utR+Hr5GRe6obiFo1toY2bhmGScelZu0EVOw9e1Rn5W4r9Ap5fRwytBaM+cuOZ5uSZGqewnKygycqBnPTvVcZbgnimlCo4Y49K8/McpjVp/wCzwVxpne6NrFsqrGFAY966dLa5lVXgMag85NeOxzSxOCjcjoK6TTvEt9tEIchQOp6V8piMBWw/8RFXPTIHngXE8kbfSsy98Qx2znzJMYPQVx1zqV64JR2ye+c1mbpZZf35JPcmuMZ3U/jS3uYWi2sOMZrEbUV35UFu/JrJjt0GSAc1WnfDYA4/KgDdbUi52qoHvSwTMXBaQj2qhpzWwAMgJP1p9xtB3x/d9qAO00dyeA2elaF7pLXTA+XuJ9q4zRNXWCTEhOa9F0vX7YRbtrSMB0AoA5i98KyeUX27aw/skNnIRJGHYHqRXa694sEsJQReWccA1xvnT3bEiAvnpQBHfXltHbkgAMO1c02sSGQiNjzXSt4fuL1syLsFV5PDv2YHgEigDoPh9fC80nxNY3EkpaSw+0q6HoYXD4I9D0rmLu7jdQykHv1ro/hgtxD47tYLUxwi7hntH8zG1g8bDBz6nFcivhi+guJYbk4khcowzxkHmgCeK7YrhDgU2e4ZFDHBNaem6Qw2h9uBTdY0xY9pXGfSgDzvXgTdl8Y3Vl10/iizaOJXwOK5igAooooAKKKKACvUvh9/yRT4p/TTf/Sg15bXqXw+/wCSKfFP6ab/AOlBoA8upKKKACiiigD0S3m/0eIeiD+VbGlR/aInOf4uv4Vy0M/7mPP90Cu38CRi50+8LDI8wc49v/r/AOeK9/hqXLjk/JnPiZctO4n2M+/fv9P/AK9Y/i23EWgXX1U/Tn/69d79jTk4Xr0x1H+f5+wrnviDa+T4TvDjncmeMc7h/ifz+mPuc0rqWDqLyZwUat5pHibfeP1pKU9TSV+TnrhRRRQAUUUUAFFFFABVrTYftF7FH6mqta3hyJpL8EAYUZ5oA6mXThGiqrHpT001mi3bs1TuLxyxRuMehq5ZST7C2SQPegDPutPlR+On1ruPCE39h+Adc1IW7Tz3V1Fp5UsAqJjfu+uRXNNcZbBziul8YXE9r8OfCmmxTxxC7llvXhjwWYFyEdu/T1rty+nUniYKkveuKSTVmc7d67ewsWigjiiyMhnBxWLc39xe3SvPmZQf9Xn5efStiDRYkwz/ADydy1aUenRsgCoPbn/P+T9K/TVgcTWVsTU07JW/E5OenD4UYC6vcQqBFaRI4Pfp+lObVdTuJlKyrAP7qICPrWpPpackqQemCKyp3jgYqoOaxhw9gqWrjf1NFV5tiaS1urwEXN5LKDg7c/Ln6dK7PwlPoWjW5e4glN9kbZEfaAPT3zXD2l8N4UsB+NbEVzahx5vzfQ9f85rpq5Vgq9F4eUFyvWwlWq0pc0G0/I9g0vxoNQn8iW3jm09gEa2cZVl6YII57V0sFjbiwkubnTktYT/qRHuLEDqMHt2rzPwB440azuTa3OkxoUHyzE7i+OefToePrXsugeLtH1yxD2fkgR5AEjAqv0P9PpX5bxNPC1JvL8Hh+WatG7WlvJr9T0cFTxeEaxtSTdPdpS1v5or+Gpo1u4Wl3Rr0QEEbvTrn3ra8caLL4g8K32m2TxxzTphGJIAOOORWJceI7Tz0ea0jlYMXDqcFc+lT3/jO0e02WYlikHQlueOMV89huEc1oYuEqasrp83a34jxnEWFxMPaKL5v5X/Vj5T8TeEtW0K9aHUokDqTzG24Vz7jaTu4Ne3+L54r1jNcENk/T/6/5V45rECi5fyjletfuMKb9gpW97qeRhq7qr3lqZxcc800yA00qoPPWjateZOpWk7aHUHG8FhkVrWbfMATWXCoeYKeg5x61tWMKtKCRz6DvXxucOLxL5d+paN/TbYzsPlq3PoMrfMi5qPSdctLctBLp2o+ZwFKIDmug1C7NpjyzvXGfm4P415s6UqduZbjOSnsprXlwBVBUPm7mUGtHWr+W6GNoAHpWA1zLEfvYrMC88QdshSDWnZWyNbneRWTZXYdjvcL6ZNbMMmB+72uT69KAMy6hSN8xkZ9q0LC9ubVT5TEZHOaju2kWX94sYqW3nj2YVAzUARHUZJpsSKXb3rqdJulhizJGQBzyKwo1CSb2iH4Vs2s/mrsdQFoAmvdZDjZApBqlEWnfM0u3PXJq9NHaxhdind7ip7PTbO6UtJHlu3NAGp4Zh06z1Kwu5X3+VPG+ByThhVD4iabNB4x1aCyZ/IE5YE9Tnn+tWYdOtrVgzpsC/MBu7jkV1vxMv7RJ9N1C58tmvbKOUNHj5yMg5x3oA8g+zXaHAdy1JdQzou+c84rWuNXHLQW3y+prA1HVHuG2v8AIB2FAGPr0bT6e5xwB3rhDxXolwgltZF3k5HSvPp02TOvoaAI6KKKACiiigAr1L4ff8kU+Kf003/0oNeW16l8Pv8AkinxS+mm/wDpQaAPLaKcFJ6Cm0AFFFFAHRRy4jUewr1j4OxG40nUCADtuAOc/wB0V4uk/wAo57ete+/s624uPDequQMC7A9f4BXqZRU9niVLyZw5jLloN+h1S2TA8D8/04rkPitamHwNfNgYDRj/AMfUf4V67/ZseMZH/fNcJ8brMQ/DbVXG370XQf8ATRa+kxeLU6E4+TPDwle9eK8z5UPU85pKc3DGm18OfVBRRRQAUUUUAddoXw78S65oltq+n2dp/Z1zc/Y4JrjULa3Es3/PNRJIpLHsAOe1RXvgDxRY6brV9d6TJFbaNOtvflpE3QO2NuU3biDuGGAI561674A8W+FNG+D3hGDxIlhqIg8T+fPZm4Pn2ybH23AjRwSFbH3gVIJGMkEXNF1nTIfjH440HxR4o03UPD3i21dDq0d1F5SnaTCzMp2IyDcmDjkL2IyAeMxfDvxXNJokcOjyySa1A11YqkkbGSIAEyEBvkXBHL4FbWneBde0uC1muoLRbe+cpBdpf28ls7LnI89XMYIx0LDpXql58QtBvvil4w0hNStbPSJvD8nh3R9QMmYYSq8HeOAjNu+bpwvNZtu1n4d+CZ8OXd9YXeq3mpC8EVncpcpAiqF3M8ZKZOOACeDQBxHiT4e+INFsY9Q1GGwhtpYxNEw1O2dpkOMNGqyFnHI+6DXOwXMkKYzXsHxP1XTL7w14Gt7S+tbl7fSVimSGVXaJhj5WAPyn2NeRalEYGLx8igBjXu1HcjOASK9H8Z2tvDeaPZxqz/YdOhjEj4/eEqGzx9cfhXm2hCS+1vTrKGHzZri5jjWM9Gyw4/KvS/HVxFc+NdVkaRSqTGNCqgAKvygDGBgAYr6vhGlz4uU+yMK7sjFgYeYBJkY7irjsIwNrY47H2HH6/wD1/SldTQxxExkFvz/z2rLEzyScSEHmv0Z6nIo82psS3HBDsMHuRz1z/Suc1DymbO4Kf5VbdGfO9yc1j31sEJYPnHOOtY4ipKnTcoRu0bUopPczXjbzeclB1INNUyISxchq1reWMWwMiYz9044P+eadZQO8sjGLdEw4LL1OcjFfln9u1/rMpyjp2uz6HEZdSo0FUjO7H+H9Rjs72JtQiWW3Y7XAbnaeox34r6O8GaR4Tm0yNtKnKeaQWjVwm1iOQQ3vXzTqlsIUjmRdhD4I6g16p4GvEuLK2V9ysBgda+hw8aua4JzjUcJp7pL9T5/FSjTfM48y7Nnq+q+GY0EYtpt4dd2O6n3/AM//AFsWTwrNu4Ye2DitjSleEplyR9eo/Gt+EoZEMmTGSM7fSlHEV8PFRcuZrrbc+YqV2pvk0TPP7jwULuH9+ScjGR6flXkvxA8G6no9y8kFpLJa9nUEgc19czLbwqmy3iaI9GAzn3561QvbbTrmF1ntzsIOUB4+nevnKXiJh4VJUqqkumx9Lh8px8EqkGpJ+Z8RW2nCdHZpV3Y78bT71UnjEMzRh0lA43Icqfoa634i2Nsvie9TS7YRR72wiZwAOO/T0rlVtJQSHAWvSyzM6NRus6jtLo0enisLPCz9nU3IkKCZGcNtUgttGSBmuyj06K209dQM0f2POPNByM9Mce9c9pUa2t2k8sqEKfmjK5Dj0PtVrVvEst/pr6fDbwQWhYNhFxnBz+HNY4yMcyxKVHW278jnWh1VnfhrUvayJMvTdH/CfcdR+NUZvtEzFvmYn1rlbfVrm3tkhjWMKp5IGC319a1NI8QSm5CyopGO3avPxWXVsPeTXujTL5tZ8fMmMVjapFtOQa6yXUFccqORWDqrRyKxUCvOGc4jA7s9R0rqdFjkuoNsR2lRXMmPl9v14q9a3s8CfuXZfpUrdnbiItUoXRevYLhJiH3E9jT7ZZUAIBzn1qgb+4kfLMSa2tI3T/6wdao4i/aSttUS4/OtW35XdCAfxqlLpismdmW7CltLC8jYbDhfQUAaEwuCnIVAKjtNRkt5ACCVzyalfKRFZfmc0WtmJssy59qAOk08HXH8ixtLi8nC7zHbxNIwUHGcAdMkc+9a/iLSbkaNoMZ0PU2vx5tvFaNav5hVfn3BcbsfhWh8FbUW+t6y0kTeX/ZM4IU4JGU6HB/ka6nU5jZeCfCmr+Gt82l6XcxTkOQ00eWYTI7cDkNt4A6+mKAPnLUJby8gvbix028lt7IA3MkULMsGScbyBheh6+lYGnf6bcAH5ee9fSvxV8M2+h+D9U07RJUx4i1M6lM2OkQAYIPbfgj8a+fLaySzvGjnfbjuKAJpYBA3lgAj1rznXYTBqUykYyc16eYEeVfKcyc1xfj+ya21BHZdu8UAcpRRRQAUUUUALg4zXqXw/GPgt8UV7kabgf8Abc15hHjAznrXt3hZbQaHatZKgjZBuIAyW7596ipPkVzCvW9jHmtc5mL4X3d74Ttte0W4m1OG8iAtLO0tHlnkmXiZCq52hP73IORXB61ouqaHdi11rTb3T7krvEV3A0T7fXawBxXda18SfEOnvf6Pol+bHSVVYIYbUtEIAh+8hUghic5Pf8q4TVdW1DVrn7Rql9d31wAFEt1M0r4HbLEnFWtTZO6uUKKU80lAxynacivQPh0PHJ0+T/hELlIbeW4EWx7yCAzTbfuIsjgu2COFB6iuI0u6hsr+K4ubC21CJM7ra5aRY3yCOTG6NxnPDDkDORkV3vw21TRtN8RR+IJ9V0jRPLuv3umPp89yfs42t/o0hEjJISGUMXRl4Ifk4cZOLumKUVJWkrmnYa18Ub/Sm1C21CRotksgjN3Alw6xZ8wrCWEjbcHJVT0PpWBF4h8aeOIbnSRfyXdsI/PuBPPHDFGilfneRyqoAdoySOSB3rR8F6noOi2up30muWiwX1tdRTaW9jI18CyyJEsVwEIUEMpYiRcjIZW4zl+FL2w0W7S3g1fSLqw1fTQmqRataXS28T+buEJ8kGRmBjjcOmBk47GrdWbVrmao007qK+45fXtHv9C1OSw1aDyLpArlQ6urKwDKyspKspBBDAkEHis6ut+JuuadrviKJtFhSLTbKzgsYCiMgcRpgsFZmYAnOAzFsYySc1yVZmoUUUUAFFFFABRRRQA5BlgPeu90yRY7NEmx0FcRYRmW7jUdSa7SS2dkAC5IHagCO7MaMTHj8DUfmlhh+cdjVdoZEfDAjnvUoIAwf1oA6v4Y29lP8QtHkvEk8m1aS7YRHBPlozgD8RWVbw6pe3MrWscMiysXXLAEZOcV03wxjubez8W6paMI/s2jSxmU4+VpGCgAHqTkiudtLx9MYbFyF44ruwOY18BJyoO1xOKe5ej8K+JLhkU20ESHGX8wEAfSt3TPhreTB2udaghk2naqx5GfQ5PSjS/HtuoEd2ki8dcZrrtJ8Q6Je48yQYPrXdU4ix8/t29ELkijnZvhVeCEN/bUbuRk/u+B9Oc+tczd/DrWI1O+8tD64zXstxPoYtgbe5CkDIAavOtd1sw3TiK4BXPXNZf27jtnUY+VFW10dNM0yO2kZZWQcuUFULh4lJUR7lHYDAqpc66ZM7pQw9qhiu43+81eVKTm3J7sZk67J58RCfII23FT3r0D4aX1lcpDFuAkUgbT1Y+/rXG6hKn2dmihDy8YyCe/61tfDXy9PvoL1VHnKeDgc5r1MJxD/ZlGVOceZP7zqoZNPNIyjCVrH0CGjRD5a47c/wCf880kD3F3OsShlQ/Lu/xqK21+4IXMMAyOmwZ79vXt/wDrq+NXmdCEdQSMErxkfT8q8epxtRiny0m30u0cceCcQpLnmrGlqcrRW62ttuLIcscZJOemP85rkLzUNThY7kRo2OMj/wDX9T+dSanfSJnYdx5Y/X27dq5y/wBRnk3bzwK+ClKpiasq1TVyd2foOAwEMNSjSitEZPirwjba2jT744Lpvm3Be/4V5ZqtpNaXbWl9HtYHCvjG6vQNTv5UfG49P1rk/Fjve2oZjwvXPU172X1atJqLd0bY7LIYqm3LdbHM3WnMo3ZGKxZ4zGx56cV0agz2aMGwMYxz2rMnhKNzzX01GtOjJTg7M/PJw5JOL6GaGG3JqNZSjbkP5Ventt/JQGmJFGBh1Ir0cXm9TE01TaSRCRfsdYWJcSrvPvTptQW4yI4wCehrPW1jfJDLmrVpaMZAAwBNeSMIbWWQAcAevXNXkjWNNm326VsadYYAyQTV6701RCXbGRSSSN62InWtzPY563sPOY7DitXT4TDIoD459KzY7sWsxBbgGuh0zUbeXHGTTMDobOESRjc+T9Ks4EakD+RrT8PLBOVDuK3NVW2jTCGPigDzq9inlnzGv6Va05JYCPMiY+tac0+JSIwPwoDSuMg0AJeM97EEJKKPwrQ8GyJbJrlkQd09g7q684MX7w5+oXFZeZA2JMAVv+CZoh4lsIUiDNcsbdlZQQyuCpGD6g4oAptfrPp+ZZAGI6Vxd7ZxXF4zFQc1sXFqAWjlkMciEqyHggjgiqj23kqXDA49TQBY0y1trXDy7QOuK5D4uiG7treeCMjZxmr9xes0mM9PesnxTMbnR3jOTjmgDzI9aSlPBxSUAFFFFADlOB716f8AD9Eb4QfEm62j7TbLYCGT+KMPMwbae2RwfavLq9S+H3/JFPin9NN/9KDQDV9zzFn3EluSe/8AWo6KKACiiigCeytZr68gtLSMy3E8ixRIOrMxwB+JNdpH8OZZb+4tYfE3hyR7SOaS8ZZpsWvlbd4b91lvvcMgZTg4Jri7K6nsb23u7SQxXMEiyxOOqspyD+BFdbe+Pp52v3tdB0Kwlv4Z4bqS1ilDS+bt3NlpGx93IVcKMn5eaAJ9X+G15p+nXV3FreiXzQWMep/Z7WSYyPauUAlG6NQBlx8pIfr8taEnw9/tGS10vTGt7W903TIr3WLmbzpP3kzgogjiV2+VZIlO1eDuLEVj6V48ubbU4p77T7S8tDp0OkT2+WTzbaN42wGycO3lgbsEcn5ag0/xveW3iHVdZu7Cx1C91CZp5HuDMjRsWJPlvFIjqPmIIDYI4INAHO6pZ/2fqV1Zme3ufIkaPzrd98cmDjcrdweoNVa0fEWr3XiDXtQ1fUChu72d7iXy12ruY5OB6VnUAFFFFABRRRQAUUUUAbvhOFX1AM38PrXcFoomDblB7cVyHhWIqDJiulleMx5kUZoAmvoorpN0Z+b1rFa3kydvOKmkuCrHyTiiKdt/zHB96AOr0uS3sfhZrssqSG6vtQtbKPH3VCbpiT7/ACYrK026tmYCdAR6Guk1mRofhx4b0+eONUubq51EhSC5ACxI5wcgH96Bn+6a48xiI4iG5aAOnhn01kKCBCPdRWfe2cJDPbkIOuBxVPTNOmuZB5ZK896177TLxIc4BUDqBQByt1NIhK7pOPQnFZN1LLknJ6+tdNMAqESx5b1rnb/KuQIyRQBnGWQPkt+VaNtcMEG7DfWs5/vEYIpyHBHJoA157vdEYwvL5Xk8Ctzw9cm3liUHjIXPvmuT3g4+bkHINammXQ3glsOD371y4qDlE+r4cr0otwfxM97gvCIlAk4C8f5/DFSLfqnUjkEH3rzK38QlhtDc+/8An2px1xi2A4/GvmngJX1PqvY3PRrm+wo5AArD1HUVMZA6nv0rDj1Iyp97gjuaivL2PYQzAE5x+tOGG5WVGlYpXc7sTj+dYl20xGJRkHseamvL0iUkFeP1qs1y0ilXOVPrgV6lODjrY1k1axjxyi2utowY36jn9KtxiGVumM+tU7q3KuZIz83pjmq9vd7ZiCec816tKSaPzvOcPKnWc3GyZ19rpaTR8Y6elUbrQ2Y9AO3Sr/h2/GRuORXZwfZblAGQZNanjnnVr4cJPLVe/sb7MNxGQK9AbRVLBrdCxxms/VLWWO3cSRYHrQBxklwYQRGoyKj+3zSrtlbj0qO+Ox2C8j6VWizkE0APlsvOYlELE81YsIJ4HH+jkVr6VMqoWO0YrQjv1Z8CPf8AQ0AQwG7cARzvAR6HpU32C9lO5tRkb6mrZh88cQsjGoZdIv8A/lnOUX0I5oAdHDdx/Ksm4Dv3q1mWJMySEeuKzt97pyFn/eAfnVNdZnvZNnlbQeMk0Ab0N8M7TufPrVqC4iguILmSJiI5FkOByQCD/SqNjGVZSdufrW0yrJAQ7Kq4xQBU8Y2cyeKdWS2kbyjcNIrMMEh/nHH/AALFc9Nb3OSsjlh716H40klkm0u/ljQG706Bwy9G2rtJx16jvXGTrcSyEggL9KAM+CxjUghN5rN8QxtJA8cce0YIOa344ruNvlxjFV9QtJZUJmI5FAHiF3GYrh1PY1DWz4ptvs2puB0JNY1ABRRRQAV6l8Pv+SKfFP6ab/6UGvLa9S+H3/JFPin9NN/9KDQB5bRS4pKACiiigAooooAKKKKACiiigAooooAKKKKAClAzSVNaIZLqNAMktQB33hy3jTTVD5ViKkuouCAcg1ftLZobNQVx8oqoeHOcdaAKMVuC2cc1pWttBKQJBjtnvV2FrQJyBvx3p+k2/wBu1a3tbRN880qpGgIG4k9OaAOq8VWFrHLo1nEWdbTTII2LY+YuWm49v3uPwrFfTbZV3g7a0fHGoZ8YasEMTQpO0MYixtVEwigY4wAoH4Vn2rRXeFZ8exNAF7TViAwuM+orbFrcvAdky7PRhWZZ2cds6vC2W9CeK32vBPaeSYdrD+JTigDktV03qXC574rm7jToSchsH3rt7vTTKcl2IPvWZLpUa/fV/wA6AOHvNLABIYGsl4PLYgqPyr0Wewttvy5B+tc9qFgBISBx60AcjLw3SkifDAgkGumawjdSCVz7is2fSAGzuBFJq6NKVWVKanEW2k3x5B6cVZWeRCMGs6HFvMYm/Amp5JV8s7TniuOUNbH3uExanRU0zRTUyvG8j6n/ABpktw0xyxJz3zWILiEt+8Eo45YY6/T0q3aMygox6jI961q4KdCKnKNr7EYbOI4mfs0x9zdLCcu2T05NEF9FKv3x+P8An3NR3lpHIpLAnviucvE8mYqMhe1TCEZo5Mdj8Rg58zScTp3kWUHa4yc/yrHk3Q3JMnzAnr6VRt3kUZVyD6dqnednx5hHHpWsabi9DxsZmNPGU7TVpHUaOA+0oSD9a7XSbqNNqyHB9TXl9jdSDiJyua27b7U2C7k1qeKezWN1sCmOQMuOmanvb2Ga1dJIzkjrivNNK1S5tGGPm9ia6BvEs8sJTygD34oAwNXtykrFFyCazEt97DetdDNcCbllOTT7W0WUncQtAGSlrGg+XK+taFs8UCHa6nFT3lmE4Rg1JZ6eZGAMRb6LQBNZ6oxlUKoxnGa1bt55QGSUgY6Cmx6MIkDmFhj1qKWeSIlUTAoArvbSXCsjueaS28NFn3K2QOetSJ9rd8hCRWla3FzEDuG38KAK/wDZxt8DBJHvTjE+RuZgvoDUrXMhbkfnSPcvt+XBoA6eWLT28I6NPJK/mRPNbOjDp828H/x+sS6u9Nhz5ZUtVmOa5vvAGqwxwRsLK8iuGl/ijRlKt+HyrXCTwRJueW4yx7A0AddaSW8x3OwwOeao65qWnRMI4/nccYXmubhiuLptizPs9uOK1E06GytvMfbn1PJoA82+IMe+eOdUKgmuOPBxXo3jxxdWfyIfl5Brzk89etACUUUUAFepfD7/AJIp8U/ppv8A6UGvLa9S+H3/ACRT4p/TTf8A0oNAHD+GpNEiuLg+Iba7nhMDCFbZwpEuPlJJ7VjE5OTSUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFanh2Iy6pFgZAOay6734UaSNS1WXcOE60AdHcXLLCVZSBjGcdaylYF8qcivSf7CVWbKAr6YqnLo9kJPmUK2ehWgDlrWCGdMkAN6Gt7wNaWqeMNOuLgmNLRjdNtGSRGpYgD14qS40e38vMfB9RWn4RsBa2XiK/8tXMFh5ayvz5bOwXj327qAOIltleeWRH+WR2fBPYkmlSAqR0x7HFXJNPgyArvxUghihiySW9jQBHbQ3AO6BpGHcFq2LSe5VCJYzx3zXPvPLvzaD9amivr/cFkjAU96AN43C7h85X6miTUIwNpZTiqVu7dZlPPoM1aaS1fCrb89ywoAi8y3mfg96bqGkme3LRnnrU509peYkVcelTWiXFqrib5lNAHnl9Hd2sjb1yAetZ8t5IwAI5PWuw18RShsNg5rkJLdi+Vb8aAKrI0h5BJq1a6WbjjeR9akhTawDnHuKnuNQGlqrRfPK2doPT8aqnSdWSjFXZpGtOCtF2GP4Pv5JB9m2OpGcs2Oc02XwxqtliWRVwOTg+1UF1/VUJK30y57KcVBd6nfXj7ru7nmBADBnOCPTFfS1MuxlWl7OpJW/EinVlTkpweqLD3TRArMNpHftWbqckTqTjLE8e1Nm2s/7pGRc52k5xVVoGzxXiVMpq0neMW16HpVc2q16fs6iI0TPQ05rfI5JNLHGwbAPNbWl6ZLcsMZIrkeh5hm2sTow2gnFdLZysEXdmt3S9EiyFmUZrq7TwxZvGGwKQHCJexROAwPFa9tqkWz5V5PqK3dU8M26D5EWuZu7JrVgFQcelAG3ppkvryO3tbaW7uZMhIYIy7txnhRyeK3ZNH1a18w3Gg6pCsSeZJ5lrIoROfmORwOOtcT4ZhvbzxXpUFpbTTzNdIRHEpZsBgTgD0AJ/Cvo2aWTTfjzqqahBImm61GloWdSqyq0KLkZ4PzDb+JoA850/SzJaQ3ctnN9mlfykl8s7Wb+6D0J68VvXOnjSIlN5p91a5OFMsLJn6ZHtXYa1dXHhvxH4a0bRreK9bSImlkhZhGJZHU7uT0ODkfXvWN4506zj0BdRgXUtIubi8PmabeOT5nBJlAPPfGT7j3IBxerXiy4Fuzkn+Gs6CFNwMq/nWvp+ktqWEtXCyE8tU954Wu7IZaVJT15oAgikhnjESgIBxV+PTYFTezg9+tc/cWF+pJWEH/d4qDzdUT5TbnaPU0AXb2JfPIjTcPaqdwHTgRnJ7YqzbyXajLKo/CpHvnjYb4cn2FAFnwTpUupx+IbGWY2/2zT2RPlJywYNj9DWTbeAZI9sszfLjJLV1vgbWnTxNYRiBBHPJ5T7uhVuoNcv4q8XXlvfXdnIPKMMzx+WB93DHAP4UAXGtrKwi8sFS3rism9+yuhDOMfWuL1TXbtnJJwDWSNUllYh5OKANvxKsEllNFFhuOCO1eSSLtdh6GvULRmnideoYV5xqsRhv5kPZjQBUooooAK9S+H3/JFPin9NN/8ASg15bXqXw+/5Ip8U/ppv/pQaAPLaKKKACiiigAooooAKKKKACiiigAooooAKKKKAFAyQK+l/2Z/B8t5oV9qrRgoD37180KCzADqa+y/hfrUXh74WW9nGm2WVcsw70AazwW9sZRJEpxniuN1r7G7NvIQ9hUGreLkZ3XOD71yl7qv2psknmgC7PLHDnynLirEkIHgC5l8yb7ReakIhGo+UJFHnOfUmT9KwUnAbO8nnpXfXtyLfwp4btJ7ZIxNFLdg7cM++RgGPrlQuPagDzmK1uI+QXIx6ZqZp/k2yRexNdXN+7jLIkbDHrWDdXMTsRJHj3oAzY1hLZVvLNW4kEj4Z1aoJ4YJQfKlCn64qt9klRxsmB9OaAOx02OCMDzAuPWp7m700HZuUHpwKx9JlmACvHvxxU1/bs4LeUqd+aAHMdxDWrnFTQXESgi7YD6isKG4nt5cKDtHpV14zeRltvzelAGR4quLRyVtgpJ7rXIpaSStlTgV0moWoSQqyYao4IvKT5VoAz4NCuJCu1Q2ferd74LnuYg0m6NlHDDkCrsElysoMcuO+K6GyvJZBtmXIxzzVwnKnLmg7MDyu88PvBLtW4Uj/AGh/hWXc2k1v94b1zgFa92ttD0+7O54VU59ak1PwtYPBtijQnHPFelTznFQerv6isj593L601iDwDzXqOq/DuKYs0eV+hrn5fAs0LHyySK6a2e1KtNw5bX6i5TlbaABssM81v6fevBgRoRjvV+18NTQMAyBvrV++05YLdSiDzB1rwSivFfXLkNHjNW7e71Dd88zxj2rKDzxj5Y1HOaeZ72XCgY+goA62GcyIBJeFj7ioXtIy+Xn3VzbW1wEyGk31c05rhHXzCMejUAaZS1RsLGZG9hV+zScgeRblV9arpdy/8s4Ub3FaME9yY8EBPYUABW83ANhfxrRtILox5Kbl9TVKIXMrjbkk+tdDp1vqSrgx5U80AZq61Np7EL8meOBV+y18zuGnaVh3rQe3twha9ijDD1rntYurYMBbRjH+zQB2kOr2ckACR5b0xVaSWKY5cBVz61wSXcwJ2DYPrSmS4YfNKfoDQB6AWsI4jghnPY1jX9o0oLhkCjn0rl1uXh5yzGorm5vLlMMzIntQBaF1bwalCWlY+VIrHaeeDW/4u8LWtx4rv7iWTdHcstyp6HDqGAI9RmuLitgr53Nn1rt/G15IYdEvGXa1zp0e9lGA7KSv6ACgDhvEPh2zQMtsx/Ouaj8PorndMK6G5le4kOCT+NVLm0nB4GM+9AE2n6XbwjmXP415n41t1h1yXyjlG5Bru2tpeQ0khz0A6Vx/jHT5IAksmee5oA5WkoooAK9S+H3/ACRT4p/TTf8A0oNeW16l8Pv+SKfFP6ab/wClBoA8toq3p+nXmpTeTp9rNcy4zsiQs2PXApdQ06802YQ6jaz2sxG7ZMhRsdjg0AU6KKKACiiigAooooAKKKKACiiigAooooAtaZC09/DGg5LV7cusapZaXBbGFJYlTAKnFcH8H9EGueLIYCMrxX0pqPgu3tH2DDADnHNAHhN5dXF4/MLA/SlWG7WMFUfp6V64/hC1d8x4VvStzRfA32khcpnsKAPBhdywkm5iZFUFslfSvT/F+o6dp+rWultKbk6fZW9rvcEcqgzgduvavRYvAEIuIormzEqmRdwK5BGRkflmuX8c+FRqPiTUrowxgvM2Ao4wOB+goA5B7m3mgzEvGOxrLiQGX5hkdxW9F4Zewbc+AnpmmX0NrGhKghx2oAqXNjp80OfKUP61imzVZCAW29uatC6y23y2qZYPNUsqsD9KAFsYzFzG7g1PcytICJTx61FAXgb5lIX6VYuF+0LmIjPpigDKfAOUyatWM20gsjgey80xklt3zJEcfStnTNXsY1w8Xz/SgDJvIPObciMw9xiqqgfceEiuoutQ0+VPlOxveueu5rcOdr5OeooArS6UsgLwsVPXg0yG2uISMtuA96k3TdYpPk9M1Ztyn/LQfNQBC2qParhxz9aiHinHAzn61cuNG/tFfvYzVCX4fs2XS4OewBoAu2mvs/VuD71pNfQvECNpbFc9B4XurQ4JY/ma1o/DIvotpaVG+tAGXqeqFAwULmufku5p5DuYkV1snw+uEJMLSSfWo08KXNs3+kQEAe1AHKbZGxtRsdzip7WQRNlkckHpiu20/TYIpB5wCr3BrYe10pYfuoffFAHGQ3cTqMxEdulKdKjum3GUqPTpVrVzbREmIgelYqXTPKFDfrQB0mmaTCg2ifv69a2Y/D7SEeXNkelZuhWBkAkeQjH61qzXxtTgs4HbaKANnTdMFkPnCt35q1PrC2q4aIL7g1yjak0/EbS/VuKz71Jj8zzhgfegDZ1PW7S4OHRmPoFzWBfX9qq4S3kHvtqOOV4+EQHNV5IZbhyZmCr6UAUxLbyykuZAPc4q/DNAmNiu1OeztIoSzOgP1rDulmklItmLD/ZoA6eDULOI5uFUD3NWZdc0yUeXGqha5GDS5g6tc5x7mtMW8KD5FGfpQBtfaLBozsiDMaf4lmNx4D0eZJRi1u57V4yDkFgHGO2MCudn3RLnp7VvaO63fw98RwTQiZLS5trsOBlo925GP0wB+dAHIwtyDu2+9att5TEeZKGrKdo2P7ocVn3d0EO1XwaAO4M9iIiiIpf1FcJ8Q0E1gNq9KuaZLuwTITTfEkLXVkwjUkAdaAPIDSVJOhjmdD1BIqOgAr1L4ff8kU+Kf003/wBKDXltepfD7/kinxT+mm/+lBoA4Hw/r+q+Hb77Zod9PY3RUp5sLYbB6il8Q+INV8R3ovNdv5766CCMSzNuIUdBWVRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRS0Aev/AAEhmjvZ72LHynGTXs51uea+YzOY2J654rgvghbC08OPIyDMhzzXV36AksEoA7BbrfACAjv61LourRxXi+cVQA9R1rgo3vMYiYge9TrFdghpguT3zQB9AaPqcV0yH7THIFUsRjkYFZOuQ6Jdwl5RiXruXjNcp4Ht3az1OWLAmS2KI5yQpYgfnjNJeaBrkMYKyiRB3AzQBQu9Ps5GZTKTGOzc1zWr6PaR5NrJk+grt9F0+KWZY9UJQnqwHFdZceBNLuIt9sxDdQc5BoA+emtzFId0WffFWYbsRcGIjFemeIfD5sFZbizkZR0dBkGvNNVMsM58uElM+nNACyS20oztIJ9BTovKjVjGfzrM/tBQcPC4P0q1HqCLF/qWOPSgC15hY8lCO/FV7q0t5kJYqD14FZF7eNI5aP5PY8VWS4lPDHP40AQXduIpGCliM+tQpEr9Qc1qLbPMMq6D6mpoNNZjh5kHuDQBmrC+zam5W9cVLBp96DuLhl9K1pbEW8O9Jg7emajtJ52IVtqr60ARxpcxrgEj8c07+0LyE45YU24ndHITcR64pokMnDH8aANK21YtgS8ZrQW/WPDCYAHmsUWsGwtu5qpJ8pw2CM4oA6+LxclqCAd59azNV8YTTg/LGFrnLqG2ZMl9p9QazvsscjFVuGYdcUAaNzrpkYn5S1RjUbu4XYFGz1FZ5slRslia0LW6SNAmxiOnAoAhfTftLfMxya19M8LDIkzjHqKn06RHYMsZ49q3I7lvL2ouc9gKAKUkkWnqEJBI9KSK+jmOFANQ6mm3DSW0gyOuKp2s9puImjdR9aANC/hi8veJgmewrDdk34Zy59zVrUbKK7QfZwyj6msVdOlt5/ljkZvc0AdBZ2rTECKPrVqXR5u6K1Gjy6jCo2WoYVbvtWvEB823ZCRigDldQ063Sc/aUweuAauWLWUIIUAGql4015OWkQj8aGt2jTIC/nQBqMVf5tqn61C+1R91a5+4uZ1baCx+nSn2YuJGG99i+poA0ZonuAQiA+lbngjwnc3Y161uL2SBL/TJYkUDILqySDI+iNz71Rs5lgTiQEjviun8E66R4q02BlWVLiT7MyE4yJFKf1oA86uvB8ltHh9QlPsKz4fDsEcn72ZmOe5rtrpy800Ukbo6Oy4bgjB6Gsu40vafN80A9eTQBnSaVHBEDBx7mmxwl4niJBqpqM92W8uNmKjj5VqzpMUqNmRGyR/EaAPIPElubbV50Ix82ay66/4kW/lazvwPmHauRPBNACV6l8Pv+SKfFP6ab/6UGvLa9S+H3/JFPin9NN/9KDQB5bRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUkCGSZEHUsBUdbvguwOpeJbG2UZ3SCgD6K8J6ZJp3hi1GNu5RWvGzbfmXIrrbnw1MthaW7cfIMAfSrFv4OlSIu7ZCjODQByUFxEvytHV1LZZo96YI64NSXtvHayMPKZsegqBLnzf3cKuhPquKAOp0MwWXhmdn/AHbXN2iKMf3Rk12Wna2ttar9qQmI9GUZrzfT9WksbZLS+06G9tRL5o3sysCRg4I/rXRafremTLta3vIYx1xOGx+GKAL/AIiv7K6cPaAgnrgYzUvhrWWjuEhZ/wB23BDVmxzaJPLtbULlG/vPCAK2rDw7a3Sq8d4knfKAj+dAHW3EkawsXZMYyMnrXinim1u7m9kMVumCewr02fwwGQiO6k3ds9KzV8KX4mDNeK6Z6MucUAeLSaHeNITJb4J9KvWXhxsAyRn+le43Ph+1SHKB9wGCRXLalZTQllQoUH4GgDza/wDD1u0RAjw/sK56Xw66k7WIGe4rvbqR/PYb+QcdaCiLFumkTGO5oA89fSpIQS/zAdcCq7QQgHG4GuxvtS0+Jtm5SfYZrLna2uc7Ez7igDm5JI0GNozVdp5Af3TLj0rUvbWPJycVTWwSXISbB9qANzwBp8PiLxPYaVqEkiRXBcM0LAMMIzcZBHYdqf4S0Sx1vxnLot7c3METmWOCSJgD5i5K7sg5GAeOPrWX4W1A+EPFNprAgN39mLnyvM2btyMvXBx97PTtVSbW7dNct9S0Szv7O7juftLGe7SZSd27AAjTHPqTQBvXvhMaZ4KTUtSuLpNWuL17aCAMBGETIdmBGSdwI6jqK5+504+Sm6Ulj68Vq/FHxbe+L9Rs7mC3j0+3toyqweZ5nzMxLNnA68du1cpa3VxJhbq5RwOgAxigBL7T7hF+Y7lz25qnaiaKTi3IHqa6SzntsgSSZH1rWxp/lg7l/OgDmo8kgyg4q9D5CgN5eR7iprgWryfuySPatrSzZx24E4XHuKAIbHVLGGBkJCuegpI78xyBhHlc8Gl1GexDf6Ioz7R/1qtFdS7x+63D3oA6G41uO8t0iEB3YxkisebSFkYyJgE9iasLlowRCwY+lUplvg37qOXHsuaAL1tZzrgOyBaS+RbdDJ5icVksblWJuI5PxBFQzSQsmDEAvuaALlr4l+zvsBUD3p+qagt+QVOSawT/AGcjkufm9qcLy3PETNj1BoA3NO06CV83GFX61cl0q2ZsRSiodO0vVGCSJpOoyq+Cp+zuQ2ehzjGK3ZND1uKYQzacIH6HfcRLt+vzUAYh0FAu5ZBn6Cov7JMeTtD4ram0lkujBNrei2+1isj/AGovtP0C8/gaqQw6THckXnitWhXIP2aycsfTBY4oAxZ4JMYCACn6WI7K+t7nzPKkilSQOpwVwQcg9q0J9d8JWySGf+3707TsiCRxfN7sM1hDxVoaxz/Z/Cs88zrtT7bfsyIe5wgU/rQB1vjeK3tfE2oqjpIHk81XXowb5gf1rmWkt8/PzxVa6vdQ17UpL66SODzAoEUWdqhRgAZ56AdavQJHbIDIASB3oArs8TtiKFseuKWYW8afPjd6UlxdGYlYIzj1rGuZPLY+Y3zemaAOK+JkLOI51T5Qeted16z4zP2nR3XH3RkV5Pgg470AJXqXw+/5Ip8Uvppv/pQa8tr1L4e/8kU+Kf003/0oNAHltFbHhxtESec+Ior2SAwuIRZsqsJcfKW3fw561kGgBKKKKACiiigAooooAKKKKACiiigAr1X9nPS4tR+IVmJx8isM15VXsPwKh8m5kuwWRlPBBwaAPul7C3eRXZMlRtH0qrqelR3SfI5iYDjHSvPvCXi9/PC39zK0Y4ya6zW/ENnHZiWCYSnGQAaAFHhtDk3Txso7kVBfWuiW0QWTy1I7jmuB1LxHeTyHyrhgpP3TTrG8knP79gTQBs6np1hPGXsZwzema5G+sLqKX5BxnjFb48wsPJEWT6HBq3dW93HD5tx5WMfjQBxyXE8B/wBIiLD+VdR4e1GZ5FFozBh2bisHU7xy2AsbCswX8kD5SR0b2agD3/SJrmWIfaWQn2PNaDEKpJOAK8b8K+KZUmCzzsB6lq9TstQsr+0UC4jcMOQWwaAH3mq2ltEzSPnHYAmvP77xTb3d2scqpIqk7d8eeD1Fdxc6JbzxkRySLnOPmyKwrjwoI5xKsUUoBz6UAYWraXp9wFu4dGWTdjcsUrLXL6npdg0shNpqsERORGGUhR6c16/baituBEbQRAcfK4xUt9ptjqsX70AEjkq3NAHgEmkaJDIDJHqijPPzpwM81duE8KRxbbXUtRWTPWW2UjH4Gu61jwzpUE5RrjLem7Nc7faFYwAuoEi/SgDjLuHRGGf7WvD9LHP/ALNVe0stCmnEba9PaqQf3s1gwUexIYn9K3bm1sHDLHGqN7DFYd5aKmSQSKAC90DSjKv2LxTYXKFclpIpUIPpjaaq/wBgWsWf+J1pePcSj/2Smwz20DgmPn1NWGlt7kD59n0oAW28JrqiM9v4i0FFU7SJbkxH8A4BNU5vAF2zyKmpaVKASA6ahFhh6j5qoalaAP8Au3DDsSM1DDEExvmK/QYoAfN8PdU3YW803Gf+gjD/APFVq6N8OruZnF3rGkWyqRjzNQjO76bSapxbN2FLN9asSWyumS4B9KAN9vB9hYRuJNc0wyL1ZXZ1/AhSDVODTbJpQv8Ab2mEf9tP/iK52YeS2ASQD3JqzbxecNysqEetAHoFt4Z0SS1EkviG3EmCSscDt+RwM1g3VpolvL8usXWQf4bLP/s1YEttfHhJpFX/AGTTY7WWFszHf+FAHVaWdLklVTqd4V75sccf99V2iT6DZ2he2N/cMMfK8arx3ryYSHOI9y/jWff6nrNtkW06BPc5NAHqOo6poV2CJrW6U9zuQVlNB4YMMwi06W8nY5QzXG1VHcfLXlj6jqU7H7Q6k+uKs2j3GctIxz2BxQB1+tahZ2drFFZ6Fpdvszl3QzO/1LVUh8Wa5cR28Ftdi0ghQRxx28CxqF+mKyAjyHDYP+8Sa07S3KJn5aANcyalqMqzahqt3LIFCgl8YHpxUk9hA25nuWdyOdxyTWU7FmO6UgZ7Gp4pQqfIys2O5zQBialbeSxwhIPc1nRpJJJgDg1qahcXDud4TaOnHNUWmfaQoOfagCZbCPGbiVV9qimOn2v3SGNUbjTbu5O7zHAPbNEekNEv7x8n3oAsx6wT8sMZC/SrZugyhpj3zyazHRYhgsgHTiq89zDGnXJA7UAdD/aUKoVgG5yOwrDvi3ml3jUZ96xLnU5kP7mPHoScVXW+up2yx3GgC5qiNc2cinA4ryuaHZdyIR0Jr09JXbKyNgH0rgtfhEGoOQMA0AYsnDt9a9Q+H3/JFPin9NN/9KDXl8hy7E+teofD7/kinxT+mm/+lBoA8tooooAKKKKACiiigAooooAKKKKACiiigBQMkAdTxX0F8LNOaz0MStC3zjPSvCNJgNxqVvEBks4FfWnhof2V4ftVeEkFBxj2oAr6fqC28uGDDnoa1ru4Z4g8DqR6CsXUbuCWQn7Pg/SobG5jWUKCVU0AWWuJy2Qy/lmr9lfNGwMoIx/s8GrX9nWs8JeOUA4zwaw72Q2ZKtIWX2oA66PUY5wCFCkdCtF/d3LW+1ppHTHA9K8/lvMjMFy0bfXihL3UunnJMv60AWtSunjkJWZwf7pU1nNetK3z8n6Gr0kyYUzgq/oans9SsoJAZokYeuKAKCR3Tcwxz4z/AA81oWGpX2nOGkFwyjtg10+l6xYMR5IQZ7dK7LRNW0pXAvbddnqVzQBxFn8RJ7bAWW7QD+FlJFa0fxBurxSBNP8ARRj9MV6fYf2BdAfZUsnJ7bRn9auvo+myctY2x+kYoA8dm1Rbof6Wt4Se6kiiG5aHJsbrUFz2c5r2EaNp4GBaRflTToemk5+yRA+woA8V1S6vDHveJ3f+/wB65uXUtVJKI0oX0219JDSbBRgWsX5UPpGnsMG0i/75oA+Y0bUS24o34rV62tbm7CrMWUfSvatf8J2rwvLAmwjn5egrzq9iubZitsofHGKAOan8LxSAn7RIp9Kyrrw9c2+TC5dRW3qWo6nAOLT9Kx/+EovFYpNb4A68UAZclrcqSHwKnsNPE0mJpFrRTVBdnIhUZ9RVxVKgO0Sc+lAF2w0Sy2gkjPrV6XQLHytyyxhu+a566vSoKplT7VTWeRm+ZWYHvmgC5qVhZxSfMS/PVa2dA0+xlXCrGD2Lms+xsorwAGNt5PrSaho8lodyll9CDQB1d54ZcqGili2Vk/YoLV8XWxsdgK50X1/DhTcylRxjdT5LsSJhyWY9yc0Ab80WjOpDBQfQVxuvQ23mn7Ivy5q/CrlgRGZB6iq2qRSMQFt3QDg5FAHMSIYyd2Pzq1YZcjCZrStbGMtmdAPc1Jdm1tI2KyIoA65oARk8m33lQDWa+otyN361hapr8e4xxO7+4NUra4e4+ZW2jvQB0c16c/OWUfWn2+rWsH+scgeprnJ5mQYQgt7mqIsZ798TTbUPYcUAdXceJNHRj5k+ce9Vz400hciCN5W6YUdayE8M6Wi5mO49yTTPsVhaMBboCR7UAb0fima4H7iwkA7Fqiub69uFz5ZUegNUIbt14iiLVajS8u8KV8tTQBCtvPM2HZV9y2TV/wCw28EO5yHahNLMXJlJPXk1KwBG0sPxoA5jVZBLIQiEAHAxUVpFKW+VSa6caSs5zmmT6aYeISuR3oAzYrCTeC+Fya5Px5p/2aRWUEg967RtPu3ky11tHtWL4z09habnlMhA70AeXt15r1H4ff8AJFPin9NN/wDSg15jcDEzj3r074ff8kU+Kf003/0oNAHltFFFABRRRQAUUUUAFFFFABRRRQAtFJS0AdB4IiEmv27PjCHNfRZ1oi2iiWQfKAAK8H+H1kJXnuO6MigfUH/CvRmZ0xsy3tQB1w1aNm/eICPWlnvrWSLCRgP6iuYtb/awEtu+31xWoL/TY1y52sfXigBWvL2I/wCjucehqtc39y4xPFz6k1WutSJb/RwrKemDVSS/nYfvEJHSgCwHuSQVVSPStO2neNf3kRU+orBivcP3BzWxBqG5ADhhQBLNc+ccM4z7iq80Yh+ZirA+nNLcpFKNwGG9Kz9yq4DEj60AaVhKPMDRL8wruNHuLprYiWXHHQiuL0tY1IkEiHv1rpre/EadQfoaANWO4mSXAC5z16V2fh4X10FSG5eMnuJDXBW+qwMcMgJroNOv5oWR4MjHIxQB6hYR6xZuomY3MXcFhmtyGRpFy0bRn0auY0LxVbvbhL2QrJ646101tcRXMQkgcOvqKAJaKKKAIL63FzbvGWkUEfwHBrz3VfDUNu5kZ71B9Mj8xXpNBGetAHi9zagKwWSWRemGWuF8RWoSRmWOXPX7vFfTb2lu7FmhQk+1QXdlpzRFbqGDZ6PigD5HM0/RI/zqaFdQYj5yB9a+htS8H6FqEn+iSRxSHsBkVmSfDx4STF5ToOeOtAHkFrplzIcyyNikufOtRj5SB3PWvSNV0uDT0ZZEKsK47VoYbgFYQ26gDAg1meCTdGRuFdDa+I5Z4tt3AGHqBWdp3hW9upQyLlM+tdhb+HIbaJRcIwP0NAHIX8sUpPloUBrJmjwpKyAGvRZNFsCGzGCcdTXJaxocQkby5do9KAMGG/uLRv3b5HtVmfVp7lQr4Tjr61BNpQjUnz1zVL7LcbgBJ8tAErxbiWa4fn0NZWoRQEkSFivfca35bWNLUfvV8zHrXHawXEpQvlfagCvP/ZsXULmse+1GGMFbYYHarTWts4LSBsjpWXdWu98RKQPWgDMmvbp5Dsc1Na3GpAjbIQPepvsDx/Ng8e3WlHmKMAN+VAGlb3UyqPtM34VftbtJG2xx7m+lYUUc8jD5SRmus0CHynUtGx/CgC7YwStg+Uwx7Vs28SLjdnPpWhbXa/ZinkMOMZxUMl3ZWyb5V5HXNAFC/Bwdi1kpA3mEs2BUuo+K7UkrDGxHrVW11a3lJZ1b6YzQBpRrJwqzECntbbRukuQPxqub6HHyxn8azNQHnr+7YLnnigCzfSwrkC5yfrXP6qY5ImG8scdzSiwd3xvz71cXRY/LYyzAcUAeU3Yxcyj/AGjXpfw+H/FlPilx203/ANKDXCa1YiDXZrYyCNGcbZJOgU9zjtXpnhSDQ9L+HXjTQ7rxfof2zWRZ/ZivnlR5Updtx8vjg8UAeT6fp15qM/kWFrcXU2CfLgiaRseuACaNR06802fydQtLi1mxu8ueJo2x64IrbtdT1HwRrrzeG/EEZufLx9s09m2kEcrllB+vFUPEfiPV/Et/9u17UJ7+7CCMSzHLbR0FAGRRRRQAUUUUAFFFFABRRRQAUoOOvSkooA3tJ1drK3WFd8ZDF/MibaxJA4PYjj9TW1D46vrRlMZS4jx0mUAj8R1ridx7mkJJ60CsejxfEtyMS2YT/cPFSyeLNP1NcTtsb0YYrzOjNAz1W0msnwYbpA3s9akTt0EuR65zXi4Zh0JH0NWrbUry2A8m5lUA5A3HFAHt1tbtKu5gpHqKurbiAZSRfoa8as/GOs2owlyGHo65rVtPiHexn/SbO3m9MErQB6sLuHAWYKD6imNZpOP3coI9xXARfELT5gBd6bKnqY3B5rStPG+gd5LuHPYpkfoaAOkOggt8shBPdWqyui3FvFvS6lJ9Cc1m2/iPw/clfL1aFHPZiV/mKvQ6hBKoEGr2sq+glB/rQA6O7mt3IbJI71t6dq9w+B5pA9qi022t7g5aUOD3XkVt/wBmWMKF1OMDNAGhYXh48yVifWuu0jxZNpceImWRe6nmvMpdTggJEbqcUxNXjLAlM564FAHtdn8SImcLc2Tj/aU101r4o02eIP5jIfQjpXgNpriKPLjjXJ7uDU8l9eRfvB5bIeRsNAH0PBqdnMPknT0wTirIkjdflcEHuGr5/wBO8VSwMFuR8g64ya1pfE7N89rdiNfRqAPYb67ktVBigecf7JrFvnfVF8o2otnP/LRxk1x+g/ES0tXK6jdiUf7Nauo/ELS3hDWcRkfrkgUAa0Hhq7gPmRakBjnODj+dZOseIdS01XQXcM2ONwUZFcLrHxPvY98eyRIvTFcRqHje2vHbfKyk9hmgDrNT1W8v5S1xKWBPTFT6KLDzl+1ocZ5NcTaeJEBysckv1FaS+JGmXaIPL/CgD2SzufD9lbtIkiFwuQN1cbqviH7TOyx3G1c4AxXEyXjzDAYAn0qOCwu5XLLJ+dAHWiGe5Bb7SDnnmsHUnltpMY8z8ary3t3Y4UyozAYwKzpdSuLhvmjyTQAy6fzCWfC47CqLXqx5AjZiO9WJopCoZlxx61l6hOsaMFcb6AINR1AFTxt9hWE18CxwvJ7mkujI7Es2fpWe7qOAefWgDQOyRczScHstRGSFD8qEgfrVZJVXlwT9KiuLh2JEYPNAD7mcMpA45qGOIueCTUAjnZuXRP8AeYCpFjCcyalaRgeso4oA27DTp5ioVlArorPTJoADI7N9OBXMWOu6Rpqh7jWo5sdUhjZjWhc/EzQ44tlvFdzHGM7Ao/U0AdZGwRCpbb+NVpLS0ujmeRn9uwrzS++IKyMTb2T9f+WktZMvjnUyxMCwxqegILEUAe0Wfh2ylwViUL9Kvy6XpdnEA0sEZ77mAxXgE/jXX5AQNRljU8YT5axrvUb27bddXU8reruTQB77d3nhm13Nc6jAe+FYGuO13xj4fhLJpyzTt/eC4FeUkk9TmjtigDq5vFszMTBEo543GhfE84iDSXMwkPVY1Cge2e9cnTtx9aANHWb/APtK7W4dNjFQpwc5x061nP1+nFBYnrSE5JNABk0lFFABRRRQAUUUUAFFFFABRRTo1DHBoAbRRRQAUUUUAFFFFABRRRQAUUUUAFLSUUALQCR0JFJRQBMtzOn3JpF+jEVdi17VogAmpXiqOwmbH86zKKAN6LxbrUeMXznHPzAGtmw+JviKyI8qa3bH9+FTmuIooA9Xg+OHiBABLY6TK395rfH8q0LT486kmBc6LpzjvsUrXjFFAHtbfHASyZl0KIDvtetvSPjb4VXH9q+Grt/XypQK+eaKAPpqT4zfDSUAP4R1EH1WVQf501fip8LX5Gj65bt/sSA18z0UAfRd78SPh/cZVY9VVOmHAJrCufFngUsWtnvgevzx14kOOlFAHsZ8daDGMQyTH0Gyq0vxB07nyml/74rySigD1KP4h26Pk+aV9hzWxB8WdOhTa1teOf8AeArxWigD167+KOmzSFlsLn8WFQj4sRwEfZ9M3Y/vtXk9FAHp+o/Fe4u49qaZDFx2Y1yd54rvLmUuVVc+lc5RQBqvrl4xyHxTf7bvsYEoH4VmUUAX5dWvZRhrh8e3FVnuZ5PvzSN9WNQ0UAPaR26sx/Gkz9c02igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKkh+8fpUdSQ/eP0oQEdFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFSQ/eP0qOpIfvH6UICOiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACnI205xmm0UAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    As indexed by the color bar on the right side, the flow toward the transducer is encoded in red and flow away from the transducer is encoded in blue. Note the mosaic color pattern in the LVOT indicating aliasing because of the high velocity of the blood flow.",
"    <div class=\"footnotes\">",
"     RV and LV: right and left ventricles, respectively; IVS: interventricular septum; RVOT and LVOT: right and left ventricular outflow tracts, respectively.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dev Maulik, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_26_27042=[""].join("\n");
var outline_f26_26_27042=null;
var title_f26_26_27043="Patient information: Genetic testing for breast and ovarian cancer (The Basics)";
var content_f26_26_27043=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16187\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?3/34/3627\">",
"         Lifetime risk of breast and ovarian cancer for women with BRCA mutations",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/19/2357\">",
"         Patient information: Breast cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/59/19379\">",
"         Patient information: Breast cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/63/10227\">",
"         Patient information: Cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/1/11283\">",
"         Patient information: Ovarian cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/14/27874\">",
"         Patient information: Ovarian cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/56/12167\">",
"         Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/40/36481\">",
"         Patient information: Breast cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/6/44134\">",
"         Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/15/30963\">",
"         Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/31/499\">",
"         Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/15/6386\">",
"         Patient information: Ovarian cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/genetic-testing-for-breast-and-ovarian-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H21044223\">",
"      <span class=\"h1\">",
"       What is genetic testing?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Genetic testing is a way in which doctors find out if you carry certain genes. Genes are basically the body&rsquo;s recipe book. They tell your cells how to make different proteins, and they give your body instructions about how you should look and how your body should work. Unfortunately, genes can sometimes have &ldquo;mutations,&rdquo; mistakes in the recipes that change the way your body makes proteins. These mutations can sometimes put you at risk for disease.",
"     </p>",
"     <p>",
"      There are genetic tests that look for specific mutations that are linked to all kinds of diseases. But this article is about mutations that increase the risk of breast and ovarian cancer specifically.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21044230\">",
"      <span class=\"h1\">",
"       Which genes affect a person&rsquo;s risk of breast and ovarian cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are probably hundreds of genes that affect a person&rsquo;s risk of breast and ovarian cancer. But for now, doctors focus on 2 genes that seem to be very important. They are called BRCA1 and BRCA2.",
"     </p>",
"     <p>",
"      People with certain mutations in either of these genes are at high risk of breast or ovarian cancer. Even men who carry a BRCA1 or BRCA2 mutation have an increased risk of breast cancer.",
"     </p>",
"     <p>",
"      Genes are passed down in families, so women who have family members with breast or ovarian cancer sometimes have genetic tests to find out if they carry abnormal versions of the BRCA genes. By having these tests, women can find out whether they need to take special steps to protect themselves from cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21044237\">",
"      <span class=\"h1\">",
"       Should I have a genetic test for breast and ovarian cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors recommend genetic testing only for women who have a strong family history of breast or ovarian cancer.",
"     </p>",
"     <p>",
"      Testing might make sense for you if you fit any of these descriptions:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        You have 2 or more close relatives with breast or ovarian cancer, especially if 1 or more of the relatives were diagnosed with cancer before they turned 50. (Close family members include your mother, sister, or daughter and can include men with breast cancer, such as your father, brother, or son.)",
"       </li>",
"       <li>",
"        You have a close family member with more than 1 cancer, such as cancer in both breasts, or cancer in the breast and the ovary.",
"       </li>",
"       <li>",
"        You have family members from different generations with breast or ovarian cancer. (For example, your grandmother, mother, and sister, all with cancer.) Family history on your father's side is as important as your mother's side.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Keep in mind, though, that having a strong family history of a disease does not always mean you have abnormal genes. Most women with a family history of breast or ovarian cancer do NOT have an abnormal gene. What&rsquo;s more, not all women who have an abnormal gene get cancer.",
"     </p>",
"     <p>",
"      If you are thinking about genetic testing because a family member has cancer, see if he or she is willing to be tested first. If he or she does not have an abnormal gene, it does not make sense for you to be tested. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21044244\">",
"      <span class=\"h1\">",
"       What should I do before I get tested?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before you get tested, talk with a genetic counselor. A genetic counselor is a person who can help you understand what the results of the test could mean for you and your family, and what costs might be involved with getting tested. He or she can also help you deal with the feelings you have about being at risk for cancer. Plus, after you get tested, a counselor can help you understand your results. The results are not always clearcut.",
"     </p>",
"     <p>",
"      You can find a list of trained genetic counselors by going online to",
"      <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/genetics/directory\">",
"       www.cancer.gov/cancertopics/genetics/directory",
"      </a>",
"      .",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21044251\">",
"      <span class=\"h1\">",
"       What if I test positive for BRCA1 or BRCA2?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you test positive, try to stay calm. Finding out you carry a mutation can be scary. But there are ways to lower the chances that you will get or die from cancer. And remember, not everyone with a mutation gets cancer.",
"     </p>",
"     <p>",
"      Ask your doctor and your genetic counselor what your results mean for you. Then ask what you can do to lower your chances of getting or dying from cancer. If you are a woman, this table shows what your lifetime risk of breast and ovarian cancer might be (",
"      <a class=\"graphic graphic_table graphicRef57666 \" href=\"UTD.htm?3/34/3627\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      If you test positive for a BRCA1 or BRCA2 mutation, tell your family about the results. Some family members might also want to get tested.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21044258\">",
"      <span class=\"h1\">",
"       How can I lower the chances that I will get cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have a BRCA mutation, you can lower your chances of getting breast or ovarian cancer by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Getting screened for breast and ovarian cancer often. This will not keep you from getting cancer, but it will increase the odds that you will find it early, when it is easier to treat.",
"       </li>",
"       <li>",
"        Having your breasts and ovaries removed. (For the biggest benefit, the ovaries should be removed by age 40.)",
"       </li>",
"       <li>",
"        Taking medicines that help prevent cancer",
"       </li>",
"       <li>",
"        Combining some or all of these choices",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21044265\">",
"      <span class=\"h1\">",
"       Will my insurance cover genetic testing?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In the US, most health insurance companies cover most of the costs. But your doctor or genetic counselor might need to write a letter to the insurance company to explain why you need testing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21044272\">",
"      <span class=\"h1\">",
"       Can the results of my test keep me from getting insured?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. In the US there is a law that prevents companies from using a person&rsquo;s genetic tests to make decisions about insurance coverage or employment.",
"     </p>",
"     <p>",
"      The law means that:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Employers can&rsquo;t deny you a job or fire you because of the results of genetic tests",
"       </li>",
"       <li>",
"        Health insurers can&rsquo;t use genetic test results to deny you coverage or set your insurance rates",
"       </li>",
"       <li>",
"        Employers and insurers can&rsquo;t force you to have genetic tests",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21044399\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"       Patient information: Breast cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/1/11283?source=see_link\">",
"       Patient information: Ovarian cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/59/19379?source=see_link\">",
"       Patient information: Breast cancer screening (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/14/27874?source=see_link\">",
"       Patient information: Ovarian cancer screening (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"       Patient information: Cancer screening (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"       Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link\">",
"       Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/6/44134?source=see_link\">",
"       Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=see_link\">",
"       Patient information: Breast cancer screening (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/31/499?source=see_link\">",
"       Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=see_link\">",
"       Patient information: Ovarian cancer screening (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/26/27043?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16187 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_26_27043=[""].join("\n");
var outline_f26_26_27043=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21044223\">",
"      What is genetic testing?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21044230\">",
"      Which genes affect a person&rsquo;s risk of breast and ovarian cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21044237\">",
"      Should I have a genetic test for breast and ovarian cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21044244\">",
"      What should I do before I get tested?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21044251\">",
"      What if I test positive for BRCA1 or BRCA2?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21044258\">",
"      How can I lower the chances that I will get cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21044265\">",
"      Will my insurance cover genetic testing?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21044272\">",
"      Can the results of my test keep me from getting insured?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21044399\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16187\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/34/3627\">",
"      Lifetime risk of breast and ovarian cancer for women with BRCA mutations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=related_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=related_link\">",
"      Patient information: Breast cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/59/19379?source=related_link\">",
"      Patient information: Breast cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=related_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/6/44134?source=related_link\">",
"      Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=related_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/31/499?source=related_link\">",
"      Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/1/11283?source=related_link\">",
"      Patient information: Ovarian cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=related_link\">",
"      Patient information: Ovarian cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/14/27874?source=related_link\">",
"      Patient information: Ovarian cancer screening (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_26_27044="Aortogram normal aorta and infrarenal aortic aneurysm";
var content_f26_26_27044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 615px\">",
"   <div class=\"ttl\">",
"    Aortogram normal aorta and infrarenal aortic aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 595px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal aortogram (A) is contrasted with the aortogram of a patient with a large infrarenal abdominal aortic aneurysm. The arrows point to the right renal artery in both images.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_26_27044=[""].join("\n");
var outline_f26_26_27044=null;
var title_f26_26_27045="Suction curettes";
var content_f26_26_27045=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Suction uterine curettes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) No. 16. (B) No. 12. (C) No. 6.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_26_27045=[""].join("\n");
var outline_f26_26_27045=null;
var title_f26_26_27046="Trichiasis and sequelae";
var content_f26_26_27046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cicatricial disease: trichiasis and its sequelae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 271px; height: 539px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) WHO grade TT. To make a diagnosis of TT, there must be evidence of at least one ingrown eyelash touching the globe, or evidence of epilation (eyelash removal). Trichiasis occurs when eyelid conjunctiva scar tissue contracts, distorting the lid margin and causing the eyelashes to rub on the cornea. Panel B) Pannus. Pannus is the growth of vascular tissue over the cornea as a result of edema and ulceration due to eyelash abrasion on the cornea. It is a hallmark of trachoma but is not assessed in the current grading system. Panel C) WHO grade CO. To make a diagnosis of CO, there must be evidence of corneal opacity blurring part of the pupil margin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_26_27046=[""].join("\n");
var outline_f26_26_27046=null;
var title_f26_26_27047="Inborn errors of metabolism: Classification";
var content_f26_26_27047=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inborn errors of metabolism: Classification",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/26/27047/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/26/27047/contributors\">",
"     V Reid Sutton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/26/27047/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/26/27047/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/26/27047/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/26/27047/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/26/27047/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/26/27047/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital metabolic disorders result from the absence or abnormality of an enzyme or its cofactor, leading to either accumulation or deficiency of a specific metabolite (",
"    <a class=\"graphic graphic_table graphicRef82924 \" href=\"UTD.htm?39/44/40651\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56040 \" href=\"UTD.htm?8/23/8572\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef69937 \" href=\"UTD.htm?8/13/8411\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74261 \" href=\"UTD.htm?21/62/22507\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63392 \" href=\"UTD.htm?7/60/8140\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef86411 \" href=\"UTD.htm?24/12/24780\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The major classes of IEM and their characteristic clinical and biochemical features are described below. The epidemiology, pathogenesis, clinical presentation, evaluation, and initial management of IEM are discussed separately, as are specific disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13177?source=see_link\">",
"     \"Inborn errors of metabolism: Identifying the specific disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional classification system for IEM groups the disorders according to the general type of metabolism involved. Some diseases fit into more than one category. These major categories can be further grouped based upon similarities in pathogenesis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    presenting features (",
"    <a class=\"graphic graphic_table graphicRef82924 \" href=\"UTD.htm?39/44/40651\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peroxisomal and lysosomal storage disorders, for example, often have characteristic clinical features and permanent, progressive symptoms that are independent of triggering events (eg, anemia, thrombocytopenia, and hepatomegaly in a child of Ashkenazi Jewish ancestry is suggestive of Gaucher disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other categories of IEM (amino acid disorders, organic acidemias, urea cycle disorders, disorders of carbohydrate metabolism, fatty acid oxidation disorders, and mitochondrial disorders) may be considered in two broad categories [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disorders of acute or progressive intoxication or encephalopathy &mdash; Signs and symptoms in these disorders are caused by accumulation of toxic compounds proximal to the metabolic block. Patients typically present with a symptom-free interval followed by clinical signs of acute or chronic intoxication with progressive or recurrent metabolic disturbances. This category includes amino acid disorders, most organic acidemias, urea cycle disorders, and disorders of carbohydrate intolerance (eg, galactosemia, hereditary fructose intolerance).",
"     </li>",
"     <li>",
"      Disorders associated with energy deficiency &mdash; Signs and symptoms in these disorders are caused at least partly by a deficiency in energy production or utilization in the liver, myocardium, skeletal muscle, or brain. Disorders in this category also may have signs or symptoms related to accumulation of toxic compounds. This category includes disorders of glycogenolysis and gluconeogenesis, fatty acid oxidation defects, disorders of ketogenesis, and mitochondrial disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major categories of IEM are described below, with examples of representative disorders. Individual clinical and laboratory presenting features of IEM are discussed in detail separately, as is a detailed discussion on initial and specific diagnostic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13177?source=see_link\">",
"     \"Inborn errors of metabolism: Identifying the specific disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Amino acid disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amino acids are important for the synthesis of numerous compounds, including structural proteins, peptide hormones, and enzymes needed for gluconeogenesis or in the generation of energy via acetyl-CoA formation. Of the 20 amino acids, eleven can be synthesized in vivo and nine cannot. The nine that cannot be synthesized in vivo are called \"essential amino acids\"; their bioavailability relies completely upon dietary intake (",
"    <a class=\"graphic graphic_table graphicRef61661 \" href=\"UTD.htm?2/3/2108\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Amino acid disorders (also called amino acidopathies) are caused by a defect in the metabolic pathways of amino acids. They are called amino acidemias when there is abnormal accumulation of amino acids in the plasma and amino acidurias when there is abnormal excretion of amino acids in the urine. Symptoms typically result from accumulation of the substance that cannot be metabolized. Examples of amino acid disorders include maple syrup urine disease and phenylketonuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27590?source=see_link\">",
"     \"Overview of maple syrup urine disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=see_link\">",
"     \"Overview of phenylketonuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Amino acid disorders often present in newborns who are initially well and become acutely symptomatic (metabolic decompensation with poor feeding and lethargy) after a period of protein feeding. The symptoms may progress to encephalopathy, coma, or death if not recognized and treated promptly [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/2\">",
"     2",
"    </a>",
"    ]. In older children, developmental delay or regression is usually present. Many amino acid disorders can be detected by newborn screening using tandem mass spectrometry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2088?source=see_link\">",
"     \"Newborn screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biochemical findings that may be present in amino acid disorders include metabolic acidosis, hyperammonemia, hypoglycemia with appropriate or increased ketosis, liver dysfunction, and the presence of reducing substances in the urine (",
"    <a class=\"graphic graphic_table graphicRef76373 \" href=\"UTD.htm?37/63/38908\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Confirmation of diagnosis involves measurement of quantitative plasma amino acids and qualitative urine organic acids and enzyme analysis (",
"    <a class=\"graphic graphic_table graphicRef73440 \" href=\"UTD.htm?12/14/12526\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Organic acidemias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organic acidemias, also known as organic acidurias, are characterized by accumulation of abnormal (and usually toxic) organic acid metabolites and increased excretion of organic acids in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/6\">",
"     6",
"    </a>",
"    ]. A variety of disorders may result in abnormal urine organic acid profiles, including organic acidemias, phenylketonuria, maple syrup urine disease, certain fatty acid oxidation disorders, disorders of ketogenesis, and mitochondrial disorders (",
"    <a class=\"graphic graphic_table graphicRef50227 \" href=\"UTD.htm?12/23/12669\">",
"     table 10",
"    </a>",
"    ). Examples of organic acidemias include methylmalonic acidemia and propionic acidemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"     \"Organic acidemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most organic acidemias become clinically apparent during the newborn period or early infancy. After an initial period of well-being, affected children develop a life-threatening episode of metabolic decompensation with poor feeding, vomiting, and lethargy. The symptoms may progress if not recognized and treated promptly. In older children, developmental delay or regression is usually present.",
"   </p>",
"   <p>",
"    Characteristic biochemical findings of organic acidemias include metabolic acidosis with increased anion gap, mild to moderate hyperammonemia, sepsis-like features secondary to bone marrow suppression, and ketosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/3,4,6\">",
"     3,4,6",
"    </a>",
"    ]. Other biochemical findings that may be present include hypoglycemia, liver dysfunction, and secondary",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency (",
"    <a class=\"graphic graphic_table graphicRef76373 \" href=\"UTD.htm?37/63/38908\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Confirmation of diagnosis involves measurement of quantitative plasma amino acids and qualitative urine organic acids and also may include acylcarnitine profile and enzyme analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/3,7\">",
"     3,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Urea cycle disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urea cycle is the metabolic pathway that transforms nitrogen to urea for excretion from the body (",
"    <a class=\"graphic graphic_figure graphicRef60652 \" href=\"UTD.htm?2/49/2832\">",
"     figure 1",
"    </a>",
"    ). Deficiency of any of the enzymes in the pathway causes a urea cycle disorder (UCD). Examples of UCD include ornithine transcarbamylase deficiency and citrullinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=see_link\">",
"     \"Urea cycle disorders: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19225?source=see_link\">",
"     \"Urea cycle disorders: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    UCDs often present in newborns who are initially well and become hyperammonemic after a period of protein feeding. However, patients with partial enzyme activity may present later. The characteristic biochemical findings of urea cycle defects include hyperammonemia, respiratory alkalosis, and ketosis (",
"    <a class=\"graphic graphic_table graphicRef76373 \" href=\"UTD.htm?37/63/38908\">",
"     table 8",
"    </a>",
"    ). Liver dysfunction may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The diagnosis of UCD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=see_link\">",
"     \"Urea cycle disorders: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Carbohydrate disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of carbohydrate metabolism can lead to hypoglycemia, liver dysfunction, myopathy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiomyopathy. These disorders include deficiencies of enzymes in the pathways of the metabolism of glycogen (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"     figure 2",
"    </a>",
"    ), galactose (",
"    <a class=\"graphic graphic_figure graphicRef50614 \" href=\"UTD.htm?43/16/44301\">",
"     figure 3",
"    </a>",
"    ), and fructose. Examples of carbohydrate disorders include galactosemia and the glycogen storage diseases (",
"    <a class=\"graphic graphic_table graphicRef56040 \" href=\"UTD.htm?8/23/8572\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=see_link\">",
"     \"Clinical features and diagnosis of galactosemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with disorders of carbohydrate metabolism may present with lethargy, encephalopathy, and hypoglycemia during times of decreased carbohydrate intake or fasting; hepatomegaly is sometimes present [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristic biochemical findings of carbohydrate disorders include hypoglycemia and ketosis (",
"    <a class=\"graphic graphic_table graphicRef76373 \" href=\"UTD.htm?37/63/38908\">",
"     table 8",
"    </a>",
"    ). Metabolic acidosis, liver dysfunction, and nonglucose reducing substances in the urine may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Nonglucose reducing substances are usually present in disorders of carbohydrate intolerance (eg, galactosemia, hereditary fructose intolerance) and usually absent in disorders of glycogenolysis and gluconeogenesis.",
"   </p>",
"   <p>",
"    Confirmation of diagnosis of disorders of carbohydrate metabolism typically involves DNA analysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    assay of enzyme activity in cultured skin fibroblasts, liver, white blood cells, or red blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/3,7\">",
"     3,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fatty acid oxidation disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial fatty acid oxidation plays an important role in energy production, particularly during fasting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/8\">",
"     8",
"    </a>",
"    ]. Examples of fatty acid oxidation disorders include MCAD deficiency, fatty acid transportation defects, and defects of beta-oxidation enzymes (",
"    <a class=\"graphic graphic_table graphicRef86411 \" href=\"UTD.htm?24/12/24780\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=see_link\">",
"     \"Etiology of hypoglycemia in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with disorders of fatty oxidation metabolism may present with lethargy and encephalopathy during times of decreased carbohydrate intake or fasting; hepatomegaly is sometimes present [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/2\">",
"     2",
"    </a>",
"    ]. Characteristic biochemical features of fatty acid oxidation disorders include hypoglycemia with inappropriately absent ketosis and liver dysfunction (",
"    <a class=\"graphic graphic_table graphicRef76373 \" href=\"UTD.htm?37/63/38908\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Hyperammonemia and metabolic acidosis also may occur.",
"   </p>",
"   <p>",
"    Diagnosis of fatty acid oxidation disorders involves plasma acylcarnitine analysis followed by confirmation through enzyme or in vitro assay in cultured skin fibroblasts or other specialized diagnostic testing, such as DNA mutation analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/3,7\">",
"     3,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mitochondrial disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of recognition of disorders of mitochondrial metabolism is increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Within the mitochondria, organic acids, fatty acids, and amino acids are metabolized to acetyl-CoA, which condenses with oxaloacetate to form citric acid, which is oxidized in the Krebs cycle (",
"    <a class=\"graphic graphic_figure graphicRef67253 \" href=\"UTD.htm?11/55/12148\">",
"     figure 4",
"    </a>",
"    ). Mitochondrial disorders can affect muscle alone, muscle and brain, or multiple systems with variable involvement of the heart, kidney, liver, skeletal muscle, or brain. The genetics and clinical manifestations of defects of the respiratory chain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=see_link&amp;anchor=H4#H4\">",
"     \"Renal involvement in the mitochondrial cytopathies\", section on 'Clinical characteristics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal involvement in the mitochondrial cytopathies\", section on 'Mitochondrial respiratory chain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examples of mitochondrial disorders include (",
"    <a class=\"graphic graphic_table graphicRef69937 \" href=\"UTD.htm?8/13/8411\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytochrome c oxidase deficiency (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11015?source=see_link&amp;anchor=H23#H23\">",
"       \"Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn\", section on 'Cytochrome c oxidase deficiency'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Kearns-Sayre syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/15/20726?source=see_link&amp;anchor=H3#H3\">",
"       \"Myopathies affecting the extraocular muscles in children\", section on 'Kearns-Sayre syndrome'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with mitochondrial disorders may present with skeletal or visceral abnormalities, poor feeding, vomiting, cardiomyopathy, myopathy, liver failure, seizures, central nervous system abnormalities, developmental delay, retinopathy, blindness, deafness, focal neurologic findings (such as choreoathetosis), or renal Fanconi syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/2,4,9\">",
"     2,4,9",
"    </a>",
"    ]. Kidney involvement is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=see_link\">",
"     \"Renal involvement in the mitochondrial cytopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biochemical features of mitochondrial disorders may include metabolic acidosis, lactic acidosis, hypoglycemia with appropriate or increased ketosis, and liver dysfunction (",
"    <a class=\"graphic graphic_table graphicRef76373 \" href=\"UTD.htm?37/63/38908\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Confirmation of diagnosis of mitochondrial disorders may involve either assay of enzyme activity in cultured skin fibroblasts, muscle, or liver, or DNA testing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. Muscle biopsy for routine histology and electron microscopy and magnetic resonance imaging",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spectroscopy of the brain may be helpful in diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Peroxisomal disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous catabolic and anabolic functions in cellular metabolism occur in peroxisomes. Catalytic functions include beta-oxidation of very long chain fatty acids (VLCFA); oxidation of pipecolic, phytanic, pristanic, and many dicarboxylic acids; and degradation of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    by catalase. Anabolic functions include synthesis of bile acids and plasmalogen (an important component of cell membranes and myelin).",
"   </p>",
"   <p>",
"    Peroxisomal disorders are a heterogeneous group of IEM that result in impairment of peroxisome function. Some features of peroxisomal disorders include microcephaly, dysmorphic facial features, hepatomegaly, hypotonia, and neurologic dysfunction to a varying extent. Examples of peroxisomal disorders include Zellweger syndrome and adrenoleukodystrophy (",
"    <a class=\"graphic graphic_table graphicRef74261 \" href=\"UTD.htm?21/62/22507\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link\">",
"     \"Peroxisomal disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of peroxisomal disorders may be suspected in patients with an increased plasma concentration of very long chain fatty acids (VLCFA)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    phytanic acid. Confirmation requires specialized testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link&amp;anchor=H14#H14\">",
"     \"Peroxisomal disorders\", section on 'Approach to diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lysosomal storage disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lysosomes are cytoplasmic, single membrane-bound organelles that contain enzymes responsible for the degradation of a variety of compounds including mucopolysaccharides, sphingolipids, and glycoproteins. Deficient activity of specific enzymes leads to progressive accumulation of partially degraded material, leading to distention of the cell, disruption of cellular function, and, sometimes, failure of active transport of small molecules from the lysosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lysosomal storage disorders (sometime called \"storage diseases\") are caused by defective lysosomal metabolism or export of naturally occurring compounds that leads to accumulation of various glycosaminoglycans, glycoproteins, or glycolipids within lysosomes of various tissues (",
"    <a class=\"graphic graphic_table graphicRef63392 \" href=\"UTD.htm?7/60/8140\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lysosomal storage diseases can be subdivided according to the involved compound or pathway as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mucopolysaccharidoses (eg, Hurler syndrome). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=see_link\">",
"       \"Clinical features and diagnosis of the mucopolysaccharidoses\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sphingolipidoses (eg, GM1 gangliosidosis, Tay-Sachs disease, Fabry disease, Gaucher disease, Niemann-Pick disease, Krabbe disease, metachromatic leukodystrophy, multiple sulfatase deficiency). Several of these disorders are discussed in detail separately. (See appropriate topic reviews).",
"     </li>",
"     <li>",
"      Glycoproteinoses (eg, mannosidosis, sialidosis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H23#H23\">",
"       \"Overview of the hereditary ataxias\", section on 'Sialidosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disorders of lysosomal enzyme transport (eg, mucolipidoses).",
"     </li>",
"     <li>",
"      Lysosomal membrane transport disorders (eg, sialic acid storage disease, cystinosis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=see_link\">",
"       \"Cystinosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other (eg, acid lipase deficiency).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations vary depending upon the location and extent of storage that occurs, but may include progressive hepatomegaly, splenomegaly, neurologic regression, short stature, coarsening of facial features,",
"    <span class=\"nowrap\">",
"     limitation/restriction",
"    </span>",
"    of small and large joints, peripheral neuropathy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. Diagnosis of these disorders usually requires specific enzyme assay on samples of white blood cells, serum, or skin fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/3,7\">",
"     3,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Purine and pyrimidine disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purine and pyrimidine nucleotides are important constituents of RNA, DNA, nucleotide sugars and other high-energy compounds, and cofactors, such as adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide (NAD) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/13\">",
"     13",
"    </a>",
"    ]. The clinical presentation of disorders of purine and pyrimidine metabolism varies widely and may include renal calculi, neurologic dysfunction, delayed physical and mental development, self-mutilation, hemolytic anemia, and immune deficiency. Examples include Lesch-Nyhan disease, gout, and adenosine deaminase deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2488?source=see_link\">",
"     \"Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Porphyrias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The porphyrias are genetic or acquired deficiencies in the activity of enzymes in the heme biosynthetic pathway. They are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link\">",
"     \"Porphyrias: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Metal metabolism disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of metal metabolism include hemochromatosis, Wilson disease, Menkes disease, and acrodermatitis enteropathica (zinc deficiency). These disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"     \"Clinical manifestations of hereditary hemochromatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=see_link\">",
"     \"Epidemiology and pathogenesis of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1183398\">",
"    <span class=\"h2\">",
"     Congenital disorders of glycosylation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many enzymes, hormones, and other proteins require posttranslational glycosylation to function normally. This complex process of attaching sugars (oligosaccharides) to proteins occurs in the cytosol, endoplasmic reticulum, and Golgi apparatus and requires over 30 different enzymes. CDGs are caused by mutations in the enzymes required for synthesis of these oligosaccharides [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27047/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. There is a wide range in age of onset of congenital disorders of glycosylation (CDGs), although onset occurs most often in infancy. CDGs are typically multisystem disorders with varying clinical manifestations, depending upon the type of CDG. Manifestations include, but are not limited to, developmental delay, hypotonia, failure to thrive, hypoglycemia, and protein-losing enteropathy. CDGs are classified based upon the defect in the pattern of glycosylation and the causative genetic mutation. CDG Ia (PMM2-CDG) is the most common type. CDG Ib (MPI-CDG) is amenable to therapy with mannose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolic disorders result from the absence or abnormality of an enzyme or its cofactor, leading to either accumulation or deficiency of a specific metabolite. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The traditional classification system for inborn errors of metabolism (IEM) groups the disorders according to the general type of metabolism involved (",
"      <a class=\"graphic graphic_table graphicRef82924 \" href=\"UTD.htm?39/44/40651\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef56040 \" href=\"UTD.htm?8/23/8572\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef69937 \" href=\"UTD.htm?8/13/8411\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74261 \" href=\"UTD.htm?21/62/22507\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef63392 \" href=\"UTD.htm?7/60/8140\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef86411 \" href=\"UTD.htm?24/12/24780\">",
"       table 6",
"      </a>",
"      ). The major categories of IEM include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Amino acid disorders (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Amino acid disorders'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Organic acidemias (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Organic acidemias'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Urea cycle defects (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Urea cycle disorders'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Disorders of carbohydrate metabolism (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Carbohydrate disorders'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Fatty acid oxidation defects (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Fatty acid oxidation disorders'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Mitochondrial disorders (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Mitochondrial disorders'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Peroxisomal disorders (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Peroxisomal disorders'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Lysosomal storage diseases (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Lysosomal storage disorders'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Saudubray JM, Chappentier C. Clinical phenotypes: Diagnosis/algorithms. In: Metabolic and molecular bases of inherited disease, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.1327.",
"    </li>",
"    <li>",
"     Wappner RS, Hainline BE. Introduction to inborn errors of metabolism. In: Oski's pediatrics. Principles and practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams and Wilkins, Philadelphia 2006. p.2145.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27047/abstract/3\">",
"      Wappner RS. Biochemical diagnosis of genetic diseases. Pediatr Ann 1993; 22:282.",
"     </a>",
"    </li>",
"    <li>",
"     Weiner DL. Metabolic emergencies. In: Textbook of pediatric emergency medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott, Williams and Wilkins, Philadelphia 2006. p.1193.",
"    </li>",
"    <li>",
"     ACTion (ACT) sheets from the American College of Medical Genetics. file://www.acmg.net/AM/Template.cfm?Section=ACT_Sheets_and_Confirmatory_Algorithms&amp;Template=/CM/HTMLDisplay.cfm&amp;ContentID=5661 (Accessed on July 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27047/abstract/6\">",
"      Lindor NM, Karnes PS. Initial assessment of infants and children with suspected inborn errors of metabolism. Mayo Clin Proc 1995; 70:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27047/abstract/7\">",
"      Kamboj M. Clinical approach to the diagnoses of inborn errors of metabolism. Pediatr Clin North Am 2008; 55:1113.",
"     </a>",
"    </li>",
"    <li>",
"     Roe CR, Ding J. Mitochondrial fatty acid oxidation disorders. In: Metabolic and molecular bases of inherited disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.2297.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27047/abstract/9\">",
"      Schapira AH. Mitochondrial diseases. Lancet 2012; 379:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27047/abstract/10\">",
"      Pfeffer G, Majamaa K, Turnbull DM, et al. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2012; 4:CD004426.",
"     </a>",
"    </li>",
"    <li>",
"     Wappner RS. Lysosomal storage disorders. In: Oski's pediatrics: Principles and practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.2199.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27047/abstract/12\">",
"      Wenger DA, Coppola S, Liu SL. Insights into the diagnosis and treatment of lysosomal storage diseases. Arch Neurol 2003; 60:322.",
"     </a>",
"    </li>",
"    <li>",
"     Wappner RS. Disorders of purine and pyrimidine metabolism. In: Oski's pediatrics: Principles and practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.2223.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27047/abstract/14\">",
"      Woods AG, Woods CW, Snow TM. Congenital disorders of glycosylation. Adv Neonatal Care 2012; 12:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27047/abstract/15\">",
"      Vodopiutz J, Bodamer OA. Congenital disorders of glycosylation--a challenging group of IEMs. J Inherit Metab Dis 2008; 31:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27047/abstract/16\">",
"      Thiel C, K&ouml;rner C. Therapies and therapeutic approaches in Congenital Disorders of Glycosylation. Glycoconj J 2013; 30:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27047/abstract/17\">",
"      Goreta SS, Dabelic S, Dumic J. Insights into complexity of congenital disorders of glycosylation. Biochem Med (Zagreb) 2012; 22:156.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2930 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-B12D491B22-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_26_27047=[""].join("\n");
var outline_f26_26_27047=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Amino acid disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Urea cycle disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Carbohydrate disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fatty acid oxidation disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mitochondrial disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lysosomal storage disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Purine and pyrimidine disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Porphyrias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Metal metabolism disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1183398\">",
"      Congenital disorders of glycosylation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2930\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2930|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/49/2832\" title=\"figure 1\">",
"      Urea cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/62/5089\" title=\"figure 2\">",
"      Pathways of glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/16/44301\" title=\"figure 3\">",
"      Galactose metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/55/12148\" title=\"figure 4\">",
"      Mitochondrial pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2930|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/44/40651\" title=\"table 1\">",
"      Types of inborn errors of metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/23/8572\" title=\"table 2\">",
"      Disorders of carbohydrate metab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/13/8411\" title=\"table 3\">",
"      Mitochondrial disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/62/22507\" title=\"table 4\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/60/8140\" title=\"table 5\">",
"      Selected lysosomal storage disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/12/24780\" title=\"table 6\">",
"      Disorders of fatty acid oxidation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/3/2108\" title=\"table 7\">",
"      Amino acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/63/38908\" title=\"table 8\">",
"      Laboratory findings inborn errors of metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/14/12526\" title=\"table 9\">",
"      Amino acid levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/23/12669\" title=\"table 10\">",
"      Abnormal urine organic acids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2488?source=related_link\">",
"      Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=related_link\">",
"      Clinical features and diagnosis of galactosemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=related_link\">",
"      Clinical features and diagnosis of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=related_link\">",
"      Cystinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=related_link\">",
"      Epidemiology and pathogenesis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=related_link\">",
"      Etiology of hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=related_link\">",
"      Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13177?source=related_link\">",
"      Inborn errors of metabolism: Identifying the specific disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=related_link\">",
"      Mitochondrial myopathies: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/15/20726?source=related_link\">",
"      Myopathies affecting the extraocular muscles in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2088?source=related_link\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27590?source=related_link\">",
"      Overview of maple syrup urine disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11015?source=related_link\">",
"      Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=related_link\">",
"      Overview of phenylketonuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=related_link\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=related_link\">",
"      Renal involvement in the mitochondrial cytopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=related_link\">",
"      Urea cycle disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19225?source=related_link\">",
"      Urea cycle disorders: Management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_26_27048="CMV pneumonitis";
var content_f26_26_27048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CMV pneumonitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 279px; height: 186px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph shows an infected pneumocyte in a patient with cytomegalovirus pneumonitis. The infected cell (arrow) is enlarged and contains an eosinophilic intranuclear inclusion and coarse basophilic cytoplasmic inclusions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph shows alveoli containing capillaries within a narrow interstitium. The alveoli are lined with thin, elongated type I pneumoctes (red arrow) and smaller numbers of cuboidal type II pneumocytes (green arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_26_27048=[""].join("\n");
var outline_f26_26_27048=null;
var title_f26_26_27049="Injectable soft tissue fillers: Overview of clinical use";
var content_f26_26_27049=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Injectable soft tissue fillers: Overview of clinical use",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/26/27049/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/26/27049/contributors\">",
"     Alastair Carruthers, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/26/27049/contributors\">",
"     Jean Carruthers, MD, FRCSC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/26/27049/contributors\">",
"     Shannon Humphrey, MD, FRCPC, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/26/27049/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/26/27049/contributors\">",
"     Jeffrey S Dover, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/26/27049/contributors\">",
"     Charles E Butler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/26/27049/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/26/27049/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/26/27049/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1194103\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of injectable soft tissue fillers are available for clinical use, including biodegradeable products (hyaluronic acid, collagen, calcium hydroxylapatite, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/21/13651?source=see_link\">",
"     poly-L-lactic acid",
"    </a>",
"    ), products that remain indefinitely in tissue (polymethylmethacrylate microspheres, hydrogel polymers, and silicone), and viable autologous fat. Soft tissue fillers are used for multiple cosmetic and therapeutic indications. Adequate clinician training in the use of these agents is essential for the prevention of adverse events.",
"   </p>",
"   <p>",
"    Examples of indications for injectable soft tissue fillers and the basic principles of treatment will be reviewed here; details on the efficacy, use, and adverse effects of specific soft tissue filling agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=see_link\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=see_link\">",
"     \"Injectable soft tissue fillers: Permanent agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1194111\">",
"    <span class=\"h1\">",
"     COSMETIC APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facial aging results from a combination of changes that involve the skin (eg, wrinkling, dyspigmentation, and vascular changes) and underlying tissues. A progressive loss of tissue volume due to the atrophy and displacement of subcutaneous fat, as well as a reduction in structural support due to bone atrophy, contribute significantly to facial aging [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Soft tissue fillers can be used to restore a semblance of youth through the replacement of lost tissue volume and the filling and effacement of coarse wrinkles. Examples of age-related features that may be treated with soft tissue fillers include (",
"    <a class=\"graphic graphic_figure graphicRef61178 \" href=\"UTD.htm?41/3/42037\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Upper face",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Glabellar lines &ndash;",
"      </strong>",
"      Deep vertical lines in the glabellar area form as a result of repetitive contraction of the muscles that mediate brow depression (",
"      <a class=\"graphic graphic_picture graphicRef71122 \" href=\"UTD.htm?4/3/4149\">",
"       picture 1",
"      </a>",
"      ). Soft tissue fillers can be used to soften the appearance of these lines. Because of the important role of muscular activity in the creation and exacerbation of glabellar lines, concomitant treatment with botulinum toxin is often beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/20/14665?source=see_link&amp;anchor=H4080948#H4080948\">",
"       \"Botulinum toxin for cosmetic indications: Treatment of specific sites\", section on 'Glabellar rhytides'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Horizontal forehead lines &ndash;",
"      </strong>",
"      Horizontal forehead lines result from the repetitive elevation of the brow over time (",
"      <a class=\"graphic graphic_picture graphicRef50165 \" href=\"UTD.htm?11/4/11334\">",
"       picture 2",
"      </a>",
"      ). Similar to glabellar lines, placement of a soft tissue filler into deep horizontal forehead lines can diminish their appearance. Horizontal forehead lines may also be improved with botulinum toxin injection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/20/14665?source=see_link&amp;anchor=H4080955#H4080955\">",
"       \"Botulinum toxin for cosmetic indications: Treatment of specific sites\", section on 'Horizontal forehead rhytides'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lateral brow lift and temporal fossa changes &ndash;",
"      </strong>",
"      The natural loss of periorbital fat that occurs with aging results in lateral brow ptosis and reduced lateral brow projection (",
"      <a class=\"graphic graphic_picture graphicRef71706 \" href=\"UTD.htm?31/11/31920\">",
"       picture 3",
"      </a>",
"      ). Fillers can be used to elevate the lateral brow and restore its anterior projection [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Temporal fossa wasting &ndash;",
"      </strong>",
"      Volume replacement with soft tissue fillers can minimize the appearance of age-related concavity in the temporal area.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mid-face",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Nasojugal fold (tear trough depression) &ndash;",
"      </strong>",
"      With aging, pronounced depressions may occur between the rim of the orbital bone and the nasal sidewall due to the relaxation of suspensory ligaments of the eye and the descent of the malar fat pad. This can be difficult to correct surgically. The nasojugal fold has been successfully managed with the injection soft tissue fillers [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Cheeks &ndash;",
"      </strong>",
"      Hypoplasia of the zygoma and the descent and atrophy of midfacial fat contribute to loss of the heart-shaped contour that is characteristic of the young female face. Injection of soft tissue fillers into the malar area increases anterior projection of the cheek and diminishes the appearance of nasolabial folds, leading to a more youthful appearance [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/2,6\">",
"       2,6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lower face",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Nasolabial folds &ndash;",
"      </strong>",
"      Nasolabial folds are the most common sites treated with soft tissue fillers (",
"      <a class=\"graphic graphic_picture graphicRef77905 \" href=\"UTD.htm?40/43/41648\">",
"       picture 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/9-13\">",
"       9-13",
"      </a>",
"      ]. United States Food and Drug Administration approval for many products is limited to use in this area.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Oral/perioral",
"       </strong>",
"      </span>",
"      &ndash;",
"      Vertical perioral wrinkles and mouth frown can be corrected with soft tissue fillers (",
"      <a class=\"graphic graphic_picture graphicRef50746 graphicRef76339 \" href=\"UTD.htm?1/45/1751\">",
"       picture 5A-B",
"      </a>",
"      ); lip augmentation also can be performed with these agents [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/14-25\">",
"       14-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Chin &ndash;",
"      </strong>",
"      Melomental folds (marionette lines) and horizontal creases in the chin are amenable to treatment (",
"      <a class=\"graphic graphic_picture graphicRef55290 graphicRef80633 \" href=\"UTD.htm?24/23/24950\">",
"       picture 6A-B",
"      </a>",
"      ). Fillers have also been used for chin and mandibular augmentation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/6,26\">",
"       6,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Nonfacial sites",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Hand rejuvenation &ndash;",
"      </strong>",
"      Soft tissue augmentation can camouflage the skin laxity, wrinkling, and prominence of bone that characterize the appearance of the aged hand [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/27-30\">",
"       27-30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Neck and chest &ndash;",
"      </strong>",
"      Soft tissue fillers can ameliorate signs of flaccidity, atrophy, and wrinkling in the neck and presternal chest [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the indications described above, soft tissue fillers may also be used to repair cosmetic contour defects that are unrelated to age. Soft tissue fillers are minimally invasive alternatives to traditional rhinoplasty for patients who wish to avoid surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. Fillers have also been used to correct post-surgical contour deficiencies and asymmetries in the nose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1194119\">",
"    <span class=\"h1\">",
"     THERAPEUTIC APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue fillers play an important role in the correction of defects that result from medical disorders, trauma, or surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1195125\">",
"    <span class=\"h2\">",
"     HIV-associated lipoatrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human immunodeficiency virus (HIV)-associated lipoatrophy is the most extensively studied therapeutic indication for injectable soft tissue fillers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/38-49\">",
"     38-49",
"    </a>",
"    ]. Patients present with facial lipoatrophy, characterized by sunken cheeks, bitemporal wasting, and deep nasolabial folds. These features can be stigmatizing and can have a significant psychosocial impact on affected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/50\">",
"     50",
"    </a>",
"    ]. Treatment has been associated with an improved sense of well-being and a high level of patient satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/44-46,51,52\">",
"     44-46,51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=see_link\">",
"     \"Treatment of HIV-associated lipodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=see_link&amp;anchor=H44882068#H44882068\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\", section on 'Calcium hydroxylapatite (Radiesse&reg;)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=see_link&amp;anchor=H44882103#H44882103\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\", section on 'Poly-L-lactic acid (Sculptra&reg;)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1195023\">",
"    <span class=\"h2\">",
"     Scarring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facial scars, particularly the pitted atrophic scars that often result from acne vulgaris, can be difficult to treat (",
"    <a class=\"graphic graphic_picture graphicRef66410 \" href=\"UTD.htm?7/35/7733\">",
"     picture 7",
"    </a>",
"    ). Soft tissue fillers can improve the appearance of individual scars and overall skin texture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. Injectable fillers have also been used to improve depressed scars that result from the treatment of skin cancer, trauma, or other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1195499\">",
"    <span class=\"h2\">",
"     Facial asymmetry and soft tissue defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facial asymmetry may be congenital or acquired (surgical or traumatic), and can result from bony or soft tissue abnormalities. Soft tissue fillers can be used to restore volume to underlying tissues in a manner that restores symmetry. Patients with trauma-induced lipoatrophy, hemifacial atrophy (Parry-Romberg syndrome), and linear scleroderma (linear morphea) have benefited from treatment with these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/59-62\">",
"     59-62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/133?source=see_link&amp;anchor=H16539077#H16539077\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults\", section on 'Linear morphea'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40985?source=see_link&amp;anchor=H9#H9\">",
"     \"Localized scleroderma in childhood\", section on 'Linear scleroderma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examples of other defects that have been corrected with soft tissue fillers include mandibular prognathia, surgical or traumatic skull defects, and residual cosmetic defects following cleft palate surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. Multiple disorders involving the eyelids such as eyelid malposition, lid margin asymmetry, epiblepharon, and paralytic lagophthalmos, as well as loss of periorbital volume in anophthalmic enophthalmos have also been managed with these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/66-71\">",
"     66-71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1195748\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue fillers are utilized for medical purposes in nonfacial sites. Examples include nipple contouring and improvement of chest wall defects after mastectomy and breast reconstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/72-74\">",
"     72-74",
"    </a>",
"    ], and treatment of glottic insufficiency (vocal cord dysfunction) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/75-79\">",
"     75-79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1194127\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient interview and clinical examination are used to identify appropriate candidates for treatment and to aid in the selection of the proper filling agent and injection technique. The assessment should begin with a review of the patient's relevant medical history that incorporates the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of prior cosmetic procedures",
"     </li>",
"     <li>",
"      Presence of bleeding disorders or immunosuppression",
"     </li>",
"     <li>",
"      Current medications, particularly anticoagulants",
"     </li>",
"     <li>",
"      Allergies and history of anaphylaxis",
"     </li>",
"     <li>",
"      Presence of contraindications to soft tissue fillers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The specific contraindications for the selected filler should be reviewed prior to treatment. General contraindications to treatment with soft tissue fillers include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection at or near the site of injection",
"     </li>",
"     <li>",
"      Allergy to product components",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The safety of these agents in pregnancy and lactation has not been established. Additional contraindications for specific soft tissue fillers are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=see_link\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=see_link\">",
"     \"Injectable soft tissue fillers: Permanent agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The physical examination should occur while the patient is seated upright. Asking the patient to identify problematic areas with the use of a mirror will help to ensure that the clinician has a clear understanding of the patient&rsquo;s concerns. The unique nature of patient anatomy requires an individual approach to the management of each patient; in some cases, treatment of additional locations or the inclusion of adjunctive cosmetic procedures is necessary to achieve the best results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3205537\">",
"    <span class=\"h1\">",
"     FILLER SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient is an appropriate candidate for treatment with a soft tissue filler, the clinician must then determine which agent should be used. The properties of fillers vary widely, and agents cannot be blindly interchanged. As an example, the use of polymethylmethacrylate microspheres in the lip or in areas of thin skin is not recommended due to a high risk for implant visibility, lumpiness, or beading after injection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=see_link&amp;anchor=H15763905#H15763905\">",
"     \"Injectable soft tissue fillers: Permanent agents\", section on 'Polymethylmethacrylate microspheres'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The desired duration of effect must also be considered; fillers that are eventually degraded in tissue, such as hyaluronic acid, offer the advantage of reversibility in the case of undesirable placement, but require multiple subsequent treatments to maintain the desired effect (",
"    <a class=\"graphic graphic_table graphicRef71066 \" href=\"UTD.htm?22/45/23261\">",
"     table 1",
"    </a>",
"    ). Permanent fillers should only be used in carefully selected patients; the use of biodegradeable agents is particularly advisable for cosmetic patients who are receiving a filling agent for the first time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=see_link&amp;anchor=H3502728#H3502728\">",
"     \"Injectable soft tissue fillers: Permanent agents\", section on 'Precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinician experience also influences the choice of soft tissue filler; improper use can result in an unacceptably high risk for adverse effects. Clinicians who have not been trained in the use of particular soft tissue fillers should refrain from use of those agents.",
"   </p>",
"   <p>",
"    Common clinical uses for specific types of fillers are provided in a table (",
"    <a class=\"graphic graphic_table graphicRef71066 \" href=\"UTD.htm?22/45/23261\">",
"     table 1",
"    </a>",
"    ). The specific properties of soft tissue fillers that influence the selection of an agent are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=see_link\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=see_link\">",
"     \"Injectable soft tissue fillers: Permanent agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3205551\">",
"    <span class=\"h1\">",
"     INFORMED CONSENT AND DOCUMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Realistic expectations for treatment outcomes must be thoroughly discussed with patients, as optimal patient satisfaction is dependent not only on the clinician&rsquo;s technical skill, but also on the fulfillment of patient expectations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/80\">",
"     80",
"    </a>",
"    ]. In addition, the risks associated with the use of the selected filler should be carefully reviewed with patients prior to treatment.",
"   </p>",
"   <p>",
"    We recommend the use of an informed consent document that confirms patient understanding of the potential adverse effects and expected treatment outcome. We have also found that digital photographs taken before and after treatment are useful for clinical follow-up and for documentation of pre-existing asymmetries or defects. The latter also may be useful in the event of medicolegal disputes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1194135\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1196003\">",
"    <span class=\"h2\">",
"     Before treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;To reduce the incidence and severity of bleeding and bruising, we instruct patients to avoid substances that impair hemostasis (acetylsalicylic acid, nonsteroidal antiinflammatory agents, excessive alcohol, vitamin E supplementation, and other dietary supplements that may have an anticoagulating effect) for one week prior to treatment, provided these agents can be discontinued safely [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to concern for reactivation of oral herpes simplex virus (HSV) infection following lip augmentation, the use of prophylactic antiviral therapy at the time of lip augmentation with a soft tissue filler is often recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. However, the risk for reactivation of HSV infection following the injection of soft tissue fillers is unknown, and the value of prescribing prophylactic antiviral agents has not been evaluated.",
"   </p>",
"   <p>",
"    In our practice, we typically prescribe prophylactic antiviral therapy for patients undergoing treatment of the lips. The preferred dosing for HSV prophylaxis in this setting is uncertain. We utilize 1 g of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    at the time of lip injection and 500 mg twice daily for 10 days following the procedure.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     Famciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    may also be given for prophylactic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1194143\">",
"    <span class=\"h2\">",
"     Skin preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is insufficient data to draw definitive conclusions on the most appropriate regimen for skin cleansing in preparation for the injection of soft tissue fillers. In general, makeup should be removed and the area of injection and the surrounding skin should be cleansed with an antiseptic agent. Cleansing the skin with alcohol is commonly used prior to the injection of hyaluronic acid or collagen fillers; however, some clinicians have suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    may be preferable due to a residual antibacterial effect [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/85\">",
"     85",
"    </a>",
"    ]. In particular, due to concern over the risk for biofilm formation and chronic infection, some clinicians have recommended use of sterile, rather than clean surgical technique when injecting long-acting agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We typically cleanse the skin with a liquid containing 4 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    and 4 percent isopropyl alcohol prior to injection. We utilize clean surgical technique during the injection of biodegradeable soft tissue fillers, and sterile technique for nonbiodegradeable (permanent) fillers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1194151\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical anesthetics or local nerve blocks are commonly used to reduce pain during treatment. Additionally, a number of injectable fillers are formulated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , which has been shown to reduce pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/87-93\">",
"     87-93",
"    </a>",
"    ]. In practice, many clinicians (including ourselves) sometimes mix lidocaine with filling agents that do not contain an anesthetic.",
"   </p>",
"   <p>",
"    Pain may also be reduced through use of the smallest suitable needle, slow infiltration, minimization of the number of needle punctures, and injecting through areas of previously anesthetized skin. Other interventions that may be useful for reducing pain include ice application, skin vibration, patient distraction, and treatment in a relaxed and soothing physical environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1194159\">",
"    <span class=\"h2\">",
"     Injection techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred injection technique varies according to the filler preparations used, area to be treated, and experience of the injector. The four techniques commonly used for the injection of soft tissue fillers are (",
"    <a class=\"graphic graphic_figure graphicRef51440 \" href=\"UTD.htm?7/53/8020\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/94\">",
"     94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Linear threading &ndash;",
"      </strong>",
"      The needle is inserted into the skin and the filler is injected in a linear fashion as the needle is withdrawn (retrograde) or inserted (antegrade). Threading is commonly used for lip augmentation or the treatment of nasolabial folds. Use of antegrade injection, also known as the &ldquo;push-ahead&rdquo; technique, may reduce the risk for bruising when treating delicate areas, such as the upper eyelid or brow [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Depot/serial",
"       </strong>",
"      </span>",
"      puncture &ndash;",
"      A bolus of the filler is deposited into tissue at the site of needle puncture. A single puncture or a series of punctures may be performed. The serial puncture method is often used for lip augmentation or for superficial wrinkles.",
"     </li>",
"     <li>",
"      <strong>",
"       Fanning &ndash;",
"      </strong>",
"      This technique is an extension of threading. An initial retrograde injection is followed by multiple cycles of redirection of the needle and retrograde injection without complete withdrawal from the skin. Fanning is used for the treatment of larger defects.",
"     </li>",
"     <li>",
"      <strong>",
"       Cross-hatching &ndash;",
"      </strong>",
"      A series of parallel linear injections are performed followed by another series of linear injections into the same area that are perpendicular to the first set of injections. Similar to fanning, cross-hatching is typically used in the treatment of large areas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The appropriate depth of injection is dependent upon the filler used and the site treated (",
"    <a class=\"graphic graphic_figure graphicRef54021 \" href=\"UTD.htm?23/19/23858\">",
"     figure 3",
"    </a>",
"    ). Injections that are placed too superficially may result in palpable or visible filler implants, and injections that are placed too deeply may not provide the desired effect. In general, coarse defects require more viscous fillers and deeper placement than less prominent lines or defects. The appropriate depth of placement of individual soft tissue fillers is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=see_link\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=see_link\">",
"     \"Injectable soft tissue fillers: Permanent agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1196127\">",
"    <span class=\"h2\">",
"     Post-procedural care",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an attempt to reduce the risk for unintended migration of the filler after injection, we typically advise patients to avoid massaging injected areas, to refrain from strenuous cardiovascular or other highly physical activity for at least six hours after treatment, and to sleep with the head elevated for one night [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/96\">",
"     96",
"    </a>",
"    ]. Short-term minimization of exaggerated and repetitive facial movements may also decrease the risk of implant migration or displacement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/97\">",
"     97",
"    </a>",
"    ]. Normal skin care regimens (including makeup) can be resumed after 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1194167\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects following soft-tissue augmentation may be classified as early reactions (0 to 14 days after treatment), late (14 days to 1 year after treatment), or delayed (appearing over one year after treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/85\">",
"     85",
"    </a>",
"    ]. Side effects that are common to the use of multiple filling agents are reviewed below; the adverse effects associated with specific filling agents are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=see_link\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=see_link\">",
"     \"Injectable soft tissue fillers: Permanent agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1196285\">",
"    <span class=\"h2\">",
"     Early adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common early side effects of injectable soft tissue fillers include bruising, edema, and erythema. The application of ice after injection may help to reduce swelling, and preoperative precautions regarding anticoagulating agents may help to reduce the severity of bruising. (See",
"    <a class=\"local\" href=\"#H1196003\">",
"     'Before treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Rarely, vascular compromise, resulting in tissue necrosis can result from compression or obstruction of blood vessels in the glabella (supratrochlear artery) or nasolabial fold (angular artery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/98-100\">",
"     98-100",
"    </a>",
"    ]). Immediate regional blanching, a reticulate, violaceous discoloration of the skin, or significant pain following treatment may indicate impending tissue necrosis. Blindness due to retinal embolism following intravascular injection of the supratrochlear artery, a branch of the ophthalmic artery, also has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aspiration prior to injection will help to prevent accidental placement of the filling agent within a vessel. Although the efficacy and safety of interventions for filler-related vascular occlusion have not been evaluated in formal studies, the following procedure has been recommended in the event of vascular compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/102\">",
"     102",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediately discontinue injection",
"     </li>",
"     <li>",
"      Gently massage the affected site",
"     </li>",
"     <li>",
"      Immediately apply heat (eg, via gauze soaked in warm water)",
"     </li>",
"     <li>",
"      Apply",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      paste under occlusion (apply cyclically for 12 hours on and 12 hours off until clinical improvement)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If treatment was performed with a hyaluronic filler,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"     hyaluronidase",
"    </a>",
"    can be injected into skin in the site of filler placement. Hyaluronidase was used successfully in combination with heat and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    paste in a patient with signs of impending vascular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/103\">",
"     103",
"    </a>",
"    ]. Prick testing to detect an immediate hypersensitivity reaction is recommended prior to the injection of hyaluronidase due to a risk for anaphylactic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/104\">",
"     104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=see_link&amp;anchor=H1117242#H1117242\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\", section on 'Reversal'",
"    </a>",
"    .) Low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has also been used in the management of patients with filler-induced vascular occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/102,105\">",
"     102,105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1196292\">",
"    <span class=\"h2\">",
"     Late and delayed onset adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late and delayed onset reactions include the formation of nodules, granulomatous or other inflammatory reactions, chronic infections, and consequences of filler migration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/80,85,106,107\">",
"     80,85,106,107",
"    </a>",
"    ]. Although some adverse reactions improve with time, the injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"     hyaluronidase",
"    </a>",
"    in the case of hyaluronic acid fillers, corticosteroid injections, or the administration of systemic agents, others may require surgical intervention or may be impossible to completely reverse [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27049/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=see_link\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=see_link\">",
"     \"Injectable soft tissue fillers: Permanent agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493808\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple soft tissue fillers are utilized for cosmetic and therapeutic indications. Soft tissue fillers reduce contour defects in the face, neck, and body through the replacement of tissue volume lost due to aging, trauma, or other events. (See",
"      <a class=\"local\" href=\"#H1194111\">",
"       'Cosmetic applications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1194119\">",
"       'Therapeutic applications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with a soft tissue filler should begin with an assessment that determines whether the patient is an appropriate candidate for therapy. Infections at or near the site of injection and allergies to product components are contraindications for treatment. (See",
"      <a class=\"local\" href=\"#H1194127\">",
"       'Patient selection and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The selection of an appropriate soft tissue filler is dependent on factors such as the defect to be treated, product availability, and clinician expertise. Soft tissue filler properties vary widely, and product-specific clinician training is required. (See",
"      <a class=\"local\" href=\"#H1194135\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risks of treatment and expected treatment outcome should be discussed thoroughly with patients. We utilize informed consent documents and pretreatment and post-treatment photographs to document patient understanding and treatment progress. (See",
"      <a class=\"local\" href=\"#H1194127\">",
"       'Patient selection and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vascular occlusion is a rare but serious complication that can occur with the use of soft tissue fillers. Initial steps for management of impending tissue necrosis include discontinuation of injection, gentle massage, heat application, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      paste. (See",
"      <a class=\"local\" href=\"#H1194167\">",
"       'Side effects and complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/1\">",
"      Donofrio LM. Fat distribution: a morphologic study of the aging face. Dermatol Surg 2000; 26:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/2\">",
"      Rohrich RJ, Pessa JE, Ristow B. The youthful cheek and the deep medial fat compartment. Plast Reconstr Surg 2008; 121:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/3\">",
"      Shaw RB Jr, Katzel EB, Koltz PF, et al. Aging of the mandible and its aesthetic implications. Plast Reconstr Surg 2010; 125:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/4\">",
"      Carruthers J, Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg 2003; 29:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/5\">",
"      Patel MP, Talmor M, Nolan WB. Botox and collagen for glabellar furrows: advantages of combination therapy. Ann Plast Surg 2004; 52:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/6\">",
"      Carruthers JD, Carruthers A. Facial sculpting and tissue augmentation. Dermatol Surg 2005; 31:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/7\">",
"      Kane MA. Treatment of tear trough deformity and lower lid bowing with injectable hyaluronic acid. Aesthetic Plast Surg 2005; 29:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/8\">",
"      Goldberg DJ. Correction of tear trough deformity with novel porcine collagen dermal filler (Dermicol-P35). Aesthet Surg J 2009; 29:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/9\">",
"      Baumann LS, Shamban AT, Lupo MP, et al. Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: a multicenter, double-masked, randomized, within-subject study. Dermatol Surg 2007; 33 Suppl 2:S128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/10\">",
"      Moers-Carpi M, Vogt S, Santos BM, et al. A multicenter, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds. Dermatol Surg 2007; 33 Suppl 2:S144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/11\">",
"      Arlette JP, Trotter MJ. Anatomic location of hyaluronic acid filler material injected into nasolabial fold: a histologic study. Dermatol Surg 2008; 34 Suppl 1:S56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/12\">",
"      Lupo MP, Smith SR, Thomas JA, et al. Effectiveness of Juv&eacute;derm Ultra Plus dermal filler in the treatment of severe nasolabial folds. Plast Reconstr Surg 2008; 121:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/13\">",
"      Salles AG, Lotierzo PH, Gimenez R, et al. Evaluation of the poly-L-lactic acid implant for treatment of the nasolabial fold: 3-year follow-up evaluation. Aesthetic Plast Surg 2008; 32:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/14\">",
"      Cohen SR, Holmes RE. Artecoll: a long-lasting injectable wrinkle filler material: Report of a controlled, randomized, multicenter clinical trial of 251 subjects. Plast Reconstr Surg 2004; 114:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/15\">",
"      Cohen SR, Berner CF, Busso M, et al. ArteFill: a long-lasting injectable wrinkle filler material--summary of the U.S. Food and Drug Administration trials and a progress report on 4- to 5-year outcomes. Plast Reconstr Surg 2006; 118:64S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/16\">",
"      Jansen DA, Graivier MH. Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation. Plast Reconstr Surg 2006; 118:22S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/17\">",
"      Perkins NW, Smith SP Jr, Williams EF 3rd. Perioral rejuvenation: complementary techniques and procedures. Facial Plast Surg Clin North Am 2007; 15:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/18\">",
"      Tzikas TL. A 52-month summary of results using calcium hydroxylapatite for facial soft tissue augmentation. Dermatol Surg 2008; 34 Suppl 1:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/19\">",
"      De Boulle K, Swinberghe S, Engman M, Shoshani D. Lip augmentation and contour correction with a ribose cross-linked collagen dermal filler. J Drugs Dermatol 2009; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/20\">",
"      Moscona RA, Fodor L. A retrospective study on liquid injectable silicone for lip augmentation: long-term results and patient satisfaction. J Plast Reconstr Aesthet Surg 2010; 63:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/21\">",
"      Pallua N, Wolter TP. A 5-year assessment of safety and aesthetic results after facial soft-tissue augmentation with polyacrylamide hydrogel (Aquamid): a prospective multicenter study of 251 patients. Plast Reconstr Surg 2010; 125:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/22\">",
"      Carruthers J, Klein AW, Carruthers A, et al. Safety and efficacy of nonanimal stabilized hyaluronic acid for improvement of mouth corners. Dermatol Surg 2005; 31:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/23\">",
"      Graivier MH, Bass LS, Busso M, et al. Calcium hydroxylapatite (Radiesse) for correction of the mid- and lower face: consensus recommendations. Plast Reconstr Surg 2007; 120:55S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/24\">",
"      Solish NJ. Assessment of recovery time for the collagen products Dermicol-P35 27G and 30G. J Am Acad Dermatol 2010; 62:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/25\">",
"      Weinkle S. Injection techniques for revolumization of the perioral region with hyaluronic acid. J Drugs Dermatol 2010; 9:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/26\">",
"      Schierle CF, Casas LA. Nonsurgical rejuvenation of the aging face with injectable poly-L-lactic acid for restoration of soft tissue volume. Aesthet Surg J 2011; 31:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/27\">",
"      Butterwick KJ. Rejuvenation of the aging hand. Dermatol Clin 2005; 23:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/28\">",
"      Man J, Rao J, Goldman M. A double-blind, comparative study of nonanimal-stabilized hyaluronic acid versus human collagen for tissue augmentation of the dorsal hands. Dermatol Surg 2008; 34:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/29\">",
"      Sadick NS, Anderson D, Werschler WP. Addressing volume loss in hand rejuvenation: a report of clinical experience. J Cosmet Laser Ther 2008; 10:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/30\">",
"      Marmur ES, Al Quran H, De Sa Earp AP, Yoo JY. A five-patient satisfaction pilot study of calcium hydroxylapatite injection for treatment of aging hands. Dermatol Surg 2009; 35:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/31\">",
"      Mazzuco R, Hexsel D. Poly-L-lactic acid for neck and chest rejuvenation. Dermatol Surg 2009; 35:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/32\">",
"      de Lacerda DA, Zancanaro P. Filler rhinoplasty. Dermatol Surg 2007; 33 Suppl 2:S207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/33\">",
"      Jacovella PF. Aesthetic nasal corrections with hydroxylapatite facial filler. Plast Reconstr Surg 2008; 121:338e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/34\">",
"      Pitkin L, Rimmer J, Lo S, Hosni A. Aesthetic augmentation rhinoplasty with Permacol: how we do it. Clin Otolaryngol 2008; 33:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/35\">",
"      Rokhsar C, Ciocon DH. Nonsurgical rhinoplasty: an evaluation of injectable calcium hydroxylapatite filler for nasal contouring. Dermatol Surg 2008; 34:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/36\">",
"      Hopkins C, Walker R, Lee S, Roberts D. Permacol in augmentation rhinoplasty: how we do it. Clin Otolaryngol 2009; 34:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/37\">",
"      Stupak HD, Moulthrop TH, Wheatley P, et al. Calcium hydroxylapatite gel (Radiesse) injection for the correction of postrhinoplasty contour deficiencies and asymmetries. Arch Facial Plast Surg 2007; 9:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/38\">",
"      Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003; 17:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/39\">",
"      Jones DH, Carruthers A, Orentreich D, et al. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial. Dermatol Surg 2004; 30:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/40\">",
"      Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004; 5:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/41\">",
"      Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 2005; 52:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/42\">",
"      Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med 2006; 7:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/43\">",
"      Silvers SL, Eviatar JA, Echavez MI, Pappas AL. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg 2006; 118:34S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/44\">",
"      Loutfy MR, Raboud JM, Antoniou T, et al. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS 2007; 21:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/45\">",
"      Levy RM, Redbord KP, Hanke CW. Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study. J Am Acad Dermatol 2008; 59:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/46\">",
"      Mest DR, Humble GM. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study. Dermatol Surg 2009; 35 Suppl 1:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/47\">",
"      James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg 2002; 28:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/48\">",
"      Carruthers A, Liebeskind M, Carruthers J, Forster BB. Radiographic and computed tomographic studies of calcium hydroxylapatite for treatment of HIV-associated facial lipoatrophy and correction of nasolabial folds. Dermatol Surg 2008; 34 Suppl 1:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/49\">",
"      Carruthers A, Carruthers J. Evaluation of injectable calcium hydroxylapatite for the treatment of facial lipoatrophy associated with human immunodeficiency virus. Dermatol Surg 2008; 34:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/50\">",
"      Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read 2000; 10:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/51\">",
"      Hanke CW, Redbord KP. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. J Drugs Dermatol 2007; 6:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/52\">",
"      Kavouni A, Catalan J, Brown S, et al. The face of HIV and AIDS: can we erase the stigma? AIDS Care 2008; 20:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/53\">",
"      Smith KC. Repair of acne scars with Dermicol-P35. Aesthet Surg J 2009; 29:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/54\">",
"      Beer K. A single-center, open-label study on the use of injectable poly-L-lactic acid for the treatment of moderate to severe scarring from acne or varicella. Dermatol Surg 2007; 33 Suppl 2:S159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/55\">",
"      Sadick NS, Palmisano L. Case study involving use of injectable poly-L-lactic acid (PLLA) for acne scars. J Dermatolog Treat 2009; 20:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/56\">",
"      Sadove R. Injectable poly-L: -lactic acid: a novel sculpting agent for the treatment of dermal fat atrophy after severe acne. Aesthetic Plast Surg 2009; 33:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/57\">",
"      Ralston JP, Blume JE, Zeitouni NC. Treatment of postoperative soft tissue loss with injectable poly-L-lactic acid. J Drugs Dermatol 2006; 5:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/58\">",
"      Kasper DA, Cohen JL, Saxena A, Morganroth GS. Fillers for postsurgical depressed scars after skin cancer reconstruction. J Drugs Dermatol 2008; 7:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/59\">",
"      Rendon MI, Keeling J. Poly-L-lactic acid for the treatment of trauma-induced facial lipoatrophy and asymmetry. Cutis 2008; 81:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/60\">",
"      Franz FP, Blocksma R, Brundage SR, Ringler SL. Massive injection of liquid silicone for hemifacial atrophy. Ann Plast Surg 1988; 20:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/61\">",
"      Onesti MG, Monarca C, Rizzo MI, et al. Minimally invasive combined treatment for Parry-Romberg syndrome. Aesthetic Plast Surg 2009; 33:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/62\">",
"      Onesti MG, Troccola A, Scuderi N. Volumetric correction using poly-L-lactic acid in facial asymmetry: Parry Romberg syndrome and scleroderma. Dermatol Surg 2009; 35:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/63\">",
"      Schweiger ES, Riddle CC, Tonkovic-Capin V, Aires DJ. Successful treatment with injected hyaluronic acid in a patient with lip asymmetry after surgical correction of cleft lip. Dermatol Surg 2008; 34:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/64\">",
"      Reytan N, Gutsche N, Rzany B. Aesthetic correction of the upper lip in a patient with mandibular prognathia with a novel long-lasting collagen filler: a case report. Dermatol Surg 2007; 33:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/65\">",
"      Vagefi MR, McMullan TF, McCann JD, Anderson RL. Osteoplasty using calcium hydroxylapatite filler. Ophthal Plast Reconstr Surg 2008; 24:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/66\">",
"      Taban M, Mancini R, Nakra T, et al. Nonsurgical management of congenital eyelid malpositions using hyaluronic Acid gel. Ophthal Plast Reconstr Surg 2009; 25:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/67\">",
"      Mancini R, Khadavi NM, Goldberg RA. Nonsurgical management of upper eyelid margin asymmetry using hyaluronic acid gel filler. Ophthal Plast Reconstr Surg 2011; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/68\">",
"      Naik MN, Ali MJ, Das S, Honavar SG. Nonsurgical management of epiblepharon using hyaluronic acid gel. Ophthal Plast Reconstr Surg 2010; 26:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/69\">",
"      Mancini R, Taban M, Lowinger A, et al. Use of hyaluronic Acid gel in the management of paralytic lagophthalmos: the hyaluronic Acid gel \"gold weight\". Ophthal Plast Reconstr Surg 2009; 25:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/70\">",
"      Vagefi MR, McMullan TF, Burroughs JR, et al. Injectable calcium hydroxylapatite for orbital volume augmentation. Arch Facial Plast Surg 2007; 9:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/71\">",
"      Kotlus BS, Dryden RM. Correction of anophthalmic enophthalmos with injectable calcium hydroxylapatite (Radiesse). Ophthal Plast Reconstr Surg 2007; 23:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/72\">",
"      Panettiere P, Marchetti L, Accorsi D. Filler injection enhances the projection of the reconstructed nipple: an original easy technique. Aesthetic Plast Surg 2005; 29:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/73\">",
"      Lennox K, Beer KR. Nipple contouring with hyaluronics postmastectomy. J Drugs Dermatol 2007; 6:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/74\">",
"      Schulman MR, Lipper J, Skolnik RA. Correction of chest wall deformity after implant-based breast reconstruction using poly-L-lactic acid (Sculptra). Breast J 2008; 14:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/75\">",
"      Herteg&aring;rd S, Hall&eacute;n L, Laurent C, et al. Cross-linked hyaluronan used as augmentation substance for treatment of glottal insufficiency: safety aspects and vocal fold function. Laryngoscope 2002; 112:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/76\">",
"      Herteg&aring;rd S, Hall&eacute;n L, Laurent C, et al. Cross-linked hyaluronan versus collagen for injection treatment of glottal insufficiency: 2-year follow-up. Acta Otolaryngol 2004; 124:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/77\">",
"      Remacle M, Lawson G. Results with collagen injection into the vocal folds for medialization. Curr Opin Otolaryngol Head Neck Surg 2007; 15:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/78\">",
"      Min JY, Hong SD, Kim K, Son YI. Long-term results of Artecoll injection laryngoplasty for patients with unilateral vocal fold motion impairment: safety and clinical efficacy. Arch Otolaryngol Head Neck Surg 2008; 134:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/79\">",
"      Rosen CA, Gartner-Schmidt J, Casiano R, et al. Vocal fold augmentation with calcium hydroxylapatite: twelve-month report. Laryngoscope 2009; 119:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/80\">",
"      Gladstone HB, Cohen JL. Adverse effects when injecting facial fillers. Semin Cutan Med Surg 2007; 26:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/81\">",
"      Dinehart SM, Henry L. Dietary supplements: altered coagulation and effects on bruising. Dermatol Surg 2005; 31:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/82\">",
"      Lafaille P, Benedetto A. Fillers: contraindications, side effects and precautions. J Cutan Aesthet Surg 2010; 3:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/83\">",
"      Hirsch RJ, Stier M. Complications of soft tissue augmentation. J Drugs Dermatol 2008; 7:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/84\">",
"      Cohen JL. Understanding, avoiding, and managing dermal filler complications. Dermatol Surg 2008; 34 Suppl 1:S92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/85\">",
"      Monheit GD, Rohrich RJ. The nature of long-term fillers and the risk of complications. Dermatol Surg 2009; 35 Suppl 2:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/86\">",
"      Rohrich RJ, Monheit G, Nguyen AT, et al. Soft-tissue filler complications: the important role of biofilms. Plast Reconstr Surg 2010; 125:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/87\">",
"      Levy PM, De Boulle K, Raspaldo H. Comparison of injection comfort of a new category of cohesive hyaluronic acid filler with preincorporated lidocaine and a hyaluronic acid filler alone. Dermatol Surg 2009; 35 Suppl 1:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/88\">",
"      Levy PM, De Boulle K, Raspaldo H. A split-face comparison of a new hyaluronic acid facial filler containing pre-incorporated lidocaine versus a standard hyaluronic acid facial filler in the treatment of naso-labial folds. J Cosmet Laser Ther 2009; 11:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/89\">",
"      Weinkle SH, Bank DE, Boyd CM, et al. A multi-center, double-blind, randomized controlled study of the safety and effectiveness of Juv&eacute;derm injectable gel with and without lidocaine. J Cosmet Dermatol 2009; 8:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/90\">",
"      Raspaldo H, De Boulle K, Levy PM. Longevity of effects of hyaluronic acid plus lidocaine facial filler. J Cosmet Dermatol 2010; 9:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/91\">",
"      Brandt F, Bank D, Cross SL, Weiss R. A lidocaine-containing formulation of large-gel particle hyaluronic acid alleviates pain. Dermatol Surg 2010; 36 Suppl 3:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/92\">",
"      Lupo MP, Swetman G, Waller W. The effect of lidocaine when mixed with large gel particle hyaluronic acid filler tolerability and longevity: a six-month trial. J Drugs Dermatol 2010; 9:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/93\">",
"      Monheit GD, Campbell RM, Neugent H, et al. Reduced pain with use of proprietary hyaluronic acid with lidocaine for correction of nasolabial folds: a patient-blinded, prospective, randomized controlled trial. Dermatol Surg 2010; 36:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/94\">",
"      Buck DW 2nd, Alam M, Kim JY. Injectable fillers for facial rejuvenation: a review. J Plast Reconstr Aesthet Surg 2009; 62:11.",
"     </a>",
"    </li>",
"    <li>",
"     Donofrio LM. Soft-tissue augmentation. In: Fitzpatrick, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al.  (Eds), McGraw-Hill, 2008. Vol 2, p.2380.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/96\">",
"      Matarasso SL, Carruthers JD, Jewell ML, Restylane Consensus Group. Consensus recommendations for soft-tissue augmentation with nonanimal stabilized hyaluronic acid (Restylane). Plast Reconstr Surg 2006; 117:3S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/97\">",
"      Lemperle G, Rullan PP, Gauthier-Hazan N. Avoiding and treating dermal filler complications. Plast Reconstr Surg 2006; 118:92S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/98\">",
"      Bachmann F, Erdmann R, Hartmann V, et al. The spectrum of adverse reactions after treatment with injectable fillers in the glabellar region: results from the Injectable Filler Safety Study. Dermatol Surg 2009; 35 Suppl 2:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/99\">",
"      Georgescu D, Jones Y, McCann JD, Anderson RL. Skin necrosis after calcium hydroxylapatite injection into the glabellar and nasolabial folds. Ophthal Plast Reconstr Surg 2009; 25:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/100\">",
"      Grunebaum LD, Bogdan Allemann I, Dayan S, et al. The risk of alar necrosis associated with dermal filler injection. Dermatol Surg 2009; 35 Suppl 2:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/101\">",
"      McCleve DE, Goldstein JC. Blindness secondary to injections in the nose, mouth, and face: cause and prevention. Ear Nose Throat J 1995; 74:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/102\">",
"      Glaich AS, Cohen JL, Goldberg LH. Injection necrosis of the glabella: protocol for prevention and treatment after use of dermal fillers. Dermatol Surg 2006; 32:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/103\">",
"      Hirsch RJ, Cohen JL, Carruthers JD. Successful management of an unusual presentation of impending necrosis following a hyaluronic acid injection embolus and a proposed algorithm for management with hyaluronidase. Dermatol Surg 2007; 33:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/104\">",
"      Andre P, Fl&eacute;chet ML. Angioedema after ovine hyaluronidase injection for treating hyaluronic acid overcorrection. J Cosmet Dermatol 2008; 7:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/105\">",
"      Kang MS, Park ES, Shin HS, et al. Skin necrosis of the nasal ala after injection of dermal fillers. Dermatol Surg 2011; 37:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/106\">",
"      Christensen L. Normal and pathologic tissue reactions to soft tissue gel fillers. Dermatol Surg 2007; 33 Suppl 2:S168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/107\">",
"      Braun M, Braun S. Nodule formation following lip augmentation using porcine collagen-derived filler. J Drugs Dermatol 2008; 7:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27049/abstract/108\">",
"      Smith KC. Reversible vs. nonreversible fillers in facial aesthetics: concerns and considerations. Dermatol Online J 2008; 14:3.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16532 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_26_27049=[""].join("\n");
var outline_f26_26_27049=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H493808\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1194103\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1194111\">",
"      COSMETIC APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1194119\">",
"      THERAPEUTIC APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1195125\">",
"      HIV-associated lipoatrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1195023\">",
"      Scarring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1195499\">",
"      Facial asymmetry and soft tissue defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1195748\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1194127\">",
"      PATIENT SELECTION AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3205537\">",
"      FILLER SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3205551\">",
"      INFORMED CONSENT AND DOCUMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1194135\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1196003\">",
"      Before treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1194143\">",
"      Skin preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1194151\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1194159\">",
"      Injection techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1196127\">",
"      Post-procedural care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1194167\">",
"      SIDE EFFECTS AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1196285\">",
"      Early adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1196292\">",
"      Late and delayed onset adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H493808\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/16532\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16532|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/3/42037\" title=\"figure 1\">",
"      Injectable soft tissue filler treatment sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/53/8020\" title=\"figure 2\">",
"      Soft tissue filler injection techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/19/23858\" title=\"figure 3\">",
"      Placement of injectable soft tissue fillers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16532|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/3/4149\" title=\"picture 1\">",
"      Glabellar rhytides at rest and contraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/4/11334\" title=\"picture 2\">",
"      Horizontal forehead rhytides at rest and contraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/11/31920\" title=\"picture 3\">",
"      Brow ptosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/43/41648\" title=\"picture 4\">",
"      Nasolabial folds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/48/30465\" title=\"picture 5A\">",
"      Perioral rhytides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/8/33921\" title=\"picture 5B\">",
"      Mouth frown",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/55/34673\" title=\"picture 6A\">",
"      Melomental folds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/21/34128\" title=\"picture 6B\">",
"      Mental crease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/35/7733\" title=\"picture 7\">",
"      Acne scars",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16532|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/45/23261\" title=\"table 1\">",
"      Biodegradeable soft tissue fillers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/20/14665?source=related_link\">",
"      Botulinum toxin for cosmetic indications: Treatment of specific sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=related_link\">",
"      Injectable soft tissue fillers: Permanent agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=related_link\">",
"      Injectable soft tissue fillers: Semipermanent agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40985?source=related_link\">",
"      Localized scleroderma in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/133?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=related_link\">",
"      Treatment of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_26_27050="Catheter-induced upper extremity venous thrombosis";
var content_f26_26_27050=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Catheter-induced upper extremity venous thrombosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/26/27050/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/26/27050/contributors\">",
"     Caroline B&eacute;rub&eacute;, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/26/27050/contributors\">",
"     James L Zehnder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/26/27050/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/26/27050/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/26/27050/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/26/27050/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/26/27050/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/26/27050/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous catheters cause endothelial trauma and inflammation, which can lead to venous thrombosis. The majority (70 to 80 percent) of thrombotic events occurring in the superficial and deep veins of the upper extremity are due to the presence of intravenous catheters. The remainder is due to mechanical compression from anatomic abnormalities (ie, venous thoracic outlet syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Superficial thrombophlebitis due to peripheral catheters is generally self-limited once the catheter is removed. Thrombosis involving the deep veins (ie, subclavian, axillary, brachial) can lead to pulmonary embolism and long-term sequelae in spite of adequate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/5\">",
"     5",
"    </a>",
"    ]. Pulmonary embolism from upper extremity sources accounts for about 6 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Upper extremity venous thrombosis (superficial and deep) as a complication of indwelling venous catheters will be reviewed here. Thrombosis involving the lower extremity veins is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=see_link\">",
"     \"Superficial thrombophlebitis of the lower extremity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General issues regarding deep venous thrombosis, primary causes of upper extremity deep venous thrombosis, and thrombosis related to hemodialysis access are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=see_link\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=see_link\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VENOUS ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The upper extremity veins are divided into the superficial and deep systems (",
"    <a class=\"graphic graphic_figure graphicRef55596 \" href=\"UTD.htm?18/3/18480\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Superficial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main superficial veins of the upper extremity include the cephalic, basilic, median antebrachial, median antecubital and accessory cephalic veins (",
"    <a class=\"graphic graphic_figure graphicRef55596 \" href=\"UTD.htm?18/3/18480\">",
"     figure 1",
"    </a>",
"    ). The basilic vein is a common access site for the placement of peripherally inserted central catheters (PICC).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Deep",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deep veins of the upper extremity include the paired ulnar, radial and interosseous veins in the forearm, paired brachial veins of the upper arm, and axillary vein. The axillary vein becomes the subclavian vein at the lower border of the teres major muscle (",
"    <a class=\"graphic graphic_figure graphicRef61941 \" href=\"UTD.htm?15/43/16053\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with central venous access, a wide variation in the incidence of vein thrombosis (1 to 66 percent) is reported and the incidence depends upon the catheter type and location, criteria for diagnosis, and population studied [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. One retrospective study from a single institution estimated the frequency of thromboembolic disease of the brachiocephalic vein or superior vena cava due to central catheters to be 6 per 10,000 hospital admissions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/9\">",
"     9",
"    </a>",
"    ]. Although peripherally inserted central catheters (PICC) reduce the incidence of pneumothorax, they appear to have an incidence of upper extremity venous thrombosis similar to that of centrally inserted catheters ranging from 3 to 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Superficial vein thrombosis is more common than deep vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/15\">",
"     15",
"    </a>",
"    ]. The most common site of deep vein thrombosis for centrally placed catheters is the internal jugular vein [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/16\">",
"     16",
"    </a>",
"    ]. For PICC catheters, the brachial, axillary, or subclavian veins may be involved.",
"   </p>",
"   <p>",
"    The highest reported incidences of upper extremity deep vein thrombosis (UEDVT) are from studies that screen for thrombus in patients with central catheters (asymptomatic and symptomatic) particularly those with cancer. In one retrospective review, ultrasound confirmed the presence of UEDVT in 60 percent of patients screened [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/10\">",
"     10",
"    </a>",
"    ]. Another prospective study in patients with malignancy found that 75 percent of patients identified with UEDVT were asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any intravenous catheter has the potential to cause venous thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/17\">",
"     17",
"    </a>",
"    ]. These include peripheral intravenous catheters, peripherally inserted central catheters (PICC) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/18\">",
"     18",
"    </a>",
"    ], tunneled and non-tunneled central catheters, port devices [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/19\">",
"     19",
"    </a>",
"    ], and pacemakers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link&amp;anchor=H3103752#H3103752\">",
"     \"Overview of central venous access\", section on 'Central catheters and devices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165302905\">",
"    <span class=\"h3\">",
"     Catheter-related factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review and metaanalysis evaluated 5636 cancer patients from 5 trials and 7 prospective studies and 425 events of catheter-related venous thrombosis (CRT) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/22\">",
"     22",
"    </a>",
"    ]. Multivariate logistic regression found an increased risk for CRT with use of peripherally inserted central catheters (PICCs), previous history of deep vein thrombosis, subclavian venipuncture insertion site and improper positioning of the catheter tip.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Catheter type &ndash; The diameter of the catheter relative to the size of the vein determines whether or not blood will flow freely around the catheter or stagnate [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/23\">",
"       23",
"      </a>",
"      ]. For a vein of similar size, thrombosis is more likely with large diameter centrally-placed catheter (eg, plasmapheresis, dialysis, multilumen catheters) compared with a small diameter catheter (eg, single lumen). PICC catheters may be associated with a greater risk for venous thrombosis overall (superficial and deep thrombosis) compared with centrally-inserted catheters [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/13,14,22,24,25\">",
"       13,14,22,24,25",
"      </a>",
"      ]. PICC catheters traverse a greater length of vein and, although the catheter is small relative to the central veins, the catheter may nearly occlude the peripheral vein into which it is inserted [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/13\">",
"       13",
"      </a>",
"      ]. As with centrally inserted catheters, the incidence of venous thrombosis increases depending upon the PICC catheter diameter [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/14,24\">",
"       14,24",
"      </a>",
"      ], and for left-sided catheters [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/26\">",
"       26",
"      </a>",
"      ]. The metaanalysis above found a lower risk of catheter-related thrombosis for implanted ports compared with PICC catheters (odds ratio 0.43, 95% CI 0.23-0.80) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/22\">",
"       22",
"      </a>",
"      ]. A prospective study evaluating outcomes for triple-lumen PICC catheters was terminated prematurely after venous thrombosis was identified in 58 percent of the patients. Only 20 percent of these patients were symptomatic and 10 percent involved the deep veins [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/15\">",
"       15",
"      </a>",
"      ]. In a prospective study evaluating 2014 PICC catheter placements, the incidence of symptomatic deep vein thrombosis (DVT) was 3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/14\">",
"       14",
"      </a>",
"      ]. Risk factors for DVT associated with PICC catheter placement include prior DVT, recent surgery, and cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/14,27\">",
"       14,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Catheter malposition &ndash; Following placement of central catheters, the position of the catheter tip is typically confirmed with plain chest radiography. Proper catheter positioning is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link&amp;anchor=H1232392311#H1232392311\">",
"       \"Overview of central venous access\", section on 'Confirmation of catheter tip positioning'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Malposition of the tip of a central catheter is associated with an increased risk of venous thrombosis. An increased risk for catheter-induced upper extremity deep vein thrombosis (UEDVT) was found for malpositioned compared with properly positioned catheters (odds ratio 1.92, 95% CI 1.22-3.02). In one study, UEDVT developed in 46 percent of patients whose catheter tip was in the innominate vein or junction of the innominate vein with the superior vena cava, compared with 6 percent of patients with a properly positioned catheter with its tip in the right atrium or superior vena cava [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Catheter infection &ndash; Bacterial infection may originate from the patient's skin, with migration along the catheter to the vascular space from contaminated intravenous fluids or from hematogenous spread from a remote site [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/28\">",
"       28",
"      </a>",
"      ]. Prior catheter infection is also a risk factor for the development of catheter-induced thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. In surgical patients, the bacteria isolated are often associated with the bacteria present at the site of surgery (eg, patients who undergo gastrointestinal surgery often have gastrointestinal flora isolated). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2055?source=see_link\">",
"       \"Suppurative (septic) thrombophlebitis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The use of appropriate sterile technique during insertion and timely removal of indwelling catheters are important practices to prevent catheter-related infection [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link\">",
"       \"Prevention of intravascular catheter-related infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      History of deep vein thrombosis &ndash; Prior deep vein thrombosis also increases the risk for catheter-induced upper extremity venous thrombosis (odds ratio 2.03, 95% CI 1.05-3.92) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Prothrombotic states",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a number of congenital or acquired systemic prothrombotic conditions may increase the risk for catheter-induced upper extremity venous thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/4,32-37\">",
"     4,32-37",
"    </a>",
"    ]. The indications for screening patients for a prothrombotic condition are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link&amp;anchor=H23#H23\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\", section on 'Screening for a hypercoagulable state'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is well documented that Factor V Leiden and prothrombin gene mutation 20210 are risk factors for non-catheter-related upper extremity deep vein thrombosis (UEDVT). Studies have also assessed at the risk of catheter-related UEDVT in carriers of these common mutations. [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/38\">",
"     38",
"    </a>",
"    ]. One prospective study of 252 consecutive patients found a nearly three-fold increased risk of developing catheter-induced UEDVT in carriers of Factor V Leiden or prothrombin gene mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/39\">",
"     39",
"    </a>",
"    ]. In a metaanalysis of 10 studies including 1000 patients with cancer, an association was confirmed for both mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/32\">",
"     32",
"    </a>",
"    ]. The estimated attributable risk of catheter-related UEDVT was 13.1 percent for factor V Leiden and 4.5 percent for prothrombin gene mutation.",
"   </p>",
"   <p>",
"    In a prospective case-control study of 260 patients, a higher incidence of upper extremity deep vein thrombosis (UEDVT) was found in patients with antibody-positive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    induced thrombocytopenia (HIT) with a central catheter compared with those without a central catheter (9 versus 0 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/40\">",
"     40",
"    </a>",
"    ]. All thrombotic sites corresponded to the side with the central venous catheter, strongly implicating an interaction between the underlying hypercoagulable state of HIT and the local injury caused by the catheter.",
"   </p>",
"   <p>",
"    A higher incidence (up to 32 percent) of symptomatic catheter-induced UEDVT is found in patients with underlying malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/2,41-46\">",
"     2,41-46",
"    </a>",
"    ]. Patients with malignant processes involving the right lung, lymph nodes, or other mediastinal structures may present with catheter thrombosis as a consequence of central vein compression and thrombosis. The management of patients with central venous obstruction and superior vena cava syndrome is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"     \"Hypercoagulable disorders associated with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=see_link\">",
"     \"Malignancy-related superior vena cava syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hormonal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between hormonal therapy and primary (ie, non-catheter-related) UEDVT has been established. Whether hormonal therapy increases the risk of catheter-related thrombosis is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H11#H11\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Venous thromboembolic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral contraceptives may increase the risk for catheter-related upper extremity deep vein thrombosis (UEDVT) when used in a patient with prothrombotic mutations, such as prothrombin 20210 or factor V Leiden [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/38,47\">",
"     38,47",
"    </a>",
"    ]. Case reports of catheter-related UEDVT (with or without coagulation abnormalities) are also reported in women undergoing ovulation induction and in vitro fertilization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Chemical irritation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical phlebitis can also occur as a reaction to the catheter material [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/52\">",
"     52",
"    </a>",
"    ], or the infused drugs. Common culprits include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    , antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    ), chemotherapy agents, and hypotonic (&lt;250",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    or hypertonic (&gt;350",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    electrolyte solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=see_link\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of these agents generally cause minor to moderate reactions that cease when the infusion is discontinued; however, chemotherapeutic agents can cause severe, persistent venous irritation. Some such agents also have vesicant properties and can cause necrosis of the subcutaneous tissues when leakage occurs. It is important to note that not all vesicant agents cause venous irritation during the injection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/13/218?source=see_link\">",
"     \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms and signs of venous thrombosis are related to local effects and to embolization, either to the pulmonary circulation or, paradoxically, to the systemic arterial bed.",
"   </p>",
"   <p>",
"    Local effects are due to the inflammatory reaction incited by the thrombus causing primarily pain and tenderness along the course of the vein. These findings are more obvious when a superficial vein is affected. Obstruction of upper-extremity flow may cause congestion of the collateral veins of the shoulder and chest wall on the affected side. The patient may or may not take notice of the venous patterning that results.",
"   </p>",
"   <p>",
"    Thrombosis of the deep veins can be asymptomatic or present with mild symptoms. A high index of suspicion is necessary to make the diagnosis, and some cases go unrecognized, especially in patients with a variety of other major medical problems. This may partially account for the wide variation in reported incidence of this disorder, and it underscores the need for careful clinical surveillance of patients with central venous catheters. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Diagnostic evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     No symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of asymptomatic catheter-induced UEDVT in prospective series of patients with subclavian catheters has ranged from 5 to 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/11,42,43\">",
"     11,42,43",
"    </a>",
"    ]. However, thrombi are detected in over 50 percent of patients with malignancy and those undergoing bone marrow transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/2,54\">",
"     2,54",
"    </a>",
"    ]. These thrombi range from nonocclusive mural thrombi to thrombi large enough to totally occlude the",
"    <span class=\"nowrap\">",
"     subclavian/innominate",
"    </span>",
"    system bilaterally. Why some individuals are asymptomatic, while others with thrombi in similar anatomic locations have debilitating symptoms, is largely unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Inability to draw blood from catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inability to withdraw blood from or infuse into an indwelling catheter in an otherwise asymptomatic patient is a common occurrence, being noted in 14 to 36 percent of patients within one to two years of central catheter placement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/55\">",
"     55",
"    </a>",
"    ]. The mechanism of the obstruction is either thrombotic or mechanical (eg, kink in the catheter tubing, tight suture, catheter tip positioned against vessel wall, precipitation of infused drugs or lipid residues). Mechanical problems account for 40 percent of catheter occlusions, while thrombi account for the remainder.",
"   </p>",
"   <p>",
"    Differentiating these two mechanisms is not possible solely on clinical grounds, and radiographic evaluation by plain film (to detect overt malposition) or injection of contrast material into the catheter is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Inability to infuse through a catheter is virtually always mechanical and is usually due to a tight anchoring suture or a subcutaneous kink.",
"   </p>",
"   <p>",
"    Occluding thrombus usually does not originate in the lumen of the catheter, but rather begins as a \"fibrin sheath\" encasing the catheter tip [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/57\">",
"     57",
"    </a>",
"    ]. The fibrin sheath blocks the withdrawal of blood from the catheter by creating a one-way valve over the catheter tip, impairing the ability to withdraw blood from the catheter but allowing infusion through it, the so-called \"withdrawal occlusion.\" Propagation of thrombus around the catheter ultimately prevents both infusion and withdrawal from the catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Symptomatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of catheter-related venous thrombosis are variable, and patients are often only mildly symptomatic while some have more debilitating symptoms. Physicians caring for patients with indwelling catheters must be vigilant in their attempts to identify and treat thrombotic catheter complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Phlebitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phlebitis refers to an inflammatory reaction within the vein, usually due to thrombus, which gives rise to clinical findings of pain, tenderness, induration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erythema along the course of a vein.",
"   </p>",
"   <p>",
"    Superficial thrombophlebitis is frequently associated with the use of peripheral intravenous catheters (eg, basilic or cephalic veins), and is more common in patients who are immunocompromised (eg, burns, transplant) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/9,41\">",
"     9,41",
"    </a>",
"    ]. Patients with central catheters, particularly PICC catheters, can also present with phlebitis of the superficial veins. Peripherally-inserted central catheters (PICC) can cause extensive superficial thrombophlebitis due to the length of vein traversed by the catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/12\">",
"     12",
"    </a>",
"    ]. Superficial phlebitis due to peripheral venous catheters is generally a benign, self-limited disorder once the catheter is removed. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The phlebitic reaction in deeper veins leads to pain and tenderness overlying the insertion site of the catheter. Induration, erythema, or congestion of tributary veins may be appreciated at the base of the neck, infraclavicular fossa, shoulder, or arm depending upon the location and type of catheter.",
"   </p>",
"   <p>",
"    The differential diagnosis of these symptoms in patients with underlying malignancy includes local tumor invasion, malignant lymphadenopathy, and bone metastasis, which may be complicated by pathologic fracture (especially of the clavicle).",
"   </p>",
"   <p>",
"    Suppurative thrombophlebitis causes significant local symptoms and the patient may be toxic with bacteremia or fungemia. Suppurative thrombophlebitis can be initiated by infection of catheter associated thrombus. Purulent material may emanate from the catheter exit site in patients with tunneled catheters. The management of suppurative thrombophlebitis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2055?source=see_link\">",
"     \"Suppurative (septic) thrombophlebitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Extremity edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstruction of the major thoracic veins can cause edema (usually unilateral) of the arm and hand, depending upon the extent of collateral venous flow from the upper extremity. Swelling is often exercise-dependent, and presents only when the arm is used vigorously. In some patients, the edema is a subjective symptom, described as a feeling of fullness in the fingers with rings feeling \"too tight.\"",
"   </p>",
"   <p>",
"    If bilateral upper extremity deep vein thrombosis (UEDVT) is suspected in a patient with bilateral upper extremity edema, it can be distinguished from more generalized fluid retention by the absence of lower extremity edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=see_link\">",
"     \"Clinical manifestations and diagnosis of edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high index of suspicion for occult subclavian vein thrombosis is necessary when evaluating a susceptible patient with symptoms suggestive of pulmonary emboli or acute neurologic insult. Symptoms consistent with embolization in an otherwise asymptomatic patient with a central catheter may provide the first clues to the presence of UEDVT. This possibility is often overlooked clinically. Although low, the risk of embolization is not negligible. Fatal pulmonary embolism has been reported, even in patients treated with anticoagulants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of pulmonary embolus is relatively low for both catheter-related and spontaneous upper extremity deep vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/5\">",
"     5",
"    </a>",
"    ]. In patients with upper extremity deep vein thrombosis, one US registry (324 patients) and one European Registry (11,564 patients) reported rates of symptomatic pulmonary embolus of 1 and 8 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The incidence is higher in patients with cancer. A higher incidence of 36 percent was reported in one study but may reflect the higher incidence of patients with thrombotic disorders and cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possibility of paradoxical systemic arterial embolism from subclavian vein thrombosis must be kept in mind. The prevalence of cardiac septal defects in the general population is high, and demonstration of patent foramen ovale is a risk factor for cryptogenic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link&amp;anchor=H3#H3\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Paradoxical emboli'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clinical prediction score",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical score for predicting the presence of upper extremity deep vein thrombosis (DVT) was developed in a derivation cohort of 140 patients, and confirmed in two separate validation cohorts with a total of 217 additional patients. All episodes were objectively confirmed by ultrasound examination. A risk score was generated from the following four parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of a catheter or access device in a subclavian or jugular vein or a pacemaker (plus 1 point)",
"     </li>",
"     <li>",
"      Unilateral pitting edema (plus 1 point)",
"     </li>",
"     <li>",
"      Presence of localized pain in that extremity (plus 1 point)",
"     </li>",
"     <li>",
"      Another diagnosis at least as plausible (minus 1 point)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Total scores were then rated as low probability (zero points or less, prevalence of upper extremity DVT 9 to 13 percent), intermediate probability (one point, prevalence 20 to 38 percent), or high probability (2 to 3 points, prevalence 64 to 70 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methods to diagnose catheter-induced upper extremity deep vein thrombosis (UEDVT) are similar to those of the primary (spontaneous) UEDVT (ie, Paget-Schroetter syndrome). However, a greater emphasis should be placed on noninvasive methods, usually beginning with duplex ultrasound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=see_link&amp;anchor=H185997417#H185997417\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Duplex ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound examination is the screening tool of choice because it is noninvasive and easy to perform [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/66\">",
"     66",
"    </a>",
"    ]. Non-compressibility of the vein with or without visible intraluminal thrombus is the major criterion for the diagnosis of thrombosis. Sensitivity and specificity range from 80 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/62,67-69\">",
"     62,67-69",
"    </a>",
"    ]. The chances of a false positive study are very low; however, nonocclusive mural thrombus and thrombus in the proximal subclavian or innominate veins (generally shadowed by the clavicle and sternum) may not be adequately visualized. Additional imaging may be needed if the clinical suspicion for thrombosis is high. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=see_link&amp;anchor=H185997417#H185997417\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When asymptomatic UEDVT is suspected, the same techniques effective in the diagnosis of symptomatic thrombi are employed. However, duplex ultrasound has a lower sensitivity in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/70\">",
"     70",
"    </a>",
"    ], making a negative study noncontributory to patient care.",
"   </p>",
"   <p>",
"    Because thrombi can organize and become a permanent impediment to subclavian catheterization, all patients who have a history of a UEDVT should be screened for patency of the central veins prior to placement of a subsequent catheter. Veins found to be obstructed on ultrasonography are unlikely to be successfully catheterized [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with asymptomatic or nonocclusive deep vein thrombus or superficial vein thrombus of veins approaching the deep venous system (eg, basilic vein, cephalic vein) who do not respond to removal of the catheter and other conservative measures, or have progression of their symptoms, should undergo repeat duplex examination to evaluate for progression or extension of clot.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Venography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venography may be indicated if clinical suspicion for upper extremity deep vein thrombosis (UEDVT) is high and the ultrasound is negative or nondiagnostic. For mechanical catheter problems, instillation of intravenous contrast into the lumen of the catheter under fluoroscopy may readily demonstrate the presence of thrombus at the tip of the catheter.",
"   </p>",
"   <p>",
"    Digital subtraction venography can be performed if an aggressive diagnostic approach is required [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/71\">",
"     71",
"    </a>",
"    ]. Venography requires cannulation of either a peripheral vein or other central vein (eg, subclavian, femoral). Because poor venous patency is one of the reasons that indwelling catheters are needed in the first place, access for venography can be challenging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals in managing catheter-related upper extremity venous thrombosis include alleviation of symptoms, minimizing the risk for embolization and providing for continued intravenous access, if it is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Phlebitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data to guide management of upper extremity superficial vein thrombosis. Fortunately, it appears that pulmonary embolus from superficial phlebitis is very rare. The initial management of superficial phlebitis related to peripheral intravenous catheters consists of discontinuing the intravenous infusion and removing the peripheral catheter. Symptomatic care includes extremity elevation, warm or cool compresses, and oral nonsteroidal anti-inflammatory agents (NSAIDS). Topical NSAIDs may also be effective in relieving local burning associated with superficial phlebitis.",
"   </p>",
"   <p>",
"    It has been shown for spontaneous lower extremity superficial thrombophlebitis that patients who are not anticoagulated have a higher incidence of persistent pain and thrombus",
"    <span class=\"nowrap\">",
"     recurrence/extension.",
"    </span>",
"    Based upon a systematic review of randomized trials, anticoagulation is suggested in patients with lower extremity superficial vein thrombosis who are at risk for deep vein thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=see_link&amp;anchor=H23#H23\">",
"     \"Superficial thrombophlebitis of the lower extremity\", section on 'Anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extrapolating from these data, it would be reasonable to also consider anticoagulation for patients with upper extremity superficial vein thrombosis who are at risk for deep vein thrombosis (eg, superficial thrombosis in proximity to the deep veins, thrombophilia).",
"   </p>",
"   <p>",
"    Patients with proximal basilic or cephalic vein thrombosis who remain symptomatic (eg, edema, pain) in spite of catheter removal may also be considered for treatment to manage symptoms. As with superficial thrombophlebitis of the lower extremity, anticoagulation in these patients should be highly effective in alleviating symptoms, especially in the setting of malignancy. Whether anticoagulation improves the future patency of the superficial veins has not been adequately investigated. The duration of therapy under these circumstances needs to be guided by clinical judgement. Ultrasound can be repeated if symptoms progress to rule out extension into the deep venous system. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Duplex ultrasonography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The catheter insertion site should also be monitored. Excessive pain may indicate suppurative phlebitis, chemical phlebitis or extravasation of infused fluid into the subcutaneous tissues. Additional treatment, including surgery, may be required to manage extravasation injuries. Antibiotics should be initiated if there is any concern for suppurative thrombophlebitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2055?source=see_link\">",
"     \"Suppurative (septic) thrombophlebitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/13/218?source=see_link\">",
"     \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Deep vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with UEDVT, embolization (either to the pulmonary circulation or, paradoxically, to the arterial circulation) is a major cause of morbidity and mortality. Thus, therapy for UEDVT is directed toward preventing this complication. Anticoagulant therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    , low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [LMWH], unfractionated heparin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ) is generally effective for preventing pulmonary embolism in patients with lower extremity deep vein thrombosis. By inference, anticoagulation should also be effective for preventing embolization of thrombi from the thoracic veins, although treatment failures occur at both locations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/59\">",
"     59",
"    </a>",
"    ]. However, no treatment scheme has been rigorously evaluated for its efficacy in preventing embolization from upper extremity sources. As a result, recommendations for the treatment of UEDVT are based largely upon indirect evidence from the experience with deep vein thrombosis of the lower extremities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with catheter-related thrombosis become rapidly asymptomatic with various combinations of observation, anticoagulation, and removal of the thrombogenic stimulus (the catheter) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/60,72-74\">",
"     60,72-74",
"    </a>",
"    ]. Individual case reports suggest that some patients with catheter-related thrombosis have symptoms that do not resolve; however, these patients appear to be in the minority [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Catheter-induced upper extremity deep vein thrombosis (UEDVT) is generally managed more conservatively compared with primary (spontaneous) UEDVT. The more aggressive approach used with spontaneous UEDVT therapy is due to a higher incidence of postphlebitic sequelae. A systematic review identified seven studies that evaluated the incidence and risk factors for post-thrombotic syndrome (PTS) following upper extremity deep venous thrombosis in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/76\">",
"     76",
"    </a>",
"    ]. The incidence ranged from 7 to 46 percent. Residual thrombosis and axillosubclavian vein thrombosis were associated with PTS, but catheter-associated UEDVT was associated with decreased risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=see_link\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite a lack of direct evidence proving safety and efficacy of anticoagulation for upper extremity deep vein thrombosis, anticoagulant therapy with a goal of relieving acute symptoms and preventing embolization remains the cornerstone of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. In patients with acute UEDVT involving the axillary or more proximal veins, we recommend anticoagulation, as described for lower extremity DVT, provided there are no contraindications, with or without catheter removal. Our recommendation is consistent with guidelines from the American College of Chest Physicians (ACCP) and other International guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type and intensity of anticoagulant therapy with catheter-induced UEDVT should be similar to that given to prevent embolization of thrombi from the deep veins of the legs. We suggest initial therapy with parenteral anticoagulants (LMWH,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    , unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ) followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or LMWH. There are no data comparing warfarin directly to LMWH in UEDVT, as well as no data on the use of new oral anticoagulants in UEDVT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/79\">",
"     79",
"    </a>",
"    ]. Therapeutic options are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine removal of the catheter is not recommended. In patients who have an ongoing need for the catheter, it is reasonable to administer anticoagulant therapy without catheter removal, provided the line remains functional and well-positioned [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/7,79\">",
"     7,79",
"    </a>",
"    ]. This approach has been associated with good clinical outcomes in small series of patients, including patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/44,73,81,82\">",
"     44,73,81,82",
"    </a>",
"    ]. The optimal duration of anticoagulation when the catheter stays in place has not been standardized. The ACCP guidelines recommend continuing anticoagulation as long as the central venous catheter remains in place, especially in patients with cancer. If the catheter needs to be removed, there are currently no data to indicate whether CVC removal should be preceded by a brief period of anticoagulation to minimize risk of embolization.",
"   </p>",
"   <p>",
"    There is uncertainty about the need to anticoagulate patients with thrombosis confined to the brachial vein [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/79\">",
"     79",
"    </a>",
"    ]. The risk of long-term chronic venous sequelae from venous obstruction at this site generally appears to be quite small. The ACCP guidelines favor anticoagulation for up to three months if the thrombosis is symptomatic, associated with cancer, or the catheter remains in place [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Asymptomatic thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of asymptomatic upper extremity deep vein thrombosis (UEDVT) is more controversial and less well-defined than treatment of symptomatic thrombi. While asymptomatic thrombi in the leg are well recognized as a source of embolization, the rate of this or other complications with asymptomatic subclavian vein thrombosis is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/62,83\">",
"     62,83",
"    </a>",
"    ]. Consequently, the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    analysis of any potential treatment cannot be determined.",
"   </p>",
"   <p>",
"    However, there is no theoretical reason to believe that the risk of embolization is different than that of symptomatic subclavian vein thrombi, unless the thrombus is chronic in nature. In addition, asymptomatic UEDVT can cause permanent obstruction in the subclavian vein and may interfere with subsequent catheter placement, resulting in loss of central venous access on the affected side. As an example of this last point, one series noted that 14 percent of patients undergoing a second or third catheter placement failed the procedure because of obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Deep vein fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some authors have advocated the use of interventions such as catheter-directed fibrinolytic therapy for catheter-induced upper extremity deep vein thrombosis (UEDVT), there is no hard evidence that better outcomes are achieved compared with more conservative therapy with anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. These interventions are time-consuming, expensive, and not without morbidity. Since thrombolytic therapy is indicated to minimize long-term symptoms, the impact of this potential problem on the patient's quality of life should first be determined.",
"   </p>",
"   <p>",
"    Catheter-directed fibrinolytic therapy would seem logical for individuals with significant symptoms in the acute stages of thrombosis (symptoms less than 14 days), who have low risk for bleeding and good long-term prognosis relative to their underlying disease and whose lifestyles require vigorous use of the affected arm. On the other hand, a patient with limited life expectancy from his or her coexistent medical problems, who does not require extensive and vigorous use of his or her arm, would probably do just as well with conservative therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Catheter management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Functioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of the catheter is justified if it is mandatory, functional, in the correct position, and not infected. Anticoagulation is instituted and clinical symptoms monitored closely for signs of improvement for as long as the catheter is present [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/77\">",
"     77",
"    </a>",
"    ]. Worsening of symptoms while anticoagulated indicates a need to remove the line and repeat the duplex examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Occluded",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occluded catheters are often removed and replaced. However, many patients have limited access sites and salvage of a catheter that has a thrombotic (ie, not mechanical) occlusion can be attempted with the instillation of fibrinolytic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/55,86\">",
"     55,86",
"    </a>",
"    ]. The decision to use thrombolytic therapy for refractory thrombi is mainly clinical, considering the available resources (drug availability, outpatient infusion pumps, etc) and the degree of need for rapid restoration of catheter function. For thrombotic occlusions unresponsive to two or more boluses of a thrombolytic agent, objective diagnosis with radiologic techniques is advisable, since many instances will be due to mechanical problems amenable only to mechanical solutions. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Venography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Tissue-type plasminogen activator (t-PA),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , the t-PA derivatives",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    , or urokinase can be used in this setting. Among these, alteplase (Cathflo, Activase) is most commonly used to manage catheter thrombosis. Alteplase is available in 2 mg vials for use in this setting. For adults or children weighing &ge;30 kg, one or two doses of 2 mg (1",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    of alteplase (tissue-type plasminogen activator) with a recommended dwell time of 30 to 120 minutes per dose, is generally successful in restoring catheter function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/87\">",
"     87",
"    </a>",
"    ]. Lower weight patients should receive a reduced dose adjusted to catheter lumen volume.",
"   </p>",
"   <p>",
"    In randomized trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    appears to be superior to urokinase [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. In one trial, up to two doses of alteplase (allowed to incubate for two hours) resulted in restoration of catheter function in 89 percent of catheters, compared with only 59 percent of catheters receiving up to two 10,000 unit boluses of urokinase [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/88\">",
"     88",
"    </a>",
"    ]. Thirteen catheters treated with alteplase had resolution of function after a single dose, compared with only 4 of 22 catheters treated with urokinase (46 versus 18 percent). The efficacy and safety of local instillation of alteplase was confirmed in subsequent trials with catheter function restored in 74 percent and 90 percent after one or two doses respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/89,90\">",
"     89,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although some reports suggest that the newer t-PA derivatives may be superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , randomized trials comparing these agents are not available [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     THROMBOSIS PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic systemic anticoagulation is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for patients with indwelling central venous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/77,79,80,91-93\">",
"     77,79,80,91-93",
"    </a>",
"    ]. Although randomized trials have not definitively demonstrated a clinically significant benefit for prophylactic anticoagulation in patients with malignancy, a decision for prophylactic anticoagulation may be reasonable if the clinical evaluation suggests the risks associated with thrombosis outweigh the risks of bleeding, taking into account tumor location and any prior history of thrombosis or bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. It may be possible to identify high-risk patients who will benefit from prophylactic anticoagulation based upon specific factors (eg, chemotherapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/22\">",
"     22",
"    </a>",
"    ]. A reasonable alternative to prophylactic anticoagulation when the perceived risk of thrombosis is high may be to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -bonded catheters, where available [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13360722\">",
"     'Heparin-bonded catheters'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H692376821\">",
"    <span class=\"h2\">",
"     Prophylactic anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most randomized trials evaluating prophylactic anticoagulation with low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (VKA) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/42,96-101\">",
"     42,96-101",
"    </a>",
"    ], unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/102\">",
"     102",
"    </a>",
"    ], or low molecular weight heparin (LMWH) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/96,99,103-108\">",
"     96,99,103-108",
"    </a>",
"    ] have been performed in patients with cancer. These patients have a high risk for venous thrombosis, yet a definitive clinical benefit for prophylactic anticoagulation in preventing catheter-related venous thrombosis has yet to be proven [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/77,109-113\">",
"     77,109-113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large randomized trial (WARP trial), 1590 patients with cancer were randomly assigned to dose-adjusted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (to maintain an INR between 1.5 and 2.0), low-dose warfarin (1 mg), or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/98\">",
"     98",
"    </a>",
"    ]. Prophylactic anticoagulation did not reduce the rate of symptomatic catheter-related thromboses (95% CI 0.57-1.72).",
"   </p>",
"   <p>",
"    An updated Cochrane analysis reviewed 12 randomized trials (3,611 patients) to assess the efficacy and safety of prophylactic",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"      heparin",
"     </a>",
"     /LMWH",
"    </span>",
"    or low dose vitamin K antagonists (VKAs) in the prevention of catheter-induced venous thrombosis in patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/93\">",
"     93",
"    </a>",
"    ]. Both treatments were associated with a trend toward a reduction of symptomatic DVT (RR 0.54, 95% CI 0.28-1.05 for heparin; RR 0.63, 95% CI 0.35-1.11 for low dose VKAs). There was no significant difference in bleeding, infection, or mortality. Interestingly, the observed baseline risk of thrombosis was lower in the most recent publications. This would suggest that recent advances in the care of central venous catheters (port flushing), choice of catheter insertion and location, and the availability of new material and design of catheters have contributed to an overall lower risk of catheter-induced thrombosis.",
"   </p>",
"   <p>",
"    Although randomized trials have not demonstrated a clinically significant benefit for routine prophylactic anticoagulation in patients with malignancies, it may be reasonable to consider in high&ndash;risk patients when the perceived risk of thrombosis outweighs the risk of bleeding. High risk factors include previous venous thrombosis, bulky disease, hereditary thrombophilia, or suboptimal catheter tip location [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/22,94\">",
"     22,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anticoagulation for prophylaxis against peripherally inserted central catheter (PICC)-related UEDVT was investigated in one small prospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/12\">",
"     12",
"    </a>",
"    ]. Larger randomized trials are needed before any conclusions can be drawn about prophylactic anticoagulation in patients with PICC catheters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13360722\">",
"    <span class=\"h2\">",
"     Heparin-bonded catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of central venous catheters are available that have",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -bonded coatings designed to reduce catheter-associated thrombosis. To date, technology has not been able to produce heparin bonding that is sufficiently sustainable for use in longer-term catheters. Two randomized trials compared the complication rates associated with heparin-bonded and standard catheters in critically ill children requiring central venous catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/114,115\">",
"     114,115",
"    </a>",
"    ]. In the larger of these trials, 209 patients were enrolled and followed with serial ultrasound and blood cultures every three days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/115\">",
"     115",
"    </a>",
"    ]. Heparin-coated catheters were associated with a decreased risk of thrombosis (0 versus 8 percent) and positive blood cultures (4 versus 33 percent). Upper extremity deep vein thrombosis (UEDVT) was also reduced (8 versus 44 percent) in a similarly designed trial in 50 pediatric intensive care unit patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/114\">",
"     114",
"    </a>",
"    ]. No advantage was found for infants less than a year old in a trial comparing heparin-bonded catheters to non-heparin-bonded catheters in infants with congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/116\">",
"     116",
"    </a>",
"    ]. Alternatives to heparin-bonded catheters with novel materials reported to have a very low incidence of thrombosis and microbial attachment are in clinical development [",
"    <a class=\"abstract\" href=\"UTD.htm?26/26/27050/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/16/21762?source=see_link\">",
"       \"Patient information: Superficial phlebitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous catheters cause endothelial trauma and vein wall inflammation, which can result in thrombosis. The majority of venous thrombotic events are due to peripheral intravenous catheters. Central catheters can cause upper extremity deep venous thrombosis (UEDVT) involving the subclavian, jugular, axillary or brachial veins, which may lead to complications such as pulmonary embolism or post-thrombotic syndrome of the upper extremity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A wide variation is reported for the incidence of catheter-induced UEDVT depending upon the catheter type, location, and the population studied. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for catheter-induced upper extremity venous thrombosis include catheter-related factors (eg, catheter malposition, catheter size), the presence of prothrombotic states (congenital or acquired), hormonal therapy, and infusion of irritating substances. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of symptoms and signs of catheter-induced venous thrombosis are related to local effects of the thrombus (ie, phlebitis, venous obstruction). Although less common, symptoms and signs arising from embolization to the pulmonary circulation, or paradoxically to the systemic circulation via a patent foramen ovale (eg, brain) can also occur. A high index of suspicion for occult UEDVT is needed when susceptible patients with symptoms suggestive of pulmonary emboli or acute neurologic insult are being evaluated. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Duplex ultrasound is the screening test of choice when UEDVT is suspected in asymptomatic and symptomatic patients. Patients who have had prior UEDVT should be screened for patency of the central veins prior to placement of a subsequent catheter. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Superficial phlebitis related to peripheral intravenous catheters should be managed first by discontinuing the intravenous infusion and removing the peripheral catheter. Symptomatic care consists of extremity elevation, warm or cool compresses, and oral nonsteroidal anti-inflammatory drugs (NSAIDs). Excessive pain not controlled with NSAIDs may indicate the presence of a suppurative phlebitis, chemical phlebitis, or extravasation injury. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Phlebitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients diagnosed with catheter-induced UEDVT, we suggest anticoagulation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For uncomplicated cases, three months of anticoagulation therapy should be sufficient. A longer duration of anticoagulation may be warranted if the catheter remains in place, particularly for patients with cancer. The catheter can be left in place if it is functional and there is an ongoing need. For noncancer patients with thrombosis confined to the brachial vein, there is uncertainty about the need for anticoagulation once the catheter has been removed in patients. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients diagnosed with catheter-induced UEDVT, we suggest not instituting deep vein thrombolysis as a first line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Compared with anticoagulation, there is insufficient evidence to suggest that thrombolysis leads to any better outcomes. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Deep vein fibrinolysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with indwelling upper extremity catheters, we recommend",
"      <strong>",
"       not",
"      </strong>",
"      administering prophylactic anticoagulation (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , low molecular weight heparin) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients with cancer, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      routinely administering prophylactic anticoagulation (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). It may be reasonable to administer prophylactic anticoagulation in high&ndash;risk patients when the perceived risk of thrombosis outweighs the risk of bleeding. High-risk factors include previous venous thrombosis, bulky disease, hereditary thrombophilia, or suboptimal catheter tip location. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Thrombosis prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/1\">",
"      AbuRahma AF, Sadler D, Stuart P, et al. Conventional versus thrombolytic therapy in spontaneous (effort) axillary-subclavian vein thrombosis. Am J Surg 1991; 161:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/2\">",
"      Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21:3665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/3\">",
"      Mustafa S, Stein PD, Patel KC, et al. Upper extremity deep venous thrombosis. Chest 2003; 123:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/4\">",
"      Flinterman LE, Van Der Meer FJ, Rosendaal FR, Doggen CJ. Current perspective of venous thrombosis in the upper extremity. J Thromb Haemost 2008; 6:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/5\">",
"      Joffe HV, Kucher N, Tapson VF, et al. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 2004; 110:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/6\">",
"      Mu&ntilde;oz FJ, Mismetti P, Poggio R, et al. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 2008; 133:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/7\">",
"      Kucher N. Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med 2011; 364:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/8\">",
"      Owens CA, Bui JT, Knuttinen MG, et al. Pulmonary embolism from upper extremity deep vein thrombosis and the role of superior vena cava filters: a review of the literature. J Vasc Interv Radiol 2010; 21:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/9\">",
"      Otten TR, Stein PD, Patel KC, et al. Thromboembolic disease involving the superior vena cava and brachiocephalic veins. Chest 2003; 123:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/10\">",
"      Rooden CJ, Tesselaar ME, Osanto S, et al. Deep vein thrombosis associated with central venous catheters - a review. J Thromb Haemost 2005; 3:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/11\">",
"      Luciani A, Clement O, Halimi P, et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 2001; 220:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/12\">",
"      Paauw JD, Borders H, Ingalls N, et al. The incidence of PICC line-associated thrombosis with and without the use of prophylactic anticoagulants. JPEN J Parenter Enteral Nutr 2008; 32:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/13\">",
"      Bonizzoli M, Batacchi S, Cianchi G, et al. Peripherally inserted central venous catheters and central venous catheters related thrombosis in post-critical patients. Intensive Care Med 2011; 37:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/14\">",
"      Evans RS, Sharp JH, Linford LH, et al. Risk of symptomatic DVT associated with peripherally inserted central catheters. Chest 2010; 138:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/15\">",
"      Trerotola SO, Stavropoulos SW, Mondschein JI, et al. Triple-lumen peripherally inserted central catheter in patients in the critical care unit: prospective evaluation. Radiology 2010; 256:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/16\">",
"      Major KM, Bulic S, Rowe VL, et al. Internal jugular, subclavian, and axillary deep venous thrombosis and the risk of pulmonary embolism. Vascular 2008; 16:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/17\">",
"      Saseedharan S, Bhargava S. Upper extremity deep vein thrombosis. Int J Crit Illn Inj Sci 2012; 2:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/18\">",
"      Safdar N, Maki DG. Risk of catheter-related bloodstream infection with peripherally inserted central venous catheters used in hospitalized patients. Chest 2005; 128:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/19\">",
"      Yukisawa S, Fujiwara Y, Yamamoto Y, et al. Upper-extremity deep vein thrombosis related to central venous port systems implanted in cancer patients. Br J Radiol 2010; 83:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/20\">",
"      Mandal S, Pande A, Mandal D, et al. Permanent pacemaker-related upper extremity deep vein thrombosis: a series of 20 cases. Pacing Clin Electrophysiol 2012; 35:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/21\">",
"      Da Costa SS, Scalabrini Neto A, Costa R, et al. Incidence and risk factors of upper extremity deep vein lesions after permanent transvenous pacemaker implant: a 6-month follow-up prospective study. Pacing Clin Electrophysiol 2002; 25:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/22\">",
"      Saber W, Moua T, Williams EC, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost 2011; 9:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/23\">",
"      Nifong TP, McDevitt TJ. The effect of catheter to vein ratio on blood flow rates in a simulated model of peripherally inserted central venous catheters. Chest 2011; 140:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/24\">",
"      Grove JR, Pevec WC. Venous thrombosis related to peripherally inserted central catheters. J Vasc Interv Radiol 2000; 11:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/25\">",
"      Liem TK, Yanit KE, Moseley SE, et al. Peripherally inserted central catheter usage patterns and associated symptomatic upper extremity venous thrombosis. J Vasc Surg 2012; 55:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/26\">",
"      Marnejon T, Angelo D, Abu Abdou A, Gemmel D. Risk factors for upper extremity venous thrombosis associated with peripherally inserted central venous catheters. J Vasc Access 2012; 13:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/27\">",
"      King MM, Rasnake MS, Rodriguez RG, et al. Peripherally inserted central venous catheter-associated thrombosis: retrospective analysis of clinical risk factors in adult patients. South Med J 2006; 99:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/28\">",
"      Brook I, Frazier EH. Aerobic and anaerobic microbiology of superficial suppurative thrombophlebitis. Arch Surg 1996; 131:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/29\">",
"      Raad II, Luna M, Khalil SA, et al. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994; 271:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/30\">",
"      van Rooden CJ, Schippers EF, Barge RM, et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005; 23:2655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/31\">",
"      O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/32\">",
"      Dentali F, Gianni M, Agnelli G, Ageno W. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost 2008; 6:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/33\">",
"      Warkentin TE, Cook DJ. Current perspective of venous thrombosis in the upper extremity: a rebuttal. J Thromb Haemost 2009; 7:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/34\">",
"      Fijnheer R, Paijmans B, Verdonck LF, et al. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 2002; 118:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/35\">",
"      Leebeek FW, Stadhouders NA, van Stein D, et al. Hypercoagulability states in upper-extremity deep venous thrombosis. Am J Hematol 2001; 67:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/36\">",
"      Riordan M, Weiden PL. Factor V Leiden mutation does not account for central venous catheter-related thrombosis. Am J Hematol 1998; 58:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/37\">",
"      Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Doggen CJ. Venous thrombosis of the upper extremity: effect of blood group and coagulation factor levels on risk. Br J Haematol 2010; 149:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/38\">",
"      Martinelli I, Battaglioli T, Bucciarelli P, et al. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation 2004; 110:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/39\">",
"      Van Rooden CJ, Rosendaal FR, Meinders AE, et al. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004; 89:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/40\">",
"      Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003; 101:3049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/41\">",
"      Anderson AJ, Krasnow SH, Boyer MW, et al. Thrombosis: the major Hickman catheter complication in patients with solid tumor. Chest 1989; 95:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/42\">",
"      Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/43\">",
"      Lokich JJ, Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer 1983; 52:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/44\">",
"      Lokich JJ, Bothe A Jr, Benotti P, Moore C. Complications and management of implanted venous access catheters. J Clin Oncol 1985; 3:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/45\">",
"      Oakley GJ, Downey GO, King LA, et al. Symptomatic central venous thrombosis and long-term right atrial catheters. Gynecol Oncol 1990; 36:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/46\">",
"      Bona RD. Central line thrombosis in patients with cancer. Curr Opin Pulm Med 2003; 9:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/47\">",
"      Vay&aacute; A, Mira Y, Mateo J, et al. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. Thromb Haemost 2003; 89:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/48\">",
"      H&eacute;ron E, Lozinguez O, Alhenc-Gelas M, et al. Hypercoagulable states in primary upper-extremity deep vein thrombosis. Arch Intern Med 2000; 160:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/49\">",
"      Loret de Mola JR, Kiwi R, Austin C, Goldfarb JM. Subclavian deep vein thrombosis associated with the use of recombinant follicle-stimulating hormone (Gonal-F) complicating mild ovarian hyperstimulation syndrome. Fertil Steril 2000; 73:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/50\">",
"      Todros T, Carmazzi CM, Bontempo S, et al. Spontaneous ovarian hyperstimulation syndrome and deep vein thrombosis in pregnancy: case report. Hum Reprod 1999; 14:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/51\">",
"      Rao AK, Chitkara U, Milki AA. Subclavian vein thrombosis following IVF and ovarian hyperstimulation: a case report. Hum Reprod 2005; 20:3307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/52\">",
"      Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral venous catheters. A randomized controlled trial. Ann Intern Med 1991; 114:845.",
"     </a>",
"    </li>",
"    <li>",
"     Skillman, JJ. Superficial phlebitis: Inflammatory, infectious associated with deep vein thrombosis. In: Decision Making in Vascular Surgery, Cronenwett, JL, Rutherford, RB (Eds), WB Saunders, NY, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/54\">",
"      Haire WD, Lieberman RP, Lund GB, et al. Thrombotic complications of silicone rubber catheters during autologous marrow and peripheral stem cell transplantation: prospective comparison of Hickman and Groshong catheters. Bone Marrow Transplant 1991; 7:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/55\">",
"      Baskin JL, Pui CH, Reiss U, et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet 2009; 374:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/56\">",
"      Stephens LC, Haire WD, Kotulak GD. Are clinical signs accurate indicators of the cause of central venous catheter occlusion? JPEN J Parenter Enteral Nutr 1995; 19:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/57\">",
"      Lund GB, Lieberman RP, Haire WD. Central venous catheters. Semin Intervent Radiol 1989; 6:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/58\">",
"      Leiby JM, Purcell H, DeMaria JJ, et al. Pulmonary embolism as a result of Hickman catheter-related thrombosis. Am J Med 1989; 86:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/59\">",
"      Monreal M, Raventos A, Lerma R, et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines--a prospective study. Thromb Haemost 1994; 72:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/60\">",
"      Donayre CE, White GH, Mehringer SM, Wilson SE. Pathogenesis determines late morbidity of axillosubclavian vein thrombosis. Am J Surg 1986; 152:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/61\">",
"      Black MD, French GJ, Rasuli P, Bouchard AC. Upper extremity deep venous thrombosis. Underdiagnosed and potentially lethal. Chest 1993; 103:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/62\">",
"      Prandoni P, Polistena P, Bernardi E, et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997; 157:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/63\">",
"      DeRook FA, Comess KA, Albers GW, Popp RL. Transesophageal echocardiography in the evaluation of stroke. Ann Intern Med 1992; 117:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/64\">",
"      Di Tullio M, Sacco RL, Gopal A, et al. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med 1992; 117:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/65\">",
"      Constans J, Salmi LR, Sevestre-Pietri MA, et al. A clinical prediction score for upper extremity deep venous thrombosis. Thromb Haemost 2008; 99:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/66\">",
"      Desjardins B, Rybicki FJ, Kim HS, et al. ACR Appropriateness Criteria&reg; Suspected upper extremity deep vein thrombosis. J Am Coll Radiol 2012; 9:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/67\">",
"      Baarslag HJ, van Beek EJ, Koopman MM, Reekers JA. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. Ann Intern Med 2002; 136:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/68\">",
"      K&ouml;ksoy C, Kuzu A, Kutlay J, et al. The diagnostic value of colour Doppler ultrasound in central venous catheter related thrombosis. Clin Radiol 1995; 50:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/69\">",
"      Knudson GJ, Wiedmeyer DA, Erickson SJ, et al. Color Doppler sonographic imaging in the assessment of upper-extremity deep venous thrombosis. AJR Am J Roentgenol 1990; 154:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/70\">",
"      Haire WD, Lynch TG, Lieberman RP, Edney JA. Duplex scans before subclavian vein catheterization predict unsuccessful catheter placement. Arch Surg 1992; 127:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/71\">",
"      Andrews JC, Williams DM, Cho KJ. Digital subtraction venography of the upper extremity. Clin Radiol 1987; 38:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/72\">",
"      Haire WD, Lieberman RP, Edney J, et al. Hickman catheter-induced thoracic vein thrombosis. Frequency and long-term sequelae in patients receiving high-dose chemotherapy and marrow transplantation. Cancer 1990; 66:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/73\">",
"      Moss JF, Wagman LD, Riihimaki DU, Terz JJ. Central venous thrombosis related to the silastic Hickman-Broviac catheter in an oncologic population. JPEN J Parenter Enteral Nutr 1989; 13:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/74\">",
"      Smith VC, Hallett JW Jr. Subclavian vein thrombosis during prolonged catheterization for parenteral nutrition: early management and long-term follow-up. South Med J 1983; 76:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/75\">",
"      Becker DM, Philbrick JT, Walker FB 4th. Axillary and subclavian venous thrombosis. Prognosis and treatment. Arch Intern Med 1991; 151:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/76\">",
"      Elman EE, Kahn SR. The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: a systematic review. Thromb Res 2006; 117:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/77\">",
"      Debourdeau P, Kassab Chahmi D, Le Gal G, et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol 2009; 20:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/78\">",
"      Martinelli I, Franchini M, Mannucci PM. How I treat rare venous thromboses. Blood 2008; 112:4818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/79\">",
"      Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/80\">",
"      Debourdeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 2013; 11:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/81\">",
"      Jones MA, Lee DY, Segall JA, et al. Characterizing resolution of catheter-associated upper extremity deep venous thrombosis. J Vasc Surg 2010; 51:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/82\">",
"      Kovacs MJ, Kahn SR, Rodger M, et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007; 5:1650.",
"     </a>",
"    </li>",
"    <li>",
"     Hirsch, J, Hull, RD. Natural history and clinical features of venous thrombosis. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, Colman, RW, Hirsch, J, Marder, VJ, Salzman, EW (Eds), JB Lippincott, Philadelphia 1987. p.1208.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/84\">",
"      Fraschini G, Jadeja J, Lawson M, et al. Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients. J Clin Oncol 1987; 5:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/85\">",
"      Seigel EL, Jew AC, Delcore R, et al. Thrombolytic therapy for catheter-related thrombosis. Am J Surg 1993; 166:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/86\">",
"      Baskin JL, Reiss U, Wilimas JA, et al. Thrombolytic therapy for central venous catheter occlusion. Haematologica 2012; 97:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/87\">",
"      Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/88\">",
"      Haire WD, Atkinson JB, Stephens LC, Kotulak GD. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. Thromb Haemost 1994; 72:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/89\">",
"      Semba CP, Deitcher SR, Li X, et al. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients. J Vasc Interv Radiol 2002; 13:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/90\">",
"      Ponec D, Irwin D, Haire WD, et al. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001; 12:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/91\">",
"      Akl EA, Kamath G, Yosuico V, et al. Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. Cancer 2008; 112:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/92\">",
"      Schiffer CA, Mangu PB, Wade JC, et al. Central venous catheter care for the patient with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol 2013; 31:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/93\">",
"      Akl EA, Vasireddi SR, Gunukula S, et al. Anticoagulation for patients with cancer and central venous catheters. Cochrane Database Syst Rev 2011; :CD006468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/94\">",
"      Prandoni P. Prophylaxis of catheter-related thrombosis in cancer patients. Lancet 2009; 373:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/95\">",
"      Klerk CP, Smorenburg SM, B&uuml;ller HR. Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. Arch Intern Med 2003; 163:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/96\">",
"      De Cicco M, Matovic M, Balestreri L, et al. Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. Ann Oncol 2009; 20:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/97\">",
"      Couban S, Goodyear M, Burnell M, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005; 23:4063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/98\">",
"      Young AM, Billingham LJ, Begum G, et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 2009; 373:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/99\">",
"      Mismetti P, Mille D, Laporte S, et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica 2003; 88:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/100\">",
"      Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J 2002; 32:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/101\">",
"      Ruud E, Holmstr&oslash;m H, De Lange C, et al. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies--a randomized, controlled study. Acta Paediatr 2006; 95:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/102\">",
"      Abdelkefi A, Ben Othman T, Kammoun L, et al. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial. Thromb Haemost 2004; 92:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/103\">",
"      Karthaus M, Kretzschmar A, Kr&ouml;ning H, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006; 17:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/104\">",
"      Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005; 23:4057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/105\">",
"      Niers TM, Di Nisio M, Klerk CP, et al. Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost 2007; 5:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/106\">",
"      Massicotte P, Julian JA, Gent M, et al. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res 2003; 109:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/107\">",
"      Monreal M, Alastrue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/108\">",
"      Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/109\">",
"      Cunningham MS, White B, Hollywood D, O'Donnell J. Primary thromboprophylaxis for cancer patients with central venous catheters--a reappraisal of the evidence. Br J Cancer 2006; 94:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/110\">",
"      Kirkpatrick A, Rathbun S, Whitsett T, Raskob G. Prevention of central venous catheter-associated thrombosis: a meta-analysis. Am J Med 2007; 120:901.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/111\">",
"      Chaukiyal P, Nautiyal A, Radhakrishnan S, et al. Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost 2008; 99:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/112\">",
"      Rawson KM, Newburn-Cook CV. The use of low-dose warfarin as prophylaxis for central venous catheter thrombosis in patients with cancer: a meta-analysis. Oncol Nurs Forum 2007; 34:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/113\">",
"      Carrier M, Tay J, Fergusson D, Wells PS. Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials. J Thromb Haemost 2007; 5:2552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/114\">",
"      Krafte-Jacobs B, Sivit CJ, Mejia R, Pollack MM. Catheter-related thrombosis in critically ill children: comparison of catheters with and without heparin bonding. J Pediatr 1995; 126:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/115\">",
"      Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med 2000; 26:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/26/27050/abstract/116\">",
"      Anton N, Cox PN, Massicotte MP, et al. Heparin-bonded central venous catheters do not reduce thrombosis in infants with congenital heart disease: a blinded randomized, controlled trial. Pediatrics 2009; 123:e453.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8195 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_26_27050=[""].join("\n");
var outline_f26_26_27050=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VENOUS ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Superficial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Deep",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H165302905\">",
"      - Catheter-related factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Prothrombotic states",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hormonal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Chemical irritation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      No symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Inability to draw blood from catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Symptomatic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Phlebitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Extremity edema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clinical prediction score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Duplex ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Venography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Phlebitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Asymptomatic thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Deep vein fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Catheter management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Functioning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Occluded",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      THROMBOSIS PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H692376821\">",
"      Prophylactic anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13360722\">",
"      Heparin-bonded catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8195\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8195|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/3/18480\" title=\"figure 1\">",
"      Anterior view superficial veins of the upper extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/43/16053\" title=\"figure 2\">",
"      Deep veins of the upper extremity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=related_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/13/218?source=related_link\">",
"      Extravasation injury from chemotherapy and other non-neoplastic vesicants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/16/21762?source=related_link\">",
"      Patient information: Superficial phlebitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=related_link\">",
"      Primary (spontaneous) upper extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=related_link\">",
"      Superficial thrombophlebitis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2055?source=related_link\">",
"      Suppurative (septic) thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_26_27051="Stage of pelvic organ prolapse";
var content_f26_26_27051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pelvic organ prolapse staging",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"1\" rowspan=\"2\">",
"        Stage 0",
"        <br/>",
"       </td>",
"       <td>",
"        No prolapse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aa, Ba, Ap, Bp are -3 cm and C or D&le; -(tvl - 2) cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Stage 1",
"       </td>",
"       <td>",
"        Most distal portion of the prolapse -1 cm (above the level of hymen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Stage 2",
"       </td>",
"       <td>",
"        Most distal portion of the prolapse &ge; -1 cm but &le; +1 cm (&le;1 cm above or below the hymen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Stage 3",
"       </td>",
"       <td>",
"        Most",
"distal portion of the prolapse &gt; +1 cm but &lt; +(tvl - 2) cm",
"(beyond the hymen; protrudes no farther than 2 cm less than",
"the total vaginal length)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Stage 4",
"       </td>",
"       <td>",
"        Complete eversion; most distal portion of the prolapse &ge; + (tvl - 2) cm",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Aa: Point A of anterior wall; Ba: point B of anterior wall; Ap: point A of posterior wall; Bp: point B of posterior wall; -: above the hymen; +: beyond the hymen; tvl: total vaginal length.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Harvey, M-A, Versi, E. Urogynecology and pelvic floor dysfunction. In: Kistner's Gynecology and Women's Health, 7th ed, Ryan, KJ, Berkowitz, RS, Barbieri, RL, Dunaif, A (Eds), St. Louis, Mosby 1999. Copyright &copy; 1999 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_26_27051=[""].join("\n");
var outline_f26_26_27051=null;
var title_f26_26_27052="Mixed additive challenge";
var content_f26_26_27052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F86672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F86672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mixed food additive challenge",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food additive",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acceptable daily intake (mg/kg body weight)*&nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose per capsule",
"       </td>",
"       <td class=\"subtitle1\">",
"        Capsules administered in challenge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Tartrazine (Yellow dye #5)",
"       </td>",
"       <td>",
"        &nbsp;0-0.75",
"       </td>",
"       <td>",
"        50 mg",
"       </td>",
"       <td>",
"        1 capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Aspartame (NutraSweet)",
"       </td>",
"       <td>",
"        &nbsp;40",
"       </td>",
"       <td>",
"        50 mg",
"       </td>",
"       <td>",
"        1 capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Potassium metabisulfite",
"       </td>",
"       <td>",
"        &nbsp;0-0.7",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        1 capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. MSG",
"       </td>",
"       <td>",
"        Not specified&nbsp;",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        5 capsules (2500 mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Sodium benzoate",
"       </td>",
"       <td>",
"        &nbsp;0-5",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        1 capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Methylparaben",
"       </td>",
"       <td>",
"        0-10&nbsp;",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        1 capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. BHA",
"       </td>",
"       <td>",
"        &nbsp;0.5-2",
"       </td>",
"       <td>",
"        250 mg",
"       </td>",
"       <td>",
"        1 capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. BHT",
"       </td>",
"       <td>",
"        &nbsp;0-0.5",
"       </td>",
"       <td>",
"        250 mg",
"       </td>",
"       <td>",
"        1 capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Sunset yellow (Yellow dye #1)",
"       </td>",
"       <td>",
"        &nbsp;~8",
"       </td>",
"       <td>",
"        50 mg",
"       </td>",
"       <td>",
"        1 capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Sodium nitrate",
"       </td>",
"       <td>",
"        &nbsp;0-5",
"       </td>",
"       <td>",
"        50 mg",
"       </td>",
"       <td>",
"        1 capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11. Sodium nitrite",
"       </td>",
"       <td>",
"        &nbsp;0-0.4",
"       </td>",
"       <td>",
"        50 mg",
"       </td>",
"       <td>",
"        1 capsule",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Courtesy of Dr. Ronald A. Simon. See text for discussion of appropriate use of this challenge in assessing patients for allergic reactions to food additives.",
"    <div class=\"footnotes\">",
"     <p>",
"      * Data gathered from reports of the&nbsp;Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO).&nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_26_27052=[""].join("\n");
var outline_f26_26_27052=null;
var title_f26_26_27053="Contents: Sexual and gender identity disorders";
var content_f26_26_27053=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?41/24/42381\">",
"       Psychiatry",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Sexual and gender identity disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Sexual and gender identity disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/47/36600\">",
"           Female orgasmic disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/55/43895\">",
"           Fetishism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/48/2824\">",
"           Treatment of female orgasmic disorder",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-E638F85C68-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f26_26_27053=[""].join("\n");
var outline_f26_26_27053=null;
var title_f26_26_27054="Otorrhea no inflammation";
var content_f26_26_27054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Otorrhea without external auditory canal inflammation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 348px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AOM: acute otitis media; CSF: cerebrospinal fluid.",
"     <br>",
"      * Concurrent bacterial otitis exterra may be present.",
"      <br>",
"       &bull; Often associated with a periauricular mass, chronic ear drainage, and a normal tympanic membrane.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_26_27054=[""].join("\n");
var outline_f26_26_27054=null;
var title_f26_26_27055="Intussusception lymphoma CT";
var content_f26_26_27055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intussusception of small bowel lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography&nbsp;scan of the abdomen demonstrates a large mass in the lumen of a distended loop of small bowel. Note mesenteric fat in the center of this intraluminal mass (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_26_27055=[""].join("\n");
var outline_f26_26_27055=null;
